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SUMMARY
The purpose of this study was to assess the prevalence of positive results to 
cutaneous patch testing in patients with oral mucosal diseases and to assess 
the relevance of exclusion of identified allergens to the disease process. It 
was also attempted to identify microscopic features that were related to a 
hypersensitivity aetiology in patients with oral lichenoid eruptions.
The analysis was carried out retrospectively in the Departments of Oral 
Medicine and Oral Pathology in Glasgow Dental Hospital And School and 
the Contact Dermatitis Investigation Unit in the Royal Infirmary, Glasgow. 
A total of 1,252 patients with oral mucosal diseases who had been referred 
to the Contact Dermatitis Unit were assessed, and the prevalence of positive 
reactions to patch testing and contact urticaria testing in each disease cohort 
was compared to the prevalence of positive reactions in 100 control 
volunteers. Sections of specimens from patients with oral lichenoid 
eruptions were analysed using photographic standards and by counting cells 
and measuring the sections.
The results indicated that patients with oral mucosal diseases were 
significantly more likely to have demonstrable hypersensitivity to food 
additives, especially benzoic acid, and perfumes and flavourings, especially 
cinnamaldehyde, than controls. Dietary avoidance therapy to identified 
allergens caused improvement in the majority. Patients with oral lichenoid 
eruptions were significantly more likely to react to mercurial allergens on 
patch testing than patients with recurrent aphthous stomatitis or orofacial
granulomatosis. Microscopic examination revealed that the density of the 
inflammatory infiltrate was higher in those patients with oral lichenoid 
eruptions who had one or more positive patch tests or contact urticaria tests. 
They also had more disruption of the basal cell layer though this was of 
borderline significance.
It was concluded that patch testing and contact urticaria testing, together 
with the resultant allergen avoidance therapy, are useful adjuncts in the 
management of oral mucosal diseases. The presence of a florid (in terms of 
thickness and density) inflammatory infiltrate and disruption of the basal 
cell layer in cases of oral lichenoid eruptions, suggested that an allergic 
aetiology was more likely.
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CHAPTER 1 LITERATURE REVIEW
1.1. Allergy: Historical Review and Basic Mechanisms
1.1.1. Historical Review
Although doubtless many thousands of people in past generations suffered 
and indeed may have died from allergic diseases, it has only been in the last 
200 years that allergic processes have been identified as causing clinical 
disorders.
“All diseases occur at all seasons, but some diseases are more 
apt to occur and to be aggravated at certain seasons.”
Hypocrites Aphorisms III 19 (Guthrie 1958)
It is very unlikely that Hypocrites when he wrote these words was referring 
to allergic diseases, however the first discovery of ailments mediated by 
allergic processes was of what we now term ‘hay fever’, to which the above 
quotation certainly applies.
A doctor, John Bostock in 1819 described his own symptoms while 
speaking to the Royal Medical Society of London. He suffered from a 
‘periodical affection of the eyes and chest’ to which he gave the name 
Catarrhus aestivus or ‘summer catarrh’ (Avenberg & Harper 1982). Later 
in the 19th century, Charles Blackley another doctor also afflicted with hay 
fever discovered that pollen was able to cause hay fever, conjunctivitis, 
rhinitis and asthma, and, when rubbed into a scratch on his arm a reaction 
became visible. He furthered these observations with studies relating the
amount of pollen in the air to his symptoms. He used sticky microscope 
slides to count pollen grains and even sent up a kite to determine that pollen 
was airborne to a height of 500 m above ground level.
Other ‘allergic’ diseases recorded in the 19th century were vasomotor 
rhinitis (recorded in 1881 by Herzog) and Quinke oedema (angioedema) 
which was described by Dr Heinrich Quinke (Mattingly, Rodu, & Ailing 
1993). At this time the mechanisms underlying the disease processes were 
not known although it was understood that the exogenous materials e.g. 
pollen were not noxious to mankind per se but only to certain individuals 
(Mygind et al. 1996). Jadassohn introduced what we now know as allergic 
contact dermatitis in 1895 by reproducing a reaction to iodoform on the 
skins of five individuals (Jadassohn 1895).
Scientists in the early 20th century began to investigate further the effects of 
toxic substances on humans and whether repeated dosing of small amounts 
of toxins could induce some sort of tolerance. This idea had been tried as 
early as in the 1st century BC by the Greek King Mithradates who upon 
noticing strange tastes in his food suspected poison and for the remainder of 
his long life took a daily dose of both various antidotes and poisons. That 
he succeeded in rendering himself immune to one of the poisons was proved 
after he failed to die from taking a lethal dose to end his own life (Duggan 
1974).
The scientists involved were the Frenchmen, Charles Richet and Paul 
Portier, who in 1901 injected repeated doses of the toxin gathered from the 
jellyfish the Portuguese man-of-war, into an unfortunate large dog. Twenty- 
two days after the first injection, a further injection of one tenth of the fatal
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dose was given which resulted in the rapid death of the dog within minutes. 
They used the word anaphylaxis to describe the reaction as it had had the . 
opposite effect of prophylaxis. The next year Maurice Arthus demonstrated 
that anaphylaxis could be triggered using a substance that was not usually 
toxic to humans. He used horse serum injected into rabbits -  the first dose 
showing no effect and the repeated dose giving rise to local inflammation 
and in some cases necrosis (Arthus 1903).
In 1905, an Austrian scientist Clemens Von Pirquet coined the word 
‘allergy’ to describe the ‘changed reactivity’ of the subject to the provoking 
substance (from the Greek words ‘alios’ meaning altered and ‘ergos’ 
meaning work). He had been working in the fledgling discipline of 
immunology, trying to find vaccines for the common diseases of the day and 
discovered the paradoxical situation in that some individuals developed 
immunity to the disease, while in others, a reaction (what he termed a 
supersensitive response ) deleterious to the patient occurred.
"The vaccinated person behaves towards vaccine lymph, the syphilitic 
towards the virus o f syphilis, the tuberculous patient towards tuberculin, the 
person injected with serum towards this serum, in a different manner from  
him who has not previously been in contact with such an agent. Yet he is 
not insensitive to it. We can only say o f  him that his power to react has 
undergone a change. ” (von Pirquet 1906)
Von Pirquet also refers to episodes of acute urticaria following the ingestion 
of foods such as egg white and buckwheat though these are case reports 
rather than controlled clinical experiments. He gave the name ‘anergy’
(lack of reactivity) to what had been termed antianaphylaxis (decrease in
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sensitivity following repeated doses of antigen) and ‘allergen’ to describe 
an antigen that provoked an allergic reaction (von Pirquet 1911).
In 1923, Cooke and Coca named the clinical forms of allergy ‘atopy’. They 
defined those who suffered thus as;
“the individuals as a group possess a peculiar capacity to become sensitive 
to certain proteins to which their environment and habits o f  life frequently 
expose them. ” (Coca & Grove 1924)
They also realised that atopic subjects had an inherited predisposition to 
become sensitised. Other features of allergy were the ability to transfer the 
‘supersensitivity’ to another by the transfer of serum. Prausnitz and Kiistner 
in 1921 conducted the classic experiment to prove that passive transfer of 
allergy was possible (Prausnitz & Kiistner 1921). They obtained some 
serum from Kiistner who had a severe allergy to cooked fish and injected 
this intradermally into the abdominal skin of Prausnitz. The next day they 
injected the same area with fish extract and he elicited a marked reaction to 
it, similar to the reaction that Kiistner had from the fish extract. Coca and 
Cooke named the ‘transfer factor’ ‘reagin’.
Later it became clear that reagin was associated with antibody but with 
distinctive features; it could not be demonstrated in serum by the usual 
precipitation reaction, was heat labile and had the ability to become fixed to 
the skin for prolonged periods. Reagin was also capable of producing the 
wheal and flare response.
Developments in the field of allergology continued apace with the discovery 
of the two main immunological pathways of response to an allergen, the 
humoral and cellular mechanisms. Developing this further, in 1962 Coombs
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and Gell in their book ‘Clinical Aspects of Immunology’, gave a simplified 
view of four main allergopathological mechanisms. They based this 
classification on the circumstances of the initial antigen-antibody reaction 
and stressed that it was merely a classification of the initiating mechanisms 
of the allergic response which were secondarily classified by other 
differences.
“Again it must be emphasised that the pattern seen in any one human 
disease is often complex, involving not just one but several o f  the above 
pathways or responses ” (Gell & Coombs 1968)
Considered in this classification were types of allergic reaction that firstly, 
resulted in tissue damage and secondly, involved the sensitisation of host 
cells. Therefore excluded were immune tolerance reactions and allogenic 
reactions. The authors were well aware of the variety of ways that allergies 
could be grouped e.g. by allergen type or source, by drug reactions, 
autoallergies, time and duration of response after allergen contact, but were 
successful in choosing a basic classification that is still helpful today (Gell 
& Coombs 1968). The types of allergic reactions as originally described are 
outlined below:
Type I Reaction (anaphylactic, reagin-dependent)
Initiated by the allergen reacting with tissue cells that have been passively 
sensitised by antibody that was produced elsewhere. This leads to the 
release of vasoactive hormones such as histamine.
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Type II Reaction (cytotoxic)
Here the antibody reacts with either a) an antigenic component of a cell or 
tissue element or b) antigen or hapten that is closely linked with these. 
Complement is usually necessary to effect tissue damage.
Type III Reaction (damage by toxic complexes)
This starts when the antigen reacts with potentially precipitating antibody in , 
the tissue spaces, forming microprecipitates in and around the small vessels 
which in turn causes cellular damage; or when antigen in excessive 
quantities reacts with potentially precipitating antibody in the blood stream, 
forming soluble circulating antigen-antibody complexes which are deposited 
in the blood vessel walls or basement membrane and cause damage by local 
inflammation.
Type IV Reaction (delayed, tuberculin-type, cell-mediated)
This reaction is initiated by the reaction of specifically modified 
mononuclear cells (previously sensitised) containing a substance or 
mechanism capable of responding specifically to an allergen deposited at a 
local site. The exact mechanism of this type of reaction is still uncertain, 
but it is manifested by the infiltration of cells, at the site where that antigen 
is, without the necessary participation of free antibody.
(Gell & Coombs 1968)
Bendixen in 1966 attempted a classification of allergy based on the clinical 
diseases that the different mechanisms produced. He divided 
hypersensitivity (note that he thought that the word ‘allergy’ had already 
lost its meaning and used ‘hypersensitivity’ to describe what Von Pirquet
had by ‘allergy’!) into two parts between which he thought there was a clear 
distinction. Humoral (immediate) type and the cellular (delayed) type. He 
based the distinctions primarily on the method by which passive transfer of 
hypersensitivity could be done (serum and reagin compared with the 
injection of killed micro-organisms), on the time of onset of symptoms after 
allergenic challenge (minutes compared with hours and days) and by the 
different histological pictures produced by e.g. a local anaphylactic response 
(essentially a vascular reaction) and the tuberculin hypersensitivity response 
(antigen containing tissue invaded by mononuclear cells). He further 
divided the humoral hypersensitivities into four main types; Arthus, 
anaphylactic, reagin, and cytotoxic types, and the cellular hypersensitivities 
into five groups; infection, transient, contact, transplantation and organ- 
specific types. He was however aware of the provisional nature of his 
classification and of the amount of information that was lacking about these 
mechanisms and diseases (Bendixen 1966).
In 1967, reagin was identified to be IgE and allergology became integrated 
into the discipline of clinical immunology. Teruko and Kimishige Ishizaka, 
a husband and wife team, did this by eliminating anti-IgA, IgD, IgM and 
IgG antibodies from the serum (obtained from a rabbit which had been 
previously inoculated with the serum of a person with an extreme allergy to 
ragweed pollen) by precipitation with human IgA, IgD, IgM and IgG and 
found that a substance capable of transferring sensitivity to a particular 
allergen was still there. Thus they discovered that reagin antibody belonged 
to the same class of immunoglobulins and named it gamma E globulin 
(Ishizaka, Ishizaka, & Hombrook 1966). At the same time, though
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independently, Johansson and Bennich isolated IgE though it was more by 
luck while working with a patient whose disease processes (myeloma) 
caused excessive production of reagin which they isolated and named IgND 
after the patient’s initials. They demonstrated by radioimunoassay that 
IgND is present in very small quantities in human serum and discovered 
also that the level of IgND was raised in atopic patients. The two teams met 
in 1967 and agreed to call it IgE (Mygind et al. 1996).
Allergy definition: Hypersensitivity caused by exposure to a particular 
antigen (allergen) resulting in a marked increase in reactivity to that antigen 
upon subsequent exposure, sometimes resulting in harmful immunologic 
consequences (Stedman’s Medical Dictionary 2000).
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1.1.2. Basic Mechanisms and Oral Mucosal Immunity
Although the allergic mechanisms are often still classified according to the 
Gell and Coombs definition, the groups often overlap or exist 
simultaneously (Krogh & Maibach 1982). Much more is now known about 
the individual processes involved and there are elements of both the 
humoral and the cell mediated pathways in most allergopathogenic 
mechanisms.
1.1.2.1.Saliva
The oral cavity has physical and immunological defence mechanisms to 
cope with the exogenous immunogenic challenge that presents itself in food 
stuffs, liquids and airborne materials. Potential allergens are washed away 
through the cleansing effect of saliva minimising contact time. The average 
unstimulated flow rate of saliva in healthy individuals is 0.3ml/minute 
(Colin Dawes 1996). The average bacterial load alone in 1ml of saliva is 
109 so the swallowing action removes a considerable antigenic load from the 
oral mucosa (Bowen 1996). The saliva also contains digestive enzymes and 
many types of proteins including immunoglobulins (predominantly 
secretory IgA), which commence the breakdown of food stuffs and other 
carbohydrates, and remove some antigens, particularly viral ones, 
respectively (Mandel 1987). The role of IgA in the serum may be 
detrimental to the host against some capsulated bacteria such as gonococci,
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since it may block the bactericidal activity mediated by complement, IgG 
and IgM though this has only been shown in serum and not in saliva as yet 
(Croitoru & Bienenstock 1991).
1.1.2.2.Mucosa
The mucosa of the gastrointestinal tract has to maintain a fine balance 
between defence of the host and attacking and neutralising noxious 
chemicals and harmful bacteria, viruses and fungi. Its immune systems 
have to be selective to avoid immune mediated damage to itself, while at the 
same time the function of much of the gastrointestinal tract is to absorb 
nutrients.
The oral mucosa consists of keratinized (hard palate and alveolar ridges) 
and non-keratinized stratified squamous epithelium (all the rest except the 
dorsum of the tongue which is covered with keratinized, specialised oral 
epithelium). Protective mechanisms such as a high epithelial turnover and 
the presence of a lipid permeability barrier in the superficial epithelium 
assist in guarding the epithelium even though the oral mucosal permeability 
is much lower than that of abdominal skin (Healy et al. 2000). Despite the 
fact that the non-keratinized oral epithelium doesn’t have the protective 
layer of keratin as the skin does, the ability of the oral mucosa to become 
sensitised to an antigen is less than that of the skin, indeed irritant reactions 
to chemicals are rare (de Groot, Weyland, & Nater 1994; Jones & Beltrani 
1997). This is because when an allergen is absorbed through the mucosa, 
the dense vascularity underlying the oral epithelium ensures rapid clearance
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of allergens away from the local area and into the blood stream (Andersen
1978). However this can lead to systemic effects occurring; exacerbation of 
asthma was reported after exposure to toothpaste (Subiza et al. 1992) and 
extra-oral contact dermatitis was reported after a nickel plated fixed 
orthodontic appliance was fitted in a 12 year old boy who developed marked 
perioral and periorbital eczema with involvement of the anterior scalp and 
loss of hair. A nickel patch test elicited a positive reaction and the eczema 
resolved after removal of the metal appliances (de Silva & Doherty 2000). 
The Langerhan’s cell density in oral mucosa is reduced compared to that of 
skin: 84-308 mm' in oral mucosa compared to 4500 mm' in skin, which 
reduces the sensitising potential in oral mucosa (Kaaber 1990).
1.1.2.3.CelIs 
Antigen Presenting Cells
Much work has been done on the functions and structures of antigen 
presenting cells. In the human oral mucosa, the main antigen presenting 
cells (APC) are the Langerhan’s cells (LC) which express major 
histocompatibility (MHC) class II antigen on their cell surfaces. However, 
the presence of MHC class II molecules on the cell surfaces of oral 
keratinocytes and the fact that there is, in allergic inflammation, a 
significant presence of intraepithelial T lymphocytes, suggests that they too 
have a role to play in antigen presentation (Eversole 1994). The numbers of 
LCs in the skin are depleted markedly when exposed to UVA light and
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correspondingly reaction to noted sensitisers such as dinitrofluorobenzene 
(DNFB) decreases rapidly. This has been shown to be a local rather than a 
systemic response in a murine model (Toews et al. 1980). Crutchley et al 
found a regional variation in Langerhan’s cell distribution in normal oral 
mucosa with the highest to lowest concentration areas as follows; dorsum of 
the tongue, buccal mucosa, lip mucosa, lateral border of tongue/hard palate 
and floor of mouth (Cruchley et al. 1989). Langerhan’s cell numbers have 
been found to be increased in human contact dermatitis lesions of the skin, 
and in the early stages of erythema multiforme lesions (Farthing, Matear, & 
Cruchley 1990; Lombardi, Hauser, & Budtz Jorgensen 1993).
Lymphocytes
The so called cell mediated response of delayed hypersensitivity is one in 
which the following must happen; the antigen must penetrate the stratum 
comeum, interact with dermal or epidermal cells, interact with the immune 
system and finally an inflammatory response occurs (Thestrup-Pedersen, 
Larsen, & Ronnevig 1989). The primary cell involved here is the T 
lymphocyte although in concert with a host of other cells and mediators.
The T cell response is now known to exist as two different and mutually 
repressive systems, one subset of T helper cells (Thl) leading to a Type IV 
hypersensitivity reaction and the other subset of T helper cells (Th2) leading 
to a Type I reaction. Naive T helper cells (ThO) are influenced by either 
interleukin 12 (IL-12) or IL-4. IL-12 is produced by the action of microbial 
antigens stimulating macrophages. It stimulates Thl to produce gamma
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interferon (IFN-g) which both inhibits the stimulation on Th2 cells and 
attracts macrophages, and IL-2 which is chemotactic to other T cells.
IL-4 is produced by an as yet unknown monocytic antigen presenting cell 
and switches ThO to produce IL-10 which inhibits the Thl pathway, IL-4 
which acts on B cells to produce IgE and IL-5 which attracts eosinophils 
(Mygind et al. 1996).
Eosinophils
In 1879 Paul Erlich noticed for the first time a mononuclear cell, in the 
circulatory system. He named it Eos after the Greek goddess of the dawn as 
it could be stained bright red with the histological stain eosin (Mygind et al.
1996). Tissue eosinophilia has been used as a marker for allergic 
responsiveness and atopy.
Mast cells and Basophils
Mast cells and their granules were described by Paul Erlich in 1877 
(Avenberg & Harper 1982). Mast cells and basophils are the main cells 
involved in a Type 1 hypersensitivity reaction mediated by IgE. Mast cells 
and basophils are often considered together despite the difference in their 
maturation, development and site of action. Mast cell progenitor cells 
differentiate from stem cells in the bone marrow and enter the circulatory 
system to migrate into the tissue in which they develop into mature mast 
cells. Basophils develop along a common pathway with eosinophils from 
myeloid progenitor cells and it is the action of interleukin 5 (IL-5) that
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determines which is the ultimate cell type. Basophils remain in the 
circulatory system throughout their lifetime (Mygind et al. 1996). However, 
they share many common features; both possess high affinity IgE receptors 
which when activated stimulate both cells to release mediators from 
granules contained within their cytoplasm, both also manufacture secondary 
mediators such as eicosanoids (Barrett 1991). Most of these chemical 
mediators are shared, though both manufacture different ones too.
Mast cells can be divided into two groups; those found primarily in the 
connective tissue of the skin and containing the enzymes tryptase and 
chymase, and those found in mucosal tissues such as lungs and 
gastrointestinal mucosa which contain the enzyme tryptase only (Irani et al. 
1986). These are classed as M C tc and M C t respectively. The relative 
proportions of each vary in different tissues and in different disease states 
(Mygind et al. 1996).
1.1.2.4.Cytokines and Mediators
Cytokines are small soluble proteins that act as the messengers of the 
immune system, produced by cells to have an influence on other cells.
Their known number is growing rapidly as more research is carried out and 
more are discovered. Cytokines have a crucial role to play in controlling the 
T cell differentiation as has already been described.
Histamine remains the most important of the chemical mediators as can be 
realised from the amount of antihistamine preparations available to treat 
some allergic disorders (British Medical Association & Royal
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Pharmaceutical Society of Great Britain 2000a). It is released from both 
mast cells and basophils following degranulation and is widely used as a 
marker of mast cell activation (Barrett 1991).
1.1.2.5.Humoral Mechanisms in Oral Mucosa
IgE has been termed the ‘master hypocrite of our body’s defence system’. 
Though it exists in minute quantities in the human serum and performs 
useful functions in the host response to antigens, it is also capable of 
inflicting harmful and sometime severe effects on many individuals in our 
society today (Katz 1984). Type I reactions, though essentially immediate 
and short lasting, may also have a late phase response occurring hours after 
the immediate response (Solley et al. 1976). Type I reactions occur in some 
angioedema and urticarial reactions and in some drug reactions. The effect 
of Type I reactions on the oral mucosa is usually localised erythema, 
oedema and smooth muscle spasm (Spouge & Diamond 1963).
Oral allergy syndrome (OAS) has been described in the last 12 years 
comprising a number of IgE mediated hypersensitivity reactions localised in 
the oral cavity and sometimes followed by systemic symptoms. It is elicited 
upon exposure to food allergens related to pollens such as fruits and nuts 
e.g. papaya, avocado, banana, melon, peanut, chestnut, passion fruit, kiwi 
fruit, tomato, mango ,pineapple and peach, and is often associated with'latex 
allergy -  the Tatex-fruit syndrome’ (Brehler et al. 1997). These are also 
often associated with pollen allergy (particularly birch, ragweed and grass) 
due to the presence of cross reacting allergens. Reactions may be severe
and require emergency medical treatment as in one case of OAS to chestnut 
(Antico 1996). Two separate reports of OAS to uncooked pork have been 
described suggesting that this syndrome has a wider aetiology than fruit and 
latex, though one patient had a family history of pollinosis and herself had 
experienced rhinoconjuctivitis to horse dander while the other had allergy to 
Dermatophagoides species (Asero, Mistrello, & Falagiani 1997 Liccardi, 
D'Amato, & D'Amato 1996).
Type II or cytotoxic reactions are not usually seen in the oral cavity though 
they may exert secondary effects such as thrombocytopenic purpura as a 
result of thrombcytopenia (Mygind et al. 1996).
Type III or immune complex reactions are seen in the oral cavity in 
erythema multiforme (EM) where in nearly half of cases the antigen is 
estimated to be of pharmacological origin. The other major antigen 
associated with EM is herpes simplex virus (Manganaro 1996). Circulating 
immune complexes may also act directly on blood vessels and precipitate 
angioedema (Kao & Zeitz 1993).
1.1.2.6.CeIlular Mechanisms in Oral Mucosa
As has already been stated, the oral mucosa is more resistant to contact- 
sensitivities than the skin and this is shown by the relatively small number 
of patients that present with allergic contact stomatitis (ACS). However 
Type IV hypersensitivity reactions or contact sensitivities have been found
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in a number of cases, though the prevalence of contact stomatitis among the 
general population is at present unknown. Type IV reactions are 
characterised by the death of individual cells which in epithelium may lead 
to vesiculation and/or ulceration (Spouge & Diamond 1963). On a review of 
the literature pertaining to ACS, Jones and Beltrani found that a wide range 
of materials have been implicated as allergens in these cases (Jones & 
Beltrani 1997). It is recognised that ACS occurs less frequently than 
allergic contact dermatitis (ACD) and this may be due to the fact that the 
skin contains proteins that more readily combine with simple chemicals to 
form allergens (Rietschel & Fowler 1997). In contrast, Cawson and Odell 
consider that contact stomatitis is rarely if ever seen (Cawson & Odell 
1998).
There is some overlap with humoral immunity and Types I and IV have 
been identified to coexist in some cases of allergy to castor bean (Kanerva, 
Estlander, & Jolanki 1990) and latex (Placucci et al. 1996). Absorption of 
an allergen through the skin may not only result in a Type IV 
hypersensitivity reaction, but occasionally also a Type I or III reaction 
(Friedman & Perry 1985).
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1.1.3. Antigens and Allergy Testing
1.1.3.1.Antigens and the Oral Mucosa
Allergic contact dermatitis is by definition a disease of the skin and is often 
diagnosed by patch testing. However, other epithelial structures such as the 
oral mucosa may be involved in a similar way and these patients are less 
likely to be seen in a patch testing clinic. Allergic contact stomatitis 
presents primarily by the subjective symptoms experienced by the patient 
(burning, itching, loss of taste, soreness) rather on the physical signs which 
may be less prominent but include erythema, oedema, and rarely 
vesiculation (de Groot, Weyland, & Nater 1994). The pathological 
mechanisms of many oral diseases have been linked to allergic processes. 
These are such diseases as lichenoid reactions of the oral mucosa, recurrent 
aphthous stomatitis, erythema multiforme, angioedema, desquamative 
gingivitis, plasma cell gingivitis, oral dysaesthesia and orofacial 
granulomatosis (Lamey & Lewis 1990; Lewis et al. 1989; McGivem et al. 
2000; Rosen et al. 1993; Silverman & Lozada 1977; Staines, Felix, & 
Forsyth 1998; Whitley, Shepherd, & Ferguson 1991; Wray, Vlagopolous, & 
Siraganian 1982). Some have a very strong link, for example in the case of 
OFG (Rees 1999), and some, such as angioedema, have a weaker link where 
the role of allergopathologic mechanisms have a major contribution only in 
certain subtypes of the disease and play a lesser part in the pathogenesis of 
the other types (Rees & Gibson 1997).
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The antigens involved in stimulating the allergic processes in the above 
diseases can be complete or incomplete such as those acting as haptens, 
organic e.g. viral, or inorganic e.g. nickel.
Potentially, all elements and compounds have the ability to elicit an allergic 
response from a human being. Foods stuffs have by far the most potential to 
elicit hypersensitivity reactions given that it has been estimated that the 
average person’s gastrointestinal tract will process more than 100 tons of 
food during a lifetime (Sampson & Metcalfe 1991). However, most 
substances humans interact with do not provoke an adverse immune 
response. Fortunately the immune system usually copes with the onslaught 
of potentially immunopathogenic material with no resultant clinical 
problems and though the prevalence of allergy to ingested materials is at 
present unknown, it is estimated to be in the region of 1-2% of the general 
population (Anderson 1997b). This figure takes into account the much 
higher incidence among infants of food intolerance and allergy which may 
be as high as 8% in some groups (Anderson 1997b).
As well as food stuffs themselves, food additives (substances with no 
nutritional value) are added to foods to alter their chemical properties. 
Modem Western civilisation demands pre-prepared foods with long shelf 
lives, enhanced food colours and flavours, and high yield farming that 
ensures that most foods are available all year round. It is estimated that 
between 2,000 and 20,000 types of food additives are available for 
incorporation into foods (Bosso & Simon 1991). Some foods and 
substances added to enhance, preserve or stabilise foods are known to be
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more likely than others to elicit a response from the immune system though 
most have little or no history of provoking adverse reactions.
The antigenic agents commonly involved in stimulating allergic responses 
in the oral cavity can be divided into seven groups:- 
Dental home care products 
Dental materials and medicaments 
Metals used in dentistry 
Rubber products used in dentistry 
Foods
Food additives 
Cosmetics
(Fisher 1995; Jones & Beltrani 1997; Lewis, Shah & Gawkrodger 1995).
It is o f course to be remembered that many other materials are habitually 
placed in the mouth. A case of desquamative gingivitis resolved after a 
patient changed her type o f nail varnish. She was patch tested which 
elicited a positive result to formaldehyde resin and this was found in the 
patient’s nail varnish (Staines, Felix, & Forsyth 1998).
The standard procedure for allergy testing involves: a history o f exposure to 
the allergen, a positive allergy test, allergen avoidance leading to resolution 
of the symptoms and/or signs and a double-blind placebo controlled allergen 
rechallenge leading to recurrence of the symptoms and/or signs (Sicherer & 
Sampson 1999; Williams & Bock 1999). In the diagnosis of food allergy, 
the double-blind placebo controlled food challenge is considered the gold 
standard of allergy testing, often used without any other positive test results
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(Sicherer & Sampson 1999). Unfortunately all these steps are rarely carried 
out and much of the literature includes anecdotal case reports.
Dental home care products
In a study involving 16 patients who had allergic reactions to toothpastes, 
Lamey et al found that the compound most likely to have caused these was 
cinnamaldehyde (Lamey et al. 1990). Cinnamaldehyde was identified by 
patch testing to be the cause of oral symptoms in 7 patients in another study 
(Kirton & Wilkinson 1975) and another study reported one patient reacting 
to cinnamaldehyde in a toothpaste (Downs, Lear, & Sansom 1998). Mint oil 
constituents are found in toothpastes and mouthwashes as well as 
confectionery, cosmetics etc, and have been reported as causing allergic 
manifestations (Downs, Lear, & Sansom 1998; Smith 1968; Wormet al. 
1998). Though most authors have reported local effects, systemic effects 
have been noted after oral contact with toothpastes. There has been a report 
of asthma being provoked by the mint flavours in toothpastes and 
confectionery, though the mechanism for this was considered by the authors 
to be idiosyncratic as skin prick tests were negative and specific IgE could 
not be demonstrated (Subiza et al. 1992). A Danish study found that 
allergic contact dermatitis (ACD) of the skin was aggravated by the oral 
contact. Three children aged between 2 and 3 years had vaccination 
granulomas following the aluminium hydroxide containing triple 
vaccination programme and in each, patch testing gave a positive reaction to 
aluminium chloride. The lesions had failed to respond to corticosteroids 
and questioning revealed that each child used a brand o f toothpaste that 
utilises aluminium oxide as its abrasive agent, the lesions resolved upon
ceasing use of the aluminium containing brand and in two out of the three 
cases, the ACD reappeared within four days after rechallenge with the 
toothpaste (Veien, Hattel, & Laurberg 1996b).
A Finnish study was carried out in 1995 to assess the pH of all available 
toothpastes on the market in Finland. They found that as far as the pH is 
concerned toothpastes are unlikely to cause irritant reactions as the pH was 
fairly neutral in all of the 48 toothpastes studied (pH 5.5-8.9). On an 
extensive review of the literature the authors found that most of the 
constituents in most types of dentifrices have in the past been reported to 
have caused allergic reactions. They found that the most common allergens 
were identified as cinnamaldehyde, cinnamon oil and peppermint (Sainio & 
Kanerva 1995). Anethole is another toothpaste flavouring agent that has 
been reported to cause adverse reactions in certain people, in the case 
reported giving rise to both extraoral (cheilitis and perioral eczema) and 
intraoral (erythema and desquamation of the mucosa) manifestations 
(Franks 1998). Mouthwashes also can contain flavourings such as eugenol 
and peppermint which have been reported as causing contact dermatitis and 
intraoral oedema respectively (Dooms-Goossens et al. 1977).
Dental materials and medicaments
That dental materials are of importance in causing allergic reactions is 
shown by the fact that a standard list of patch test allergens common in­
dentistry has been drawn up (Axell et al. 1979).
Materials used in dental products such as instruments, medicaments and 
medicines contain a wide variety of compounds and in order to elucidate
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sensitivity information more easily from patients with suspected allergy to 
dental materials, dental screening series of allergens have been developed . 
(Axell, Bjorkner, Fregert, & Niklasson 1979). Prophylactic paste contains 
similar ingredients to toothpastes and therefore has been dealt with in the 
previous paragraph.
A peppermint containing antiseptic spray used in the oral cavity of a patient 
who was later found to be allergic to some of the ingredients of peppermint 
oil, caused intraoral oedema and a burning sensation (Dooms-Goossens et 
al. 1977).
Eugenol
Eugenol is a constituent of many dental preparations including temporary 
and intermediate tooth dressings which often combine zinc oxide with 
eugenol, periodontal and endodontic dressings, denture base material and 
impression material (Wiltshire, Ferreira, & Ligthelm 1996). Eugenol has 
been reported as causing allergic contact dermatitis after occupational 
exposure in a dental nurse (Kanerva, Estlander, & Jolanki 1998), and acute 
allergic reactions in the oral cavity of a patient after a temporary dressing 
was placed and again after a small amount of eugenol-containing 
endodontic sealer was used (Barkin, Boyd, & Cohen 1984).
Colophony
Colophony is used together with eugenol in many periodontal dressings 
(Wiltshire, Ferreira, & Ligthelm 1996), and has been shown to cause 
allergic reactions. It is also a component of cavity varnishes and other resin 
based formulations. In a study of 18 patients with a history of reacting to
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dental materials, 16 had a positive patch test to either colophony, eugenol or 
both. It was likely that these patients had become sensitised to these 
ingredients during dental treatment (placement of periodontal dressings was 
thought the most likely procedure) (Koch, Magnusson, & Nyquist 1971).
Methyl methacrylate
Methyl methacrylate has been suspected of causing many allergic reactions 
in the mouth particularly when patients complain of soreness or burning in 
the denture bearing area. However many of the seen incidences of denture 
stomatitis are a direct result of infection by Candida albicans of the palate 
particularly under a complete upper denture (Brunelle et al. 1997). This 
having been said, methacrylate has been shown to have caused a cutaneous 
allergic contact dermatitis which clinically and histologically had a lichen- 
planus like appearance (Kawamura et al. 1996) which lends credence to the 
possible aetiology of methacrylate allergy in some acrylic denture wearers 
as has been suggested by the following authors; one patient (Lamey et al. 
1994), one patient (Stenman & Bergman 1989), one patient (van Joosst, van 
Ulsen, & van Loon 1988) and two patients (Kaaber & Nielsen 1979). Out 
of 690 patients referred for patch testing with suspected methacrylate 
allergy, only 3.6% (n=25) had a positive result on patch testing (Franz 
1982), thus indicating that the numbers of true methyl methacrylate allergies 
are fairly small.
Thiomersal
Though not specifically used in dentistry, thiomersal sensitisation is found 
in increased numbers among medical and dental personnel. The cause of
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this is likely to be the vaccination courses administered to those in contact 
with blood and blood products against Hepatitis B Virus.
Metals used in dentistry
Allergic reactions have been shown to many of the metals that are used in 
the manufacture of various dental alloys. Several patients react to up to six 
different metals and the term ‘dental restoration metal intolerance 
syndrome’ has been suggested for those patients (Hay & Ormerod 1998; 
Koch & Bahmer 1995).
Mercury
Mercury is used in amalgam which has been in use for over 150 years 
(Kaaberl990) and has been the subject of much speculation and research 
regarding its effect on oral tissues and the body as a whole. Oral disease 
related to mercury hypersensitivity is usually in the form of lichenoid 
reactions, though intraoral bullae and urticaria affecting the skin of the head 
and neck has been reported following a repair to an amalgam restoration 
(McGivem et al. 2000). A more detailed review is dealt with in section
1.2.5.2.
Nickel
Nickel allergy is the most common cause of allergic contact dermatitis 
(ACD) and this has been attributed in the main to the increase in body 
piercing (mainly ear) and using non-precious metal jewellery for the studs 
or rings used (McDonagh et al. 1992). Jones et al found a 20% and 2% 
incidence of nickel sensitivity among 50 women and men respectively, 
while Prystowsky found that 9% of 698 women and 0.9% of 360 men gave
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positive reactions to a nickel patch test (Jones et al. 1986 ; Prystowsky et al.
1979). The differences between the sexes in part may be due to the fact that 
more women (82%) than men (0.6%) are likely to have their ears pierced 
(McDonagh et al. 1992), though with the increase of body piercing in males, 
the incidence of nickel sensitivity has also increased (Meijer et al. 1995). 
Nickel is found in the environment in many other ways: metal clasps, studs 
and buttons on clothing, personal items such as keys, spectacle frames and 
household items such as scissors, paperclips, screws nails etc. Cooking with 
stainless steel pots can contaminate foods as small amounts of nickel can 
leach out. Nickel reactions in the oral cavity are fortunately rare 
considering the amount of nickel in the environment and placed in the 
mouth in the form of fixed and removable prostheses, nickel plated pins, 
needles, metal lipstick holders and mouthpieces of musical instruments 
(Fisher 2000). Moffa et al (1977) exposed ten subjects with cutaneous 
positive reactions to nickel and ten control subjects to nickel chromium 
alloy on the skin and oral mucosa (using a removable acrylic palatal 
appliance). It was found that 80% of the nickel sensitive group responded 
positively to the cutaneous application of alloy and 30% to the intraoral 
alloy; all of the controls were negative (Moffa, Beck, & Hoke 1977). van 
Loon tested five subjects who had demonstrated a positive patch test to 
nickel sulphate with an intraoral nickel foil patch test for one week. The 
areas of mucosa adjacent were examined and biopsied revealing clinical and 
histological evidence of contact stomatitis. In five subjects not sensitive to 
nickel on patch testing, the same test gave no response (van Loon et al. 
1984). Reported cases of intraoral reactions to nickel in subjects who have
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had a positive cutaneous patch test to 5% nickel sulphate have involved 
crowns and bridges, and orthodontic appliances (de Silva & Doherty 2000; 
Lamster et al. 1986; Lyzak et al. 1994). One publication reported on a case 
where the 14 year old patient, in active orthodontic treatment utilising a 
metal face bow, developed systemic contact dermatitis affecting limbs, 
trunk, face and scalp. The patient had a positive patch test reaction to nickel 
and his symptoms resolved after removal of all the metal components from 
his mouth and face (Kerosuo & Kanerva 1997). Many nickel sensitive 
(cutaneous) people are able to tolerate nickel in relation to the oral mucosa, 
however, as was demonstrated in studies o f ; ten patients (Spiechowicz et al. 
1984), ten patients (Jones et al. 1986) and one patient (Basker 1981). The 
availability of nickel ions, their form and concentration seem to affect the 
ability of the mucosa to respond. In a study of 1,085 consecutive females in 
active orthodontic treatment or retention, none had any symptoms of nickel 
hypersensitivity in the oral cavity (Staerkjaer & Menne 1990).
Contact urticaria/angioedema has also been the sequelae of nickel contact in 
hypersensitive patients (Femandez-Redondo, Gomez-Centeno, & Toribio
1998).
Oral tolerance specific to nickel has been shown to be able to be induced by 
early oral exposure to nickel via orthodontic braces prior to ear piercing 
leading to specific unresponsiveness in some patients (van-Hoogstraten et 
al. 1991). In guinea pigs, oral tolerance to nickel and chromium was 
induced by oral feeding prior to cutaneous sensitisation (van Hoogstraten et 
al. 1992). One nickel sensitive individual experienced resolution of long
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standing forearm and hand eczema after placement of four intraoral nickel 
containing crowns (Spiechowicz et al. 1984).
New developments to decrease the exposure of nickel to mucosa and skin 
include the manufacture of metals bonded to resins, new nickel-free alloys 
and metals coated with titanium oxide (Vilaplana & Romaguera 1998).
Cobalt-Chrome
Cobalt-chrome is a common metal used in cast partial dentures primarily 
and has been reported as precipitating allergic contact dermatitis in a small 
number of patients (Fisher 2000).
Gold. Palladium and Copper
Gold hypersensitivity has been reported as being as high as 13% in 100 
patients referred for routine patch testing at a contact dermatitis clinic 
(Sabroe, Sharp, & Peachey 1996) yet ten years earlier it was considered 
very rare (Rapson 1985). This also may be due to the increase o f ear 
piercing as Sabroe et al (1996) considered that ear piercing might be a risk 
factor for gold hypersensitivity and found that 92% of the 13 with positive 
patch tests to gold had had their ears pierced. An intraoral contact lesion to 
gold in a dental crown was reported in 1984 which was confirmed by patch 
testing (Wiesenfeld et al. 1984).
The incidence of palladium allergy has increased in recent years and will 
probably continue to do so given that manufacturers are using it in more 
alloys as they develop more nickel-free products (Vilaplana & Romaguera
1998). Palladium was reported causing an intraoral reaction in a patient 
who had four successive bridge prostheses made using palladium containing
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alloys (Koch & Baum 1996), though van Loon et al had found that in five 
patients who had positive reactions to palladium in a cutaneous patch test,. 
none reacted to palladium foil when placed intraorally, next to the mucosa 
for one week (van Loon et al. 1984). One study found that the frequencies 
of gold, palladium, nickel and chromium allergy was significantly elevated 
in patients referred with oral symptoms compared to eczema sufferers 
(Marcusson 1996).
Copper is much less likely to elicit allergic responses but has been reported 
as a “possible cause of oral lesions of lichen planus” (Fryholm et al. 1969).
Electrogalvanism
Intraoral currents with saliva acting as an electrolyte between different 
metals used in dental restorations have been suspected of causing lichen- 
planus like reactions (Banoczy, Roed-Petersen, & Pindborg 1979), 
symptoms of pain and altered taste, and increasing the corrosion rate thus 
providing free metallic ions that may act as sensitisers of the oral mucosa. 
However no correlation has been found between high electric potentials 
between metallic contacts in the mouth and oral disease (Hugoson 1986) 
and a study investigating the metal ions present in saliva found that there 
was no correlation between oral galvanic activity and metal ions in saliva or 
burning mouth symptoms, though the study group was small (Nilner & 
Glantz 1982). Lind et al (1984) reported a case of lichen planus-like 
lesions of the oral mucosa related to corroded amalgams and suspected-that 
the corrosion of metals increased by galvanism with the cathode being a 
cobalt -chrome partial denture and the anode the amalgam restorations.
This led to mucosal sensitisation to mercury (the patient tested positive to
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mercury on cutaneous patch testing and to the lymphocyte transformation 
test) (Lind, Hurlen, & Stromme-Koppang 1984).
Rubber products used in dentistry
With the increased awareness of viral infections such as HIV and Hepatitis, 
gloves manufactured from natural rubber latex (NRL) are being increasingly 
used by healthcare personnel. Accordingly, there has been an increase in 
the reports of adverse reactions to them with the prevalence of adverse 
reactions among dentists in the UK being between seven and ten percent 
(Field 1998). NRL is also used in dental dam and orthodontic elastics and 
Type I reactions to dental dam in particular have been reported (Field et al.
1997). There are copious references in the literature regarding allergy to 
NRL and special care has to be taken with affected patients as the sequelae 
of an encounter with the allergen can be fatal (Placucci et al. 1996; Rosen et 
al. 1993). Concurrent allergy to peanut, fruits such as banana and melon 
and others associated with OAS, or a history of repeated exposure to NRL 
are all risk factors for developing NRL allergy (Field et al. 1998). Contact 
with NRL in sensitive individuals can also elicit contact dermatitis without 
the usual IgE mediated pathways (Shaffrali & Gawkrodger 1999). 
Coexistence of Types I and IV hypersensitivity reactions to NRL has been 
reported (Placucci et al. 1996).
Rubber products also contain vulcanising and antioxidising agents such as 
thiuram, carba and mercapto chemicals that have the potential to give rise to 
delayed type hypersensitivity reactions.
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Foods
“One man’s meat is another man’s poison”
Lucretius (1st century B.C.) (Avenberg & Harper 1982) 
The prevalence of food allergies appears to be on the increase in recent
years with the prevalence among an American population estimated at 1.5% 
of the general population, and 5% of children under 3 years (Sampson 
1997). In Gran Canaria, the prevalence is also estimated to be under 1.6 % 
among adults (Castillo et al. 1996), while in the UK a prevalence rate of 
1.4% has been reported in the general population (all ages) (Ranee et al.
1999). Food allergies have been implicated as a causative or complicating 
factor in many and sometimes diverse diseases such as coeliac disease, 
allergic eosinophilic gastro-enteritis, dermatitis herpetiformis (Sampson
1997), asthma (Bruijnzeel-Koomen et al. 1995) cystic fibrosis (Lucarelli et 
al. 1994) and migraine (Grant 1979). Atopic dermatitis has been linked to 
IgE mediated food allergies particularly in children (Eigenmann et al. 1998) 
though the link with food allergy in adults to atopic dermatitis was not 
shown by Castillo (Castillo et al. 1996) and is considered to be controversial 
(Wuthrich 1998).
In the area of adverse reactions to foods, the terminology used has been 
confused in the past and efforts to standardise nomenclature have been 
attempted (Bruijnzeel-Koomen et al. 1995). A summary of the 
classification given by the European Academy of Allergology and Clinical 
Immunology subcommittee is given here, to which I shall endeavour to 
adhere in this thesis.
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Adverse reactions to foods can be divided up into toxic (dose dependant and 
affect potentially all individuals) and non toxic (depend on the susceptibility 
of a certain individual). Non toxic adverse reactions to foods can be either 
immunologically mediated (food allergy) or non-immunologically mediated 
(food intolerance). Food allergy can be further subdivided into IgE- 
mediated and non-IgE-mediated reactions and food intolerance into enzyme, 
pharmacologic and undefined intolerances (Bruijnzeel-Koomen et al. 1995). 
IgE-mediated or Type I reactions are the most common reactions associated 
with food allergy, with various clinical manifestations such as itching, 
urticaria/angioedema, rhinoconjunctivitis, asthma, oral allergy syndrome, 
allergic eosinophilic gastro-enteritis and systemic anaphylaxis. The 
definition of anaphylaxis is usually regarded as, an IgE reaction involving 
three or more organs (Bruijnzeel-Koomen et al. 1995), with anaphylactic 
shock extending that definition to include a dramatic fall in blood pressure 
with its associated sequelae (Sampson 1997).
Non-IgE-mediated reactions involving Type II mechanisms have been 
implicated in a few reports of Type II antigen-antibody-dependant cytotoxic 
reactions such as antibody-dependant thrombocytopenia secondary to the 
ingestion of cows milk (Sampson 1997). Type III reactions have been 
incriminated in some patients with subjective symptoms and elevated levels 
of food antigen-antibody complexes though these levels have also been 
found in normal individuals (Sampson 1997).
Type IV hypersensitivity reactions to foods are classically seen in allergic 
contact dermatitis lesions on the hands of those who work in the food 
preparation industry with the lesions being exacerbated by ingestion of the
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offending foods (Wuthrich 1998). Treatment of food allergies is based 
around identification and complete avoidance of the offending allergen 
(Sampson 1997). In some food allergies, this is extremely difficult to do, 
due to the pervasive nature of some food stuffs . Pharmaceutical therapy 
and immunomodification by the induction of oral tolerance or 
desensitisation are controversial as they have not been documented in 
carefully controlled studies (Bruijnzeel-Koomen et al. 1995). The 
relationship between atopy and the type of milk that a subject was fed as an 
infant has been extensively investigated and efforts made to hydrolyse milk 
proteins continue to ensure that modem infant milk formulas induce less 
sensitisation to cows milk. Currently, it is considered that breast feeding 
delays the onset of atopic dermatitis and other atopic diseases and may 
moderate the severity of these diseases. Delaying the introduction of solid 
food until six months is also considered to be beneficial in allowing the 
immune system to mature before coming into contact with potentially 
sensitising food allergens.
Food Additives And Flavouring Agents
Food additives are substances added to foods that have no inherent 
nutritional value and act as preservatives, stabilisers etc. The prevalence of 
allergies to food additives in the US population has been estimated at 0.-1% 
in adults and 1% in children (Sampson 1997).
Non-immunologic contact urticaria (NICU) is a disease entity in which the 
precise mechanisms of its action are not known. Known urticariants that
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cause NICU are trans-cinnamic acid (found in many foods as a flavouring 
agent) and benzoic acid (a food additive) (Basketter & Wilhelm 1996). It 
may be that most individuals could react in this way given a high enough 
dose as in toxic reactions (Basketter & Wilhelm 1996). It is not clear what 
the exact mechanism for these reactions are; histamine and prostaglandins 
may play a role or the urticant chemical may have a direct effect on the 
dermal vasculature (Basketter & Wilhelm 1996).
Sulphites
Sulphites occur naturally in many foods and have a long history of use as 
food additives and they are also used in pharmaceuticals. Different 
chemical formulas include bisulphites and metabisulphites.
There is a large array o f symptoms attributed to the ingestion o f sulphite, 
including localised angioedema, dysphagia, contact dermatitis and urticaria. 
Reactions to sulphites are thought to be IgE mediated and they can trigger 
asthma in a small number of sensitive individuals which may be severe and 
life threatening (Taylor, Bush, & Nordlee 1991).
Monosodium glutamate
One of the most widely used food additives in the world, monosodium 
glutamate (MSG), has been used for hundreds o f years naturally occurring 
in seaweed and used extensively as a flavouring agent throughout Asia. It 
was only in 1908 that MSG was isolated from the seaweed as the active 
component. Glutamic acid is a natural component of proteins (20% of most 
proteins) and is present naturally in tomatoes and mushrooms. The so called
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Chinese restaurant syndrome was first described in 1968 -  headache, 
burning sensation, chest tightness, nausea and sweating all within hours of. 
eating a Chinese meal. The prevalence in the normal population is 
estimated at 30%! The mechanisms of these symptoms are thought to be due 
to peripheral neuroexcitatory phenomenon rather than an immune mediated 
allergy. Also asthmatic attacks have also been reported to have followed 
exposure to MSG, these are also thought to be a secondary response to the 
neurone excitation of irritant receptors in the lungs which gives rise to reflex 
bronchoconstriction (Allen 1991). There have been a few reports of 
hypersensitivity reactions of an immediate IgE mediated type (Bosso & 
Simon 1991), and recurrent angioedema of the face and extremities was 
reported in a 50 year old man following ingestion of MSG (Squire 1987).
Tartrazine
One of the coal tar derived azo dyes and colourings available for use in 
foods, these have had great interest in the lay press in recent years in 
particular with reference to immediate hypersensitivity reactions and 
hyperactivity in children. Most of the studies making these claims are 
defective in design and adverse reactions to azo dyes are extremely rare 
(Stevenson 1991) though one patient has been reported as having a fixed 
drug eruption due to tartrazine (Orchard & Varigos 1997).
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Benzoates and parabens
Benzoic acid and sodium benzoate are grouped as benzoates and the methyl, 
n-propyl, n-butyl and n-heptyl esters of parahydroxybenzoic acid are 
grouped together as parabens. Benzoates are widely used as antimycotic 
and antibacterial preservatives in food and beverages while parabens are 
used extensively in cosmetic and pharmaceutical preparations as well as in a 
limited number of food stuffs. The quantities of benzoates consumed world 
wide (10 million pounds) per year indicates that these are one of the most 
commonly used food additives. Incidences of benzoate hypersensitivity in 
patients with chronic urticaria have been suggested from 3% to 60% after 
oral provocation tests. Again many of these studies had no control groups 
and did not use standardised, double blind, cross over trial protocols. In 
studies with more stringent design parameters, the incidence is reported to 
be in the region of 1 -20% of patients with chronic urticaria. Benzoic acid 
can also produce contact urticaria and contact dermatitis (Ortolani et al.
1999). Among asthmatics the incidence of benzoate induced asthma is 
estimated at 1-4% (Jacobsen 1991), and incidences of anaphylaxis are rare 
(Ortolani et al. 1999). Benzoic acid is one of the substances that is known 
to effect NICU in some individuals and in a study carried out among 200 
unselected volunteers, 157 subjects had a visible reaction to application of 
500mM benzoic acid in petrolatum though in many cases this was barely 
perceptible (Basketter & Wilhelm 1996). The mechanism for action in most 
sensitive patients is thought to be not mediated by histamine as 
antihistamines have little effect (Lahti 1980).
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Sodium benzoate used as a preservative in a toothpaste has been reported to 
have caused perioral contact urticaria in a five year old boy (Munoz et a l . . 
1996).
The effect on allergic contact dermatitis (ACD) lesions being exacerbated 
by oral challenge with the offending allergen (in this case parabens) was 
investigated in 14 patients using a placebo controlled oral challenge (not 
stated whether this was carried out single or double blind). Two patients 
experienced specific aggravations of their ACD sites in response to oral 
challenge with parabens but not to the placebo, two further patients had non 
specific reactions to parabens and eleven had no reactions to either placebo 
or parabens. The two patients with specific reactions showed no 
improvement on a parabens free diet for one to two months. The authors 
concluded that oral challenge was not useful as a test procedure for ACD 
and the lack of response to elimination diet cast some doubt on the 
significance of the result (Veien, Hattel, & Laurberg 1996a)
Cinnamon
Cinnamaldehyde and cinnamyl alcohol are related flavouring agents used in 
a wide variety of foods. Cinnamaldehyde can act as a hapten and cause 
contact allergy and urticaria under some conditions but has also been shown 
to cause irritant positive reactions too (Taylor & Dormedy 1998).
Balsam of Peru
Vanillin, the fragrant constituent of vanilla, is found in Balsam of Peru and 
as a constituent of many perfumes and cosmetics (Ferguson & Beck 1995).
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Peppermint flavours
Peppermint oil constituents are commonly found in confectionery as well as 
in the previously mentioned oral preparations and have been reported as 
causing intraoral oedema after chewing mint flavoured gum in sensitive 
people (Sugarman 1950).
Cosmetics
Cosmetics used near the oral cavity are lipsticks, lip-salves, foundation and 
nail varnishes (in nail biters). Parabens have been often implicated in 
reactions to cosmetics given that they are a common preservative used in 
many cosmetic preparations and can cause severe contact dermatitis in 
susceptible individuals (Bosso & Simon 1991). Flavouring agents, 
antioxidants, dyes and colouring agents are also involved in the manufacture 
of cosmetics and there are reports of adverse reactions from each of those 
groups (Giordano-Labadie, Schwarze, & Bazex 2000; Maibach 1986; 
Ophaswongse & Maibach 1995). There are reports of allergic reactions to 
vanilla/Balsam of Peru in patients using lip salves (Downs, Lear, & Sansom 
1998; Ferguson & Beck 1995).
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1.1.3.2.Allergy Tests
The ‘gold standard’ for allergy testing is the double blind placebo control 
(DBPC) challenge (Bruijnzeel-Koomenet al. 1995; Sampson 1997).
Tests for IgE-mediated allergic reactions include in vivo methods such as 
skin prick tests, scratch tests and intradermal skin tests. Variations of the 
skin prick test include prick-by-prick testing to food stuffs where the lancet 
is used to prick the fruit or vegetable and then the same lancet is used on the 
patient (Antico 1996). This method is of particular use in patients suffering 
from oral allergy syndrome where the allergens implicated are particularly 
labile and the use of fresh foods give a more reliable result for the individual 
patient than the commercial preparations (Bock 2000). The scratch test 
offers no advantage over the skin prick test and is more technically difficult 
to perform (Bruijnzeel-Koomen et al. 1995). There is thought to be no place 
for intradermal testing since it may provoke severe systemic reactions and 
introduce a physical ‘wheal’ that may mimic a positive reaction (Williams 
& Bock 1999). Suspected food allergens have been tested by the use of a 
labial food challenge (food placed on the lower labial mucosa for 2 minutes 
and then removed) (Ranee et al. 1999) though this type of test requires 
further research (Bock 2000).
In vitro testing has improved over the years and will no doubt continue to 
provide more accurate diagnostic information that will aid in the 
investigations of suspected allergies and may reduce the need for time 
consuming DBPC oral challenges for foods and additives (Bock 2000).
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. The mainstay of in vitro allergy testing has been radio allergosorbent tests 
(RAST) that give the specific IgE content of serum to a number of food 
allergens. The test is only as useful as the allergens that can be used; egg, 
milk, pollens and mite allergens have been identified and reasonable 
extracts compounded. A newer test that utilises fluorescein instead of a 
radioisotope as in the RAST, has been developed in recent years. The CAP 
system fluorescein-enzyme immunoassay quantifies the reaction result and 
serves as a predictor for positive DBPC food challenge (Eigenmann et al.
1998).
Testing in non-IgE-mediated reactions utilises various cutaneous patch 
testing techniques, usually closed patch testing (see next paragraph), though 
open testing and rub testing may also be used and all three may be used to 
detect allergens causing contact urticaria and contact urticaria syndrome 
(Wuthrich 1998).
Patch testing
The first datable skin test carried out under the auspices of a physician was 
by Pierre Borel in 1656, who confirmed a patient’s hypersensitivity to egg 
by applying some to his skin, duly raising a blister (Avenberg & Harper 
1982).
Patch testing as an investigative tool has developed alongside the increasing 
awareness of contact sensitivity over the last 100 years. Allergic contact 
dermatitis was first described in 1817 (Hjorth 1989) where eczema caused 
by exposure to mercury was demonstrated. Patch testing was initially used 
to try and treat mercury allergy (Jadassohn 1895) in 1896, and then
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introduced as a diagnostic method in 1911 (Bloch 1911). As the techniques 
were expanded and the tests more widely used, the need to standardise the . 
procedures, allergen vehicles and the types and concentrations of allergens 
became more obvious. In 1961, the Nordic Dermatological Societies 
decided to embark upon a joint Scandinavian study to develop a standard 
series of allergens and a standard technique. From this the European 
Standard Series was developed, though this has been modified over the 
years as contact sensitivities change and new allergens become important 
(Andersen et al. 1988; Bruynzeel et al. 1995; Gollhausen et al. 1988; 
ICDRG 1984). The effectiveness of the use of the European Standard 
Series was tested in 1992 in an international, multicenter study. It was 
found to detect contact sensitivities in, between 77% and 95% of the 
patients tested (Menne et al. 1992).
Techniques of application of tests varys between the Al test ™*, Finn 
chambers ™ and the Leukotest™ though other types are available. In 
these the amount of test substance applied may vary between observers and 
even between the same observer from application to application (Antoine & 
Lachapelle 1988; Lachapelle & Antoine 1989). As this variation may result 
in false negatives if too little is used, or sensitisation or irritant reactions if 
too much is used, newer testing systems have been developed where the test 
strip is supplied with a ready dispensed, exact amount of test substance 
already in place. Examples of these are the Epiquick™4 and the TRUE test
1 Imeco, Stockholm, Sweden.
2 Epitest, Hyryla, Finland.
3 Beiersdorf, Hamburg, Germany
4 Hermal Chemie, Reinbek, Germany
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™5. Open testing where the allergen is applied in a low concentration to a 
specified, non occluded area, often repeatedly, is also carried out.
Patch testing has been used by clinicians to ascertain the cause or 
contributing factors in the pathogenesis of various diseases. Though the 
reading of patch tests depends upon a subjective assessment by the observer, 
the results have been relevant to many patients (Podmore, Burrows, & 
Bingham 1984). Contact dermatitis remains the major disease investigated 
in this way though many other (mainly dermatological) disorders have been 
usefully investigated by patch testing, and the patients helped by avoidance 
of the causative allergens.
Patch testing attempts to elicit a delayed hypersensitivity response from 
sensitised patients. Patch testing is usually carried out to identify exogenous 
allergens to which the patient is sensitive. The allergens may be in the 
environment, or in pharmacological or other preparations applied to the skin 
but patch testing can occasionally be used successfully in systemically 
administered drug sensitivities (Felix & Comaish 1974; Houwerzijl et al. 
1977; Quirce et al. 1991). Testing in this manner is also used for reactions 
to foods and food additives in cases where the patient has no obvious skin 
symptoms (Bock 2000).
5 Pharmacia, Uppsala, Sweden.
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Patch testing is useful where a food or drug (Calkin & Maibach 1993) 
allergy is suspected provided that there are criteria in place to establish 
scientific validity. Suitable criteria are:
• History of food or drug exposure.
• The clinical morphology of the reaction.
• Positive patch test.
• Appropriate controls.
• Resolution when food or drug is discontinued.
• Recurrence of symptoms and signs upon allergen rechallenge.
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1.2. Oral Lichenoid Eruption
1.2.1. Introduction and Historical Review
Oral lichenoid eruptions (OLE) are a common group of oral diseases that 
usually present with a clinical appearance of a lichenoid (i.e. lacy) pattern 
similar to the Wickham’s striae found in cutaneous lichen planus an 
example of which is shown in Fig 1, (Boyd & Neldner 1991; Kramer et al. 
1978). The term is designed to be descriptive only and does not attempt to 
give a clue to the aetiology of such conditions. OLE is a widely 
encompassing term that will include those diseases elsewhere termed; oral 
lichen planus (OLP), oral lichenoid reactions, oral lichenoid drug eruptions, 
oral contact lesions and oral delayed hypersensitivity reactions. Many 
authors use the term ‘oral lichen planus’ to include ‘lichenoid reactions’ and 
some suggest that the clinical and histological criteria used to define what 
most call OLP, may in fact be describing several different pathological 
entities (Holmstrup et al 1988). Thus I feel ‘OLE’ should be used as the 
umbrella term and ‘OLP’ kept separate from ‘lichenoid reactions’ due to the 
differing aetiologies. Eisenberg and Kritchkoff 1992 also prefer to keep the 
diagnosis of OLP only to a restricted pattern of clinical features or to within 
strict histological parameters when the clinical features are more varied. 
These guidelines specifically excluding lichenoid reactions (Eisenberg & 
Krutchkoff 1992). Other authors who differentiate OLP from other oral 
lichenoid reactions include Pecegueiro et al 1999, Scully et al 1998 and 
Bratel et al 1998.
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Fig. 1. Photograph O f Cutaneous Lichen Planus Affecting The Flexor
Surface O f The Forearm And Showing The Characteristic 
W ickham’s Striae
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Erasmus Wilson described cutaneous lichen planus in 1869 (Wilson 1869) and 
early remedies are to be found in medical text books dating back to 1904 where 
it was thought that appropriate treatment would consist of good food and cod- 
liver oil, and that “arsenic is of considerable value” (Stevens 1904). Early 
accounts of intraoral OLP are found in dermatology textbooks where it is stated 
that -  “lichen planus affecting the mucous membranes is very obstinate and 
may last for years” (McKenna 1937). Lichen planus is a common 
mucocutaneous disease estimated to affect 0.9 -1.2% of the general 
population with an average disease duration of 8-18 months. In contrast, 
oral lesions can last for 20 years or more. Of those with cutaneous lesions 
as the primary sign, about 65% also have oral lesions (Strauss, Fattore, & 
Soltani 1989). OLP however more often occur on their own and reports of 
the percentage of OLP patients who have also cutaneous involvement range 
from 16% to 44% (Andreasen 1968; Silverman et al. 1991; Strauss, Fattore, 
& Soltani 1989; Vincent et al. 1990).
Controversy exists over whether OLE should be classified as a precancerous 
lesion. In 1978, the WHO Collaborating Centre for Oral Precancerous 
Lesions published a description of the lesions and diseases that they were 
considering as those that could be precancerous (Kramer et al. 1978). OLE 
was included though it was stated that there was “considerable uncertainty” 
about the frequency of malignant transformation in it. Eisenberg and 
Krutchkoff reviewed the literature and concluded that the reported 
malignant transformation of OLE figures were artificially high due to non 
consideration of carcinogen exposure and errors in missing 
histopathological signs of early dysplasia (Eisenberg & Krutchkoff 1992).
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In a prospective Danish study of 611 OLE patients with well defined criteria 
for inclusion, 9 (1.5%) developed squamous cell carcinomas (SCC). The . 
patients had all been followed up for at least 4.9 years prior to developing 
the SCC with no histological evidence of epithelial dysplasia on the biopsy 
taken at initial presentation. The authors calculated the estimated figure for 
development of oral SCC in the general population which was 0.18 (taking 
into consideration the age and sex of the patients) and found that there was a 
50 fold increase over the expected oral SCC rate among the OLE patients 
(Holmstrup et al. 1988). There has also been a report of an increased 
incidence of oral SCC in patients with cutaneous lichen planus (Holmstrup 
1992). Silverman and co-workers have carried out three prospective 
investigations of OLE and found that malignant transformation occurred in
1.2, 2.3 and 3.2% of 570, 214 and 95 patients (Silverman et al. 1991; 
Silverman & Bahl 1997; Silverman, Gorsky, & Lozada-Nur 1985). It 
should be noted that all but 19 of the 879 patients had mucosal biopsies and 
that the studies were not designed specifically to investigate SCC but to 
describe the clinical characteristics, patient profiles and treatment outcomes 
of OLE . A recent publication calls for stricter designed prospective studies 
to investigate the true incidence of SCC occurring in OLE patients bearing 
in mind other factors such as tobacco usage, alcohol consumption, diet, 
socio-economic status, and race (Lozada-Nur 2000).
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1.2.2. Classification and Prevalence
OLE can be classified according to site and clinical appearance 
(Baskerl981; Bays, Hamerlinck, & Cormane 1977). Andreason identified 
six different types: reticular, atrophic, plaque-like, bullous, erosive and 
ulcerated (Andreasen 1968). These are generally accepted though different 
authors may combine two or three of the classes into one; Silverman and co­
workers use reticular, atrophic and erosive designations, while Bagan- 
Sebastian et al and Axell used only two clinical classifications; those with 
exclusively white reticular lesions and those with atrophic or erosive lesions 
(Axell & Rundquist 1987; Bagan-Sebastian et al. 1992; Silverman, Gorsky, 
& Lozada-Nur 1985). The lesions may be localised or generalised, 
unilateral or bilateral. Bilateral lesions are thought to be more likely to be 
idiopathic OLP whilst unilateral lesions are thought to be more often 
lichenoid eruptions appearing secondary to identifiable causes such as drug 
reactions. The lesions may be limited to the area adjacent to a possible 
cause such as an old corroded amalgam restoration or may be found as it 
were ad hoc in the mucosa (Becker & Schuppan 1995; Bergdahl, Anneroth, 
& Anneroth 1994; Bergman 1990).
The reported prevalence of OLE among the general population is difficult to 
estimate as most studies have been based on referred groups of patients and 
do not necessarily give, or are not able to estimate, the population using that 
referral centre. Most of the prevalence studies have been carried out in 
India (Axell & Rundquist 1987). For a list of the reported prevalences of 
OLP, see Table 1. In the Indian subcontinent the estimated prevalences
have ranged between 0.02 and 1.5%, while in South East Asia they have 
been reported as higher at 2.1 -3.8%. Few surveys have been carried out 
among Caucasian populations, one was in Sweden which yielded a 
prevalence rate of 1.9% (Axell & Rundquist 1987). Most authors consider 
the prevalence rate to be in the region of 1-2% (Savin 1991; Strauss, Fattore, 
& Soltani 1989; Vincent et al. 1990).
For reported age, sex, type and site, see Table 2.
There is a female predilection of approximately 2:1 and the average age of 
disease onset is thought to be in the fifth and sixth decades. A few studies 
have found that males present on average ten years earlier (Lacy, Reade, & 
Hay 1983;)Andreasen 1968), though one investigation reported their highest 
prevalence of OLP to be among males in the 65-74 age band (3.8%) and 
females in the 55-64 age band (3.6%) (Axell & Rundquist 1987).
OLE is not site-specific in the oral cavity though most patients (approx. 
90%) have lesions affecting their buccal mucosa (Scully et al. 1998). The 
tongue is the next most common site with usually between 30 and 50 % of 
OLE patients experiencing tongue lesions (see Table 2), the alveolar ridges 
are affected less commonly though Silverman consistently found that this 
site was more prevalent than the tongue (Silverman et al. 1991; Silverman & 
Bahl 1997; Silverman, Gorsky, & Lozada-Nur 1985). The labial mucosa 
and other sites are less commonly affected. Gingival lesions may present a 
desquamative appearance and the term desquamative gingivitis is used, see 
section 1.7.2.
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Table 1. Reported Prevalences o f Oral Lichen Planus
KTTKmHi
Pindborg
1972
Southern India 7,639 Over 15 years 
o f age
1.5%
Axell
1987
Sweden 20,333 Invited to 
participate, 
>15 years
1.9
Axell
1990
Thailand 234 Consecutive
dental
outpatients
3.8%
Axell
1990
Malaysia 233 Consecutive
dental
outpatients
2.1%
Mehta
1971
India (rural) 50,915 > 15 years 0.3%
Zachariah
1966
India (urban) 5,000 Consecutive 
admission 
clinic attenders
0.4%
Pindborg
1965
India (Uttar 
Pradesh)
10,000 Consecutive 
dental clinic 
attenders
0.19%
Pindborg
1965
India
(Bombay)
10,000 Consecutive 
dental clinic 
attenders
0.22%
Pindborg
1966
India
(Bangalore)
10,000 Consecutive 
dental clinic 
attenders
0.02%
(Pindborg et al. 1972 ; Axell & Rundquist 1987 ; Axell et al. 1990)
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Table 2. Age. Sex, Type and Site o f  Lesions in Patients With OLP
1 m ruTl I
Andreasen
1968
[115]
65.2 65 57.4 42.6 99 38.3 "
Axell
1987
[4101
[47.8%
were
aged
45-64]
62.4 77.3* 3 2 . / 92 28.8 13.2
Bagan-
Sebastian
1992
[205]
Approx
51
80 28 148 89.7 50.2 27.3
Pindborg
1972
[118]
[61%
were
aged
35-54]
54.2 84.3 5.2
Silverman
1985
[570]
52
[16-86]
67 31.7 68.2 87 45 60
Silverman
1991
[214]
54
[21-83]
71 28.5 71.4 86 46 68
Silverman
1997
[95]
60F
56M
[33-92]
69 28.4 71.7 79 53 60
Thom
1988
[611]
53 66.9 92* 44*
Vincent
1990
[100]
64.2
[18-90]
76 78 44 42
* Reticular only
# Atrophic only
(Andreasen 1968; Axell & Rundquist 1987; Bagan-Sebastian et al. 1992; 
Pindborg et al. 1972; Silverman et al. 1991; Silverman & Bahl 1997; 
Silverman, Gorsky, & Lozada-Nur 1985; Thorn et al. 1988; Vincent et al. 
1990)
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The preponderances of the type of lesions found in OLE are varied between 
authors, and this may reflect variations in how rigidly the criteria were 
applied e.g. any hint of erythema should move a patient from ‘white only’ 
lesions to the ‘red lesions’ bracket. The variations may, to a certain extent, 
be accounted for by the selection bias of the patient groups. Axell 
summoned 30,00 of the general population for examination, and found an 
approximately 2:1 ratio o f ‘white’ only to ‘red’ lesions (Axell & Rundquist
1987), whereas Silverman et al found the opposite ratio of 1:2 in their study 
of referred patients (Silverman et al. 1991). Patients with ‘white’ only 
lesions are more likely to be asymptomatic and therefore never present as 
patients to a specialist clinic, whereas patients with erythema, erosions or 
bullae will be likely to experience symptoms ranging from soreness to 
severe pain (Thom et al. 1988) and thus present for treatment.
1.2.3. Aetiology, Features and Diagnosis
The aetiology of oral lichen planus is by definition unknown and once an 
allergic or traumatic or infectious cause has been found, the diagnosis is no 
longer OLP. ‘Lichenoid reactions’ is the name given to those lesions that 
have an identifiable allergic or drug induced aetiology (Pecegueiro et al. 
1999; Scully et al. 1998). Idiopathic LP is the term that should be used for 
lesions of unknown aetiology (Femiano et al. 1999).
Medical conditions such as diabetes, chronic liver disease, hypertension and 
anxiety have all been implicated in the aetiology of OLE. Drugs that have 
been suggested as contributing to lichenoid reactions include oral
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hypoglycaemics, penicillamine and anti-hypertensive drugs which may have 
clouded the issue of whether diseases, or the drugs being taken as treatment, 
cause lichenoid reactions (Scully et al. 1998).
Lacy et al found that 6% of their 108 OLE patients were also diabetic 
though they did not specify what drugs the patients were taking (Lacy, 
Reade, & Hay 1983). van Dis and Parks identified no difference in the 
prevalence of OLE between 273 patients with diabetes mellitus, and age, 
sex and race matched controls, taking into account the medications both 
controls and disease subjects were taking (van Dis & Parks 1995). In a 
larger study of 1600 diabetes patients and 617 healthy controls the authors 
also found no significant increase in the prevalence of OLE in the diabetic 
cohort, 1% of diabetic patients and none of the control subjects had clinical 
evidence of OLE (Albrecht et al. 1992). An association between chronic 
liver disease (CLD) and erosive OLE was found by Bagan et al who also 
noted a higher incidence of tongue lesions in the OLE patients with CLD 
than OLE alone (Bagan et al. 1994). Primary biliary cirrhosis has been 
linked with OLE as well (Strauss, Fattore, & Soltani 1989). Hepatitis C 
Virus (HCV) has been associated with OLE and recent studies showed that 
this association was not due to co-existent Hepatitis G Virus infection (Lodi 
et al. 1999).
Other viruses such as the Epstein Barr Virus (EBV) have been studied and 
Pedersen found that OLE was associated with an increased humoral immune 
response to EBV (Pedersen 1996). A Spanish study found that no 
relationship appeared to exist between OLE and the Human
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Immunodeficiency Virus (HIV) (Ceballos-Salobrena, Aguirre-Urizar, & 
Bagan-Sebastian 1996).
Candidal infections have been found in a number of OLE patients, 25% of 
patients in one study (Vincent et al. 1990), but there was no difference in the 
cell mediated immune response to an intradermal injection of Candida 
albicans of OLE patients when compared to a control group (Simark- 
Mattsson et al. 1999). Silverman et al found no correlations with candidal 
infection and OLE (Silverman, Gorsky, & Lozada-Nur 1985).
Coeliac disease was not found to be commonly associated with OLE though 
one patient has been reported (Scully, Porter, & Eveson 1993).
The presence of a sub epithelial band of T lymphocytes in histological 
sections of OLE supports the possibility of the involvement of immune 
mechanisms in the pathogenesis of OLE. Many authors consider that a cell 
mediated hypersensitivity reaction to an exogenous drug or environmental 
allergen is responsible for the clinical entity of OLE , while others have 
suggested an auto-immune basis (Strauss, Fattore, & Soltani 1989;
Sugarman et al. 1993). These will be further explored in sections 1.2.4 and 
1.2.5.
The drugs that have been suggested as contributing to cutaneous lichenoid 
eruptions are captopril (Phillips et al. 1994), tetracycline (Fitzpatrick 1963), 
labatalol (Grange & Wilson Jones 1978) and methyldopa (Hay & Reade 
1978; Holt & Navaratnam 1974). Other chemicals that are not drug related, 
such as para-phenylenediamine (black hair dye) are also capable of causing 
cutaneous lichenoid eruptions (Sharma et al. 1999).
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Fenclofenac (Ferguson, Wiesenfeld, & MacDonald 1984) has been reported 
as contributing to the pathogenesis of OLE. See Table 3 for other types of. 
drugs that have been implicated.
In a prospective study, in which the drugs that 49 patients with OLE took 
were noted, patients with erosive forms of OLE were nearly ten times more 
likely to be ingesting NSAIDs than patients with non-erosive OLE 
(Robertson & Wray 1992). Robertson and Wray also found that there was 
no increase in oral hypoglycaemic or psychotropic medication usage in the 
OLE group compared to a control group with non-OLE oral keratoses which 
does not contribute to the suggestion of a significant link with either 
diabetes or stress (Robertson & Wray 1992).
Stress was found to be an aggravating factor by Ostman et al in that they 
found that more of their OLE patients had lifestyle reasons to have more 
stress -  i.e. more were divorced/widowed (Ostman et al. 1996). The role of 
stress in the aetiology of OLE has not been proven (Boyd & Neldner 1991) 
though an increase in both depressed mood and levels of circulating 
memory CD4+ cells was found in patients with erosive compared to non- 
erosive OLP compared to controls (Hietanen et al. 1987).
Tobacco usage in the form of cigarette smoking has been negatively 
associated with OLE (Axell & Rundquist 1987), while subjects who chewed 
tobacco in the form of a betel quid had a higher prevalence of OLE lesions 
related to the site where the tobacco was chewed/placed (Daftary et al.
1980).
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Table 3. Drugs Implicated In Lichenoid Drug Reactions
Drug Group Drug
Antihypertensive Methyldopa
Oxyprenolol
Practolol
Propanolol
Captopril
Labetalol
Antiprotozoal Chloroquine
Dapsone
Pyrimethamine
Quinacrine
Mepacrine
Antimicrobial Ketoconazole 
Para-Aminosalicylic Acid 
Tetracycline
Metals Bismuth/Arsenic
Gold
NSAID Fenclofenac 
Phenylbutazone 
Other Nsaids
Hypoglycaemic Tolbutamide
Chlorpropamide
Antirheumatics Penicillamine
Sulphasalazine
Antipsychotics Phenothiazines
Lithium
Miscellaneous Allopurinol
Amiphenazole
Carbamazepine
Cyanamide
Levamisole
Lorazepam
Metopromazine
Pyritinol
Thiazides
Thyroxine
Triprolidine
Based on the tables in (McCartan 1997) and (Scully & Cawson 1993)
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1.2.3.1.0ther Diseases In Relation With OLE
Graft-versus-host-disease (GVHD) is an immunologically mediated disease 
that frequently complicates the transplant of allogeneic bone marrow 
(Nakamura et al. 1996). It is caused by immunologically active T cells 
being introduced into an immunocompromised, genetically disparate host 
(Mattsson et al. 1992). The clinical picture of chronic GVHD resembles 
that of spontaneously occurring autoimmune diseases such as; Sjogren’s 
syndrome, primary biliary cirrhosis, scleroderma, systemic lupus 
erythematosus and dermatomyositis (Nakamura et al. 1996). A study 
measuring the lymphocytic infiltrate in chronic GVHD found that the 
density of the infiltrate related to the stage of the disease process (Nakamura 
et al. 1996). Historically the first link of OLE with an immune aetiology 
was the similarity of its histological appearance to GVHD (Strauss, Fattore, 
& Soltani 1989). Oral lesions of GVHD are clinically and 
histopathologically similar to those of OLE (Fujiwara et al. 1996; Walsh et 
al. 1990).
Lupus erythematosus and cutaneous LP have been described occurring 
together in what is known as the overlap syndrome (Boyd & Neldner 1991) 
and lichenoid oral mucosal lesions have been described as early 
manifestations of mixed connective tissue disease (Varga, Field, & 
Tyldesley 1990).
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1.2.3.2.Histopathological Features of OLE Lesions
Some authors have found that the clinical appearance of OLE concurs with 
that of the histological appearance in 97% cases (Axell & Rundquist 1987) 
though Ostman found concurrence in only 65% cases (Ostman, Anneroth, & 
Skoglund 1994). However, while both the clinical appearance and the 
histological appearance are characteristic of OLE, they are not diagnostic 
(Holmstrup et al. 1988; Kramer et al. 1978) and the diagnosis has to be 
cautiously made. In some cases other techniques such as direct 
immunofluorescence or immunohistochemistry should be utilised (Boisnic 
et al. 1990; Ng, Ng, & Chng 1998). In cases where the gingival tissues are 
the only ones involved, the clinical appearance may be similar to that seen 
in linear IgA disease (Cohen et al. 1999), leukoplakia (Banoczy, Roed- 
Petersen, & Pindborg 1979), lupus erythematosus and lichenoid dysplasia 
(Eisenberg & Krutchkoff 1992). The histological picture may be also 
confused with linear IgA disease and bears striking resemblance in some 
cases to epithelial dysplasia (Cohen et al. 1999; Vincent et al. 1990).
Biopsy specimens of OLE with a histological appearance consistent with the 
clinical diagnosis show a number of features. The most characteristic 
features of OLE are the subepithelial band of lymphocytes and the basal cell 
degeneration (Eisenberg & Krutchkoff 1992; Sugarman et al. 1993). Most 
authors also include as characteristic features an increased keratinohyalin 
granular layer and hyperkeratinisation (Farthing & Cruchley 1989; Hedberg, 
Ng, & Hunter 1986). Some authors have noted other features such as: early 
appearance and increased numbers of Langerhan’s cells (Conklin &
58
Blasberg 1994; Lombardi, Hauser, & Budtz Jorgensen 1993), irregular 
acanthosis and an eosinophilic (fibrin) band adjacent to the basement 
membrane (Vincent et al. 1990) and apoptotic cells in the epithelium 
(Kramer et al. 1978). Saw-toothed rete ridges are regarded by some as 
characteristic features (Eisenberg & Krutchkoff 1992), but they are more 
commonly seen in cutaneous lichen planus than in the oral mucosa (Kramer 
et al. 1978).
A significant and positive correlation between the severity of the basal cell 
liquefaction and the density of the mononuclear infiltrate has been 
demonstrated in a study of the histology of specimens of 112 patients with 
OLE (Hedberg, Ng, & Hunter 1986).
The presence of parakeratosis is considered by some authors as one of the 
characteristic features (Eisenberg & Krutchkoff 1992) and Hedberg et al 
identified this in 93% of OLE sections examined (Hedberg, Ng, & Hunter 
1986), though most would accept abnormal keratinisation with either ortho- 
or para-keratosis (Kramer et al. 1978).
Apoptotic cells are those which are undergoing programmed cell death, 
which may be physiological or pathological (Lindberg 1982). This process 
is extremely rapid and is estimated to take about three hours (Bloor et al.
1999). On histological examination, they appear with chromatin 
condensation at the periphery of the nucleus, a uniformly eosinophilic 
cytoplasm, nuclear fragmentation and pyknosis and nucleolar disintegration. 
The numbers of apoptotic cells have been found to be increased in sections 
of OLE tissue compared to normal oral mucosa and appear to be related to 
the inflammatory infiltrate (Bloor et al. 1999). They are probably related to
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the Civatte, cytoid or colloid bodies often associated with OLE though these 
lack any nuclear fragments (Bloor et al. 1999; Kramer et al. 1978; Oliver, 
Winkelmann, & Muller 1989).
60
1.2.4. Pathogenesis
Though OLE has an as yet uncertain aetiology the presence of T 
lymphocytes in the superficial dermis indicates an aetiology originating in 
the immune system. Indeed the histopathology o f Type IV hypersensitivity 
reactions such as contact dermatitis lesions, show a remarkable similarity to 
those of OLE (Conklin & Blasbergl994; Miller, Gould, & Bernstein 1992; 
Walsh etal. 1990).
1.2.4.1.Immune Pathogenesis
Studies investigating HLA types have identified genetic characteristics 
among different people groups that support an autoimmune mechanism in 
various diseases. HLA phenotypes vary considerably from patients of 
different genetic background and among patients with different types of 
disease.
HLA-DR antigens have been identified on the keratinocytes of OLE patients 
suggesting a role for antigen presenting capabilities of these keratinocytes 
and thus cell mediated immunity (Mattsson et al. 1992; Takeuchi et al.
1988). HLD-DR expression is thought to be induced by the action of 
interferon-y, a cytokine produced by activated lymphocytes (Farthing, 
Matear, & Cruchley 1990). As has been stated previously Langerhan’s cells 
have been found in increased numbers in OLE lesions (Boisnic et al. 1990). 
However, Farthing et al found that there was an increase in the activity but
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not numbers of Langerhan’s cells in OLE lesions when compared to normal 
controls (Farthing, Matear, & Cruchley 1990).
Recent publications have stressed that the pathogenesis of OLE is basically 
an immune reaction directed against the basal epithelial cells which is 
mediated by the cellular infiltrate composed mainly of T lymphocytes 
(Femiano et al. 1999; Walton, Thornhill, & Farthing 1996). The cells in the 
inflammatory infiltrate have been identified as mainly T lymphocytes and 
these have been isolated into specific T cell populations; T4 and T8 (Boisnic 
et al. 1990; Strauss, Fattore, & Soltani 1989). It is suggested that diverse 
exogenous agents upregulate the expression of proteins such as heat shock 
protein (HSP) by keratinocytes. Cytotoxic T lymphocytes then react against 
these activated keratinocytes and cause the tissue destruction (Sugarman et 
al. 1995). Keratinocytes in OLE have also been shown to produce more 
lymphocyte-chemotactic factors than those in normal oral mucosa 
(Yamammoto et al. 1994). However, some authors suggest that the T cells 
autoimmune reaction might not be primarily targeted towards the 
keratinocytes but to an unknown antigen in the epithelium (Becker & 
Schuppan 1995).
Mast cells are found in increased numbers in OLE (2-3 times that of normal 
oral mucosa), particularly in the layer immediately beneath the basal cell 
layer (Zhao et al. 1997) and their role is thought to be that of influencing the 
vascular endothelium (Zhao, Savage, & Walsh 1998). They may effect this 
via mast cell - nerve interactions as these have also been found in increased 
numbers in OLE tissues compared to normal oral mucosa (Zhao et al. 1997).
62
Though cell mediated immunity plays the major role in the pathogenesis of 
OLE, humoral immunity is involved. Anti-nuclear antibodies have been 
identified in both OLE and GVHD patients and anti-basal cell antibodies 
have been isolated in OLE patients (Sugarman et al. 1993; Sun et al. 1994). 
It has been postulated that the humoral response is a secondary event, after 
the basal layer has been damaged (Hedberg, Ng, & Hunter 1986).
It is most likely that a combined Type IV and III hypersensitivity reaction 
takes place in response to a locally released mucosal or epithelial antigen 
(Pedersen & Klausen 1984).
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1.2.5. Role Of Allergy
1.2.5.1.General
It is considered that exogenous stimuli are capable of inducing changes in 
the skin or mucosa that make epithelial components antigenic, though no 
specific LP-antigen has been identified as yet (Pedersen & Klausen 1984). 
In cases where an allergen has been identified, it is likely that this antigenic 
stimulus is enough to promote the lesion (Hedberg, Ng, & Hunter 1986). 
Yiannias et al found in a recent study that 40% of patients with OLE who 
were referred for patch testing (25% of all OLP patients attending their 
clinic), had a clinically relevant positive reaction upon patch testing 
(Yiannias et al. 2000). Todd et al found a similar percentage (39.6%) of 
clinically relevant reactions in their study of 53 patients with OLE (Todd et 
al. 1990). The common allergens identified among these groups were, gold 
derivatives, mercury compounds, silver, nickel, acrylic resin monomer, 
vanillin, cinnamic aldehyde, fragrance mix, balsam of Peru, benzoic acid, 
rubber chemicals and colophony (Todd et al. 1990; Yiannias et al. 2000). 
Benzoic acid has been held responsible for causing OLE (de Groot, 
Weyland, & Nater 1994) as have metals used in dentistry such as cobalt, 
palladium and gold (Koch & Bahmer 1999). The role of mercury in 
amalgam in the aetiology of OLE is covered in the next section.
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I.2.5.2. Mercury
Mercury in amalgam has been a cause for concern regarding its well known 
toxic properties and the effects on the body have been well documented as 
well as being a topic for scaremongering and media hype to a certain extent 
(Ziff & Ziff 1995). It has been established that mercury is taken up by 
lesional (lichenoid) oral mucosa and that it can also be found in intact oral 
epithelium (Bolewska et al. 1990b). Its allergy sensitising potential has 
come under scrutiny in more recent times and it is now fairly established 
that hypersensitivity to mercury and mercuric salts is responsible for 
causing lichenoid reactions in the mouth in some individuals (Finne, 
Goransson, & Winckler 1982). Other symptoms that have been reported in 
and around the oral cavity in relation to mercury hypersensitivity are, 
perioral eczema, aphthous ulceration, gingivitis and burning sensations of 
the mouth (Brehler et al. 1993).
Hypersensitivity to metallic mercury usually manifests as a localised, Type 
IV delayed hypersensitivity reaction and is uncommon (Eley & Cox 1993). 
Some authors deny that it occurs at all, and state that allergy to mercury 
causes no intraoral problems in patients with amalgam restorations in their 
teeth even in those patients with demonstrable sensitisation to mercury 
(Cawson & Odell 1998). Old and corroded amalgams seem to be 
responsible for more allergic reactions than newly placed restorations, 
though once a patient is sensitised, they may even react to the amalgam in 
the hours and days following dental treatment using amalgam (Bleiker & 
English 1998; McGivem et al. 2000). Rarely a more acute and generalised
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reaction may occur involving pruritus and an urticarial rash within hours of 
exposure to mercury (McGivem et al. 2000).
There have been many studies carried out to investigate the relationship of 
OLE with amalgam and the effect of replacement of amalgam restorations 
with a non mercury substitute, (Table 4). The patients were tested to a 
variety of mercury compounds including, mercuric oxide, mercuric chloride, 
phenyl mercuric acetate, metallic mercury, amalgams, ammoniated mercury, 
phenyl mercuric nitrate, thiomersal, and phenyl mercuric borate. The 
number of patients with patch test results positive to mercurials varied 
widely between studies from 24.5%-100%, which may represent the 
differing referral patterns for patch testing, e.g. some would only refer those 
with a high risk of mercury allergy, whereas others referred all their OLE 
patients who had a possibility of hypersensitivity. This, however, was 
significantly more than the 3.5% reported in 2,300 eczema patients (Finne, 
Goransson, & Winckler 1982). The difference may also be due to reading 
by different dermatologists, different ethnic groups among the patients, 
variations in the patch test procedure (time of allergen exposure was 24-48 
hours, and readings were carried out on days 1-17, Finne suggesting that 
late reading of the test sites is valuable in picking up further positive results 
(Finne, Goransson, & Winckler 1982)). The different types of mercury 
allergens that the patients were exposed to would also have affected the 
results. Most lesions in patients with positive patch test results improved 
after replacement of their amalgams, the percentages showing complete 
remission varying between 37.5% and 94.1%. Many more reported marked 
improvement in the lesions, for example, in one study a total 88.7% of 56
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Table 4. Patch testing to mercury in patient with OLE lesions in relation
to amalgam restorations*
118a 76 (64.4) 56 (73.7) 25 (45.2) 6(40) 1(20)
12b 5 (41.7) - - -
33CT 15(45.5) 15(100) 7 (46.7) 18(100) 8 (44.4)
53d 13(24.5) 7 (53.8) - - -
19e 15(78.9) 15(100) 9(60) 3(75) 0(0)
65' 17(26) 17(100) 16 (94.1)! 4 3 (75)t
52g # 17(33) 13 (76.5) 11 (85) -
19h 19(100) 16(84) 13 (81.25) - -
12J J  (42) - - - -
41k 12(29.2) - - - -
33#1 18(54.5%) 10(55.6) 7(70) - -
49m 17(35) 17(100) 14(82.3) 31 19(61.3)
IT 5 (45.5) - - - -
24° 8(33) 8(100) 3 (37.5) - -
29#p 18(62) 4(22) 3(75) - -
29q 10(34) 6(60) 4 (66.7) - -
* Lesions topographically related to amalgam restoration(s).
# All OLE patients tested
t  Improvement but may not be complete (77.2% o f all patients with 
replaced amalgams had complete resolution).
+ Though clinically, the lesions were o f  lichenoid character, up to 7 o f 
these patients had a histological diagnosis that was not indicative o f 
OLE.
a (Laine, Kalimo, & Happonen 1997) 
b (Pecegueiro et al. 1999) 
c (Skoglund 1994)
6 (Todd et al. 1990) 
e (Koch & Bahmer 1999)
[ (Ibbotson et al. 1996) 
g (Smart, Macleod, & Lawrence 1995) 
h (Pang & Freeman 1995)
J (Nordlind & Liden 1992)
(Bolewska et al. 1990a)
1 (Laine et al. 1992)
m (Ostman, Anneroth, & Skoglund 1996) 
n (Koch & Bahmer 1995)
(Skoglund & Egelrud 1991) 
p (Finne, Goransson, & Winckler 1982) 
q (James et al. 1987)
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patients, experienced improvement of some kind upon replacement of 
amalgam dental restorations with a non mercury restoration even though 
only 45.2% experienced complete remission (Laine, Kalimo, & Happonen 
1997).
The percentages of those with negative patch test results to mercury who 
experience complete resolutions of their lesions ranged from 0 -  75%. 
Some authors found that the number of patients who showed clinical 
resolution following amalgam replacement in the patch test negative group 
being similar enough to the number in the patch test positive group to 
warrant the recommendation of amalgam removal and replacement in all 
patients who had lesions with a geographical relationship to amalgam 
restorations (Ibbotson et al. 1996; Ostman, Anneroth, & Skoglund 1996; 
Skoglund 1994). Other authors found a marked difference in resolution of 
lesions between the patch test positive and negative groups (Koch & 
Bahmer 1999).
Bratel et al investigated the effect of replacement of amalgams with other 
dental materials in 142 patients with OLE lesions related to amalgam 
restorations and 19 patients with both OLE lesions related and unrelated to 
amalgam restorations. They found that 95% of the lesions in the first group 
considerably improved or resolved after replacement whereas 63% of the 
lesions related to amalgam restorations in the second group improved and
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none of the lesions unrelated to amalgam restorations improved (Bratel, 
Hakeberg, & Jontell 1996).
Most authors found that the lesions resolved in under 3 months following 
amalgam removal (Camisa et al. 1999).
Garioch et al found that 14 out of 53 patients with OLE had clinically 
relevant positive patch test reactions to mercury or mercuric salts. In all 
these patients, clinical improvement was noted after replacement of 
amalgams with other materials or changing their thimerosal (thiomersal) 
containing contact lens cleaning fluid (Garioch et al. 1990). Other studies 
have found that only three out of 46, and one out of 12 OLE patients reacted 
to metallic mercury. (Hietanen et al. 1987; Yiannias et al. 2000).
In summary, contact sensitivity to mercurials as determined by patch testing 
seems to be fairly common among OLE patients who have amalgam 
restorations and that replacement is beneficial in these cases and also to a 
lesser extent in patients with OLE without a demonstrable mercury allergy.
Thiomersal is a mercurial that is used as a preservative in vaccines and 
sensitisation to it has been increasing most probably due to the increase in 
vaccination programmes (Aberer 1991). Thiomersal sensitivity has been 
found to be as high as 16% among eczema patients referred for patch testing 
(Aberer 1991). However, the minute amounts of thiomersal in vaccines 
(usually 0.05mg) are considered to be enough to sensitise an individual, but
have been shown not to provoke clinical symptoms upon vaccination if 
given intramuscularly rather that subcutaneously and so this is probably not 
of clinical relevance for further vaccinations, but only in those who have 
had problems using mercurial containing contact lens cleaning solutions 
(Aberer 1991; Cox & Forsyth 1988).
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I.2.5.3.Comparison O f‘Lichenoid’ and Drug Induced Lichenoid and 
(Idiopathic LP’ Lesions
McCullough and Radden suggest that one of the most difficult tasks in the 
diagnosis of oral mucosal diseases is the differentiation between the three 
lichenoid lesions; classic/idiopathic LP, drug related and other lichenoid 
type lesions and lesions which also show dysplastic epithelial changes 
(McCullough & Radden 1992). Making clear clinical and histological 
definitions of these lichenoid diseases will enable progress in aetiology and 
treatment and in particular will aid in discovering which are correlated with 
malignant potential (Lozada-Nur 2000).
Oliver et al (1989) investigated the histological characteristics of cutaneous 
LP (3 patients), cutaneous drug induced lichenoid reactions (DILR) (14 
patients) and allergic contact dermatitis (ACD) (6 patients). They found 
that in cutaneous DILR sections, the most distinctive feature was the 
presence of a mixed cell infiltrate. Apoptosis and hyperkeratosis were 
commonly seen. The cutaneous LP sections demonstrated features 
indistinguishable from lupus erythematosus with significant numbers of 
apoptotic cells in the dermis, abnormal keratinisation was rare and 
spongiosis was absent. The ACD sections showed little distinguishing 
features apart from the mildness of the inflammatory reaction at the 
epithelial-dermal interface and the infrequency of apoptosis (Oliver, 
Winkelmann, & Muller 1989). The numbers however in each group were 
small so the significance was debatable.
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Koch and Bahmer also distinguished between patients that had lichenoid 
lesions related to metal dental restorations and those with OLP (not related 
to metal restorations), by a lessening of the inflammatory infiltrate in the 
lichenoid group. A biopsy was taken from the positive patch test reactions 
to metal salts, and these, in contrast to the ACD patients reported by Oliver 
et al showed a marked dermal reaction with perivascular infiltrates, vacuolar 
changes and necrotic keratinocytes in the epithelium, as well as features of 
ACD; spongiosis of the epithelium and lymphohistiocytic infiltrates 
perivascularly in the dermis (Koch & Bahmer 1999).
A number of studies have compared the histopathology of both OLP lesions 
and lichenoid lesions to determine whether it is possible to establish a 
diagnosis of one against the other from the histological appearance. Some 
authors have even considered it possible that the reaction to a specific 
antigen (cinnamon) can be suggested by the histological appearance alone. 
Their histopathological criteria were; hyperkeratosis, chronic lichenoid 
mucositis with plasmacytic infiltration and marked chronic perivasculitis 
(Miller, Gould, & Bernstein 1992) but these were not quantified in any way. 
van den Haute et al studied the histological appearance of cutaneous LP and 
found that while not pathognomonic of DILR, a drug aetiology could be 
suggested when the following criteria were present; focal para-keratosis, 
focal interruption of the granular layer, cytoid bodies in the comified and 
granular layers (van den Haute, Antoine, & Lachapelle 1989).
Pecegueiro et al in 1999 retrospectively analysed 21 patient’s case records 
and histopathology specimens. They noted the presence or absence of the 
following histological features; erosion, acanthosis, atrophy, granulosis,
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keratosis (ortho or para), degeneration of the basal layer, Civatte bodies and 
lymphoid infiltrate. Dividing the patients into two groups, those with 
metallic restorations in their mouth or with a history of such, i.e. more likely 
to have a lichenoid eruption and those without, i.e. more likely to have 
idiopathic LP, they noted that those in the first group were more likely to 
react positively to patch testing to mercurials and potassium dichromate (six 
out of twelve patients had a positive patch test result), however they could 
identify no clinical or histological differences between the two groups. No 
statistical analysis of the results or drug histories of the patients were given 
(Pecegueiro et al. 1999). Bratel et al (1998) stated that it was not possible to 
reveal the difference between lichenoid contact lesions (LCL) and OLP 
lesions histologically. They compared T cell receptor V families and could 
identify no differences between the two groups (Bratel et al. 1998). 
Hietianen et al likewise could identify no histological or 
immunofluorescence alterations between the OLE lesions in contact with 
amalgams and those not (Hietanen et al. 1987). Another parameter that has 
been studied is the density of eosinophils in the two groups. No significant 
differences were found between sections from patients with OLP and DILR 
(Firth & Reade 1990). Others have distinguished DILR from OLP 
histologically but found no clinical differences between the two groups, 
though it was not stated upon what histological criteria these distinctions 
were made (Hamburger, Lawrence, & Oakes 1995). Involucrin, a marker 
for the normal maturation of the keratinocytes, has been postulated as an 
identifying feature for lichenoid reactions particularly in lichenoid dysplasia 
(Eisenberg, Murphy, & Krutchkoff 1987). McCullough and Radden tested
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this claim and found no differences between specimens of patients with 
DILR and OLP (McCullough & Radden 1992).
McCartan and Lamey found, by indirect immunofluorescence, that there 
were circulating IgG basal cell cytoplasmic antibodies in patients with 
idiopathic OLP (3%) but they were associated more often with oral 
lichenoid drug eruptions (31%) suggesting that these are a potentially useful 
marker to distinguish between the two (McCartan & Lamey 1998). They 
also found that there was a significant increase in unilaterality in the 
lichenoid lesion (Lamey et al. 1995). Ingafou et al by contrast did not 
succeed in isolating any basal cell cytoplasmic antibodies from either 
patients with idiopathic OLP or DILR lesions but their sample size was very 
small (Ingafou et al. 1997). McCartan and Lamey also found differences in 
the expression of CD1+ and HLA DR antigens by Langerhan’s cells in 
idiopathic OLP and DILR lesions and suggested that these diseases differed 
in the way that antigens were presented (McCartan & Lamey 1997). This, 
they postulated was due to the fact that systemically ingested drugs would 
be processed by antigen presenting cells elsewhere in the body, whereas, in 
cases of topically applied drugs and contact lesions with amalgams, the 
antigen crosses the oral epithelium and is processed there (McCartan & 
Lamey 1997). HLA DR antigens were only found in a third of all OLE 
patients studied in another publication, and no difference was found whether 
amalgam was in contact with the lesions or not, though the numbers of 
Langerhan’s cells found was increased compared to normal oral mucosa 
(Bolewska & Reibel 1989).
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The difference between the OLP and DILR seems to be regarded by most 
authors as the more frequent presence of the following in DILR: 
subepithelial infiltrate containing eosinophils and plasma cells, which is 
more diffuse and extends more deeply than in idiopathic LP, a perivascular 
infiltrate, and increased tendency to parakeratinisation and the presence of 
increased numbers of colloid bodies in the epithelium (McCartan & Lamey 
1997; Savage 1997; van den Haute, Antoine, & Lachapelle 1989). These 
features can also be found in sections of idiopathic LP, so the 
histopathological diagnosis cannot be certain without other clinical data 
(McCartan 1997).
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1.2.6. Treatment
Treatment of OLE involves removing aggravating trauma and infection by 
smoothing rough restorations and teeth, improving oral hygiene (Holmstrup, 
Schiotz, & Westergaard 1990) and treating any candidal infection present 
(Holmstrup et al. 1988; Thom et al. 1988; Vincent et al. 1990). Both topical 
and systemic antifungal preparations have also be utilised though the use of ' 
griseofulvin is controversial (Bagan et al. 1991b; Eisen 1993). Careful 
history taking and examination of the patient may lead to the suspicion of a 
drug or allergen aetiology and this should be dealt with by communication 
with the medical specialists involved in prescribing the suspected drugs 
and/or by appropriate allergy testing and follow up. Stopping smoking was 
not found to have beneficial effects on OLE lesions and a negative 
correlation of the incidence of OLE with cigarette smoking was found in 
one large study (Axell & Rundquist 1987; Savin 1991). The mainstay of 
symptomatic treatment revolves around immunosuppressive therapy in the 
shape of topical, local or systemic steroids (Silverman & Bahl 1997). 
Gingival lesions can be treated with steroid ointments held against the 
lesions in preformed Wenvac splints (Scully & Porter 1997). Steroids can 
also be contained in and applied to the mucosa in Orabase (sodium 
carboxymethylcellulose, pectin, gelatin and plasticized hydrocarbon gel 
which adheres to mucosa) preparations6 (Silverman et al. 1991), tablets held
6 Triamcinalone in orabase, clobestasol or fluocinonide.
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against the mucosa while they dissolve , soluble tablets added to water to be
Q
used as a mouth wash and metered dose inhalers containing 
beclomethasone which can be used as sprays9. Triamcinalone may be 
injected intralesionally or sublesionally in small areas of recalcitrant, 
symptomatic OLE. When systemic steroids are used, steroid sparing agents 
such as azathioprine (non-steroidal potent immunosuppressor) can be 
usefully employed (Silverman et al. 1991).
The use of other immunomodulators such as levamisole has been shown to 
remove anti basal cell antibody (ABA) from the serum of three out of six 
OLE patients positive for ABA. No mention of any resultant improvement 
in either symptoms or clinical appearance was made. The size and the 
‘open’ nature of the trial, make it impossible to assess the clinical efficacy 
of this treatment from this study (Sun et al. 1994).
Retinoids such as Tretinoin, Isotretinoin, Etretinate and Tremarotene have 
been formulated in topical preparations to good effect and also used 
systemically though there is still a need for carefully designed, double blind, 
placebo controlled studies to evaluate their usefulness (Eisen 1993). Regezi 
et al found that topical isotretinoin had an antikeratinising and an 
immunomodulating effect on OLE lesions when assessed histologically 
(Regezi et al. 1986). These have to be prescribed carefully as the side 
effects can be troublesome or severe; dry mouth, hair loss, cheilitis, pruritus 
and desquamation of hands and feet have all occurred after retinoid therapy 
and these effects are often dose related (Eisen 1993).
7 Corlan tablets -  0.2mg hydrocortisone
8 Betnesol tablets -0.5mg betamethasone and Prednesol tablets -5m g prednisolone
9 Becotide metered dose inhaler
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Cyclosporine is a potent immunosuppressant and therefore need careful 
monitoring and although topical use minimises systemic effects while 
retaining clinical efficacy, reduced HLA-DR and ICAM-1 have been shown 
to be a result of topical (mouthwash) cyclosporine treatment (Eisen 1993). 
Surgical procedures such as conventional surgery, cryosurgery and carbon 
dioxide laser surgery have also been used. Other experimental treatments 
that have been tried require further investigation before being widely 
accepted and include; phenytoin, tetracycline, doxycycline, dapsone, and an 
antiviral -  human fibroblast Interferon-B. Ultraviolet light therapy with or 
without a photosensitiser (psoralens) has yielded good results in some cases, 
though the link with UV light and malignancy needs to be borne in mind 
(Eisen 1993; Savin 1991).
The fact that treatments involving immunosuppressive and 
immunomodulating medications and UVA light are efficacious underlines 
the immune system involvement in the pathogenesis of OLE.
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1.3. Recurrent Aphthous Stomatitis
1.3.1. Introduction
Hippocrates (460 -  370 BC) was the first to record the word ‘aphthai’ 
though he may well have been referring to thrush (Rogers III 1977). The 
first clear description of RAS was by Miculicz in 1898 (Savage et al. 1988). 
Recurrent aphthous stomatitis (RAS) is a common condition affecting both 
males and females and is found in all age groups. The ulceration almost 
inevitably presents as pain ranging from mild discomfort that the patient is 
just aware of to severe pain that debilitates the patient to the extent that even 
taking fluids orally becomes difficult and the patient has to rely on 
intravenous nutrition. The severity of pain not only depends on the size of 
the area of ulceration, but on the site. The different areas of the oral cavity 
have different sensory outputs, are exposed to differing amounts of trauma 
during mastication or speech for example and have varying degrees of 
mobility. And this means that an ulcer on the tip of the tongue is usually 
particularly painful even though it may be small in size. This is due to the 
fact that it is an extremely sensitive area, exposed to trauma repeatedly and 
being on purely a muscle base, has high mobility.
‘Recurrence’ is defined in different ways by various authors; Sun et 
al consider RAS as having at least one lesion per month (Sun et al. 
1994) though others include those with recurrences o f over three 
month intervals (Bagan et al. 1991a; Graykowski et al. 1966). Ship 
utilises more inclusive criteria with recu rrence  defined  as two or
m ore episodes in a th ree year period (Ship 1965). Field notes that the 
some patients can identify a predictable, regular cyclic pattern while others 
have irregular recurrences of lesions (Field, Brookes, & Tyldesley 1992).
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1.3.2. Classification and Features
RAS is thought to affect 10-20% of the general population (Field, Brookes, 
& Tyldesley 1992) though higher prevalences have been found in students 
and in younger age groups and great variation has been found in the 
prevalence in different population groups (Rogers III 1977). Bagan found 
the highest prevalence in the third and fourth decade (Bagan et al. 1991a) 
but many authors have found that most RAS patients experience ulceration 
in the first and second decades (Eversole, Shopper, & Chambers 1982). 
Patients with herpetiform ulceration present more often in the third decade 
(Field et al. 1987). Three clinical types of RAS have been identified; minor, 
major and herpetiform aphthae (Cooke 1960). Histologically the features 
are of non-specific ulceration (Porter, Scully, & Pedersen 1998) with a 
lymphocytic infiltration in the subepithelium initially which migrates 
intraepithelially as the lesions progress (Savage et al. 1988). The 
mononuclear infiltration seen in histopathological specimens of RAS 
lesions, is similar to that in delayed hypersensitivity (Lehner 1969b) as 
described by Coe et al (Coe, Feldman, & Lee 1966).
1.3.2.1.Minor Aphthae
Minor oral ulcers present typically as round or oval grey/yellow, shallow 
lesions surrounded by an erythematous halo. Their size is between 2-4 mm 
in diameter and heal spontaneously in 7-14 days. These commonly affect
the non-keratinised mucosa and tongue but may affect all intraoral sites 
(Field, Brookes, & Tyldesley 1992).
1.3.2.2.Major Aphthae
The major type of RAS is very similar to the minor except that the lesions 
are larger, often exceeding 1 cm and due to this, take much longer to heal 
(up to six weeks ) and scarring may occur. Again any part of the oral 
mucosa can be affected but the ulcers are commonly found on the soft 
palate, pillars of fauces and the lips (Field, Brookes, & Tyldesley 1992).
1.3.2.3.Herpetiform Ulceration
The appearance of herpetiform ulceration, first described by Cooke has been 
likened to that herpetic stomatitis, hence the nomenclature (Cooke 1960). 
Some have regarded these lesions as viral in nature as herpetic stomatitis 
may look clinically similar (Lehner 1967) but herpetiform ulceration is now 
considered part of the clinical spectrum of RAS (Field, Brookes, & 
Tyldesley 1992). The ulcers are very small, (about 1mm in diameter) and 
may occur in large quantities of up to 100 at one time, some of which may 
coalesce to form an ulcer with a ragged edge. Usually the anterior part of 
the mouth is affected, the average duration of lesions is more difficult to 
estimate but is thought to be several weeks (Field, Brookes, & Tyldesley
1992).
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1.3.2.4.Beh9et’s Syndrome
B e lie fs  Syndrome is classified as a severe variant of RAS by some authors 
(Rogers III 1977) and regarded as a different though related entity by others 
(Porter, Scully, & Pedersen 1998). B e lie fs  Syndrome is a multisystem 
disease which is characterised by ulceration of the oral and genital mucosa 
and often ocular lesions such as uveitis as well as sometimes 
musculoskeletal, neurological, gastrointestinal and haematological problems 
(Rogers III 1977). In the early stages the lesions in the mouth may be 
indistinguishable from those of RAS (Lombardi, Hauser, & Budtz Jorgensen 
1993). An immune pathogenesis for the disease is supported by the fact that 
increased numbers of Langerhan’s cells can be induced by exposure to 
trauma in affected patients and that an autoimmune pathogenesis may be 
involved is suggested by the appearance of the macrophages and 
lymphocytes invading the epithelium (Lombardi, Hauser, & Budtz 
Jorgensen 1993). Antigenic cross reactivity may help to explain the 
involvement of many different tissues in B e lie fs  Syndrome (Lehner 
1969a). B e lie fs  Syndrome is also characterised by human leukocyte 
antigens (HLA) B5 and B27 (Challacombe et al. 1977).
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1.3.2.5.0ther Systemic Diseases Associated With RAS
Gluten-sensitive enteropathy (GSE, Coeliac disease) has been associated 
with RAS to varying degrees by different authors. There seems to be no 
doubt that the prevalence of GSE is increased in patients with RAS, with 
different authors demonstrating that 4%, 24%, 1% and 0.5% of patients with 
RAS, had GSE (Wray et al. 1975 ; Ferguson et al. 1980; Ferguson et al. 
1976; Hunter et al. 1993). Ferguson suggested that jejunal biopsy be carried 
out on all RAS patients (Ferguson et al. 1976), however most other authors 
recommend that only those with gastrointestinal symptoms or low folate or 
ferritin levels on haematological examination, be referred for jejunal biopsy 
(Ferguson et al. 1980). Field et al referred seven children with RAS and 
nutritional deficiencies for jejunal biopsy and found only one had evidence 
of GSE and recommended that children not be referred for jejunal biopsy 
unless the nutritional deficiency was accompanied by gastrointestinal 
symptoms and/or failure to thrive (Field et al. 1987). In all eight cases of 
GSE related RAS, there was complete remission of ulceration on 
commencing a gluten-free diet (Ferguson et al. 1980; Ferguson et al. 1976), 
however further studies have shown that 25% (n=5) (Wray 1981) and 25% 
(n=3) (Wright et al. 1986) of RAS patients with normal jejunal morphology, 
experienced complete remission on a gluten-free diet. Hunter et al 
investigated the effect of a gluten-free diet and also studied the effects on a 
blinded control group given gluten capsules and a gluten free diet. They 
found no significant differences between the two groups though all had a 
reduction in RAS symptoms indicating that a placebo effect may be at work 
(Hunter et al. 1993).
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Other diseases that may have RAS as part of their clinical features are cyclic 
neutropenia (Gorlin & Chaudhry 1960), Sweet’s syndrome (Von-den- 
Driesch 1994) and some immunodeficiency states including human 
immunodeficiency virus infection (Porter, Scully, & Pedersen 1998).
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1.3.3. Aetiology
Traumatic insult to the oral mucosa is thought to precipitate RAS lesions in 
susceptible subjects (and frank traumatic ulceration if the trauma is severe 
or prolonged enough) (Eversole, Shopper, & Chambers 1982). This may be 
due to the oral mucosa being more vulnerable to mild trauma as the oral 
mucosa of RAS patients has been shown to be less keratinised than that of 
healthy patients (Banoczy & Sallay 1968). Some authors consider that 
smoking is thought to have a protective role against the precipitation of 
ulceration in the oral cavity and this may be due to increased keratinisation 
of the oral epithelia in smokers that mitigates against minor trauma causing 
the ulcer (Banoczy & Sallay 1968).
Genetic factors are strongly suggested (Ship 1965) and though the exact 
mode of inheritance has not been outlined, a recessive susceptibility gene 
has been suggested (Wray et al. 1981). HLA A2 and Bw44 were shown to 
be correlated to disease activity (Wray et al. 1981) and HLA A2 was found 
in RAS patients in another study along with HLA B12 (Challacombe et al.
1977). However, these results have not been confirmed by other studies 
(Dolby et al. 1977).
Nutritional deficiencies of iron, folic acid and vitamin B12 were found in 
14.2% (n=47) of 330 patients with RAS and in 21% of 100 children with 
RAS (Field et al. 1987; Wray et al. 1978) and Nolan et al identified vitamin 
Bi, B2 and B6 deficiencies in 28% of 60 RAS patients (Nolan, McIntosh, & 
Lamey 1991).
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Evidence for a psychogenic basis for RAS is not compelling though some 
have found that anxiety levels have been higher in RAS patients (Ship 
1960). It may be that anxious people have a lower pain threshold and 
therefore present with RAS more often (Field, Brookes, & Tyldesley 1992). 
The role of exogenous antigens has been considered by many authors 
(Savage & Seymour 1994) and possible bacterial or viral antigens have been 
suggested. The role of streptococcal antigens is unclear. Some studies have 
found a possible involvement of Streptococcus sanguis strain 2A (Donatsky
1978) though this was not substantiated by a further study (Hoover, Olson,
& Greenspan 1986) and Riggio et al found no association of RAS with 
Streptococcus oralis (Riggio et al. 1999). There is a possibility of antigenic 
cross reactivity between L form bacteria and oral mucosa (Lehner 1967). 
The role that viruses may play is yet to be established and adenoviruses and 
herpes simplex viruses have been implicated (Scully 1993).
An allergic basis for RAS has been postulated though this is considered 
uncommon by some authors (Field, Brookes, & Tyldesley 1992). See 
section 1.3.4.
The onset of RAS does not seem to coincide with puberty though up to 62% 
of female patients experience recurrence premenstrually (Eversole, Shopper, 
& Chambers 1982) and this is probably due to the decrease in keratinisation 
associated with low oestrogen levels which increases the susceptibility to 
ulcer formation (Main & Ritchie 1967).
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1.3.4. Pathogenesis
Histologically the lesions of RAS show features of T cell lymphomas i.e. a 
lymphomonocytic infiltrate in the epithelium and it is well accepted that the 
pathogenesis of RAS involves immune mechanisms (Savage, Seymour, & 
Kruger 1986). It is thought that the lymphocytes interact with the 
keratinocytes in the epithelium and so mediate the damage (Lombardi, 
Hauser, & Budtz Jorgensen 1993). Savage and Seymour found that both 
CD4+ and CD8+ are capable of destroying oral mucosal epithelial cells that 
express both class I and II major histocompatibility (MHC) antigens 
(Savage & Seymour 1994). Gamma interferon (y-IFN) is responsible for 
the increased expression of class I MHC antigens and the de novo synthesis 
of class II MHC antigens (Savage, Seymour, & Kruger 1986). It is not clear 
whether antigen cross reactivity exists between antigens of the oral mucosa 
and those of environmental or dietary origins, or whether chemicals such as 
some dietary antigens conjugate with epithelial proteins and act as 
sensitisers that way (Hay & Reade 1984). Once the lesion is established, 
polymorphonuclear neutrophils (PMN) are the predominant cell type and 
their increased adherence compared to controls may assist in the 
perpetuation of the ulcer (Wray & Charon 1991).
An autoimmune mechanism has been suggested because antibodies 
(residing in the IgG and IgM fraction) to foetal oral mucosa have been ' 
found in patients with RAS and B e lie fs  Syndrome, though they were not 
specific to oral mucosa (Lehner 1967).
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1.3.5. Role of Allergy
In a survey of 338 patients attending a hospital for reasons other than RAS 
and allergic conditions, 84% of those who admitted suffering from RAS 
(n=69), also had a positive history of allergy, and 63% of those with allergic 
conditions (n=92), also had a positive history of RAS. These correlations 
were highly significant (Spouge & Diamond 1963). However, Wray found 
no increased incidence of atopy in RAS patients compared to the general 
population (Wray, Vlagopolous, & Siraganian 1982).
A study investigating the mast cell populations in RAS patients’ oral 
mucosa, found that the role of a Type I hypersensitivity reaction was 
unlikely though histamine did have some role to play (Dolby & Allison 
1969). The possibility of a Type IV hypersensitivity reaction in the 
aetiology of RAS lesions is supported but not proven by IgD positive cells 
in aphthous lesions similar to those in the acute phase of ACD (Bays, 
Hamerlinck, & Cormane 1977), and all types of RAS show histological 
features of a delayed type hypersensitivity reaction (Lehner 1972).
While Wray found that an empirical gluten-free diet resulted in complete 
resolution in 5 out of 20 RAS patients, the previously found low folate 
levels also were increased back to normal levels thus allergy to gluten was 
not the only mechanism involved (Wray 1981). However, RAS was 
induced by a variety of foods including gluten in five out of 12 patients 
who underwent an elimination diet followed by the staggered introduction 
of foods until a normal diet was achieved (Hay & Reade 1984). The foods 
eliciting RAS upon reintroduction were: tomatoes, figs, cheese, vinegar,
lemon, pineapple, French mustard, wheat flour and cow milk. The 
ulceration appeared in 8-48 hours after ingestion of the offending food item, 
this latent period being consistent with a Type IV hypersensitivity reaction 
(Hay & Reade 1984). Another study found that six out of 12 patients 
experienced complete remission from RAS after avoiding the following 
foods; gluten (n=3), food additives (tartrazine, benzoic acid, sunset yellow, 
and new coccine) (n=2), and cows milk products (n=l) (Wright et al. 1986). 
Six out of seven patients had no recurrence of RAS during a ‘non- 
allergenic’ dietary regime (Ship 1960).
The response to challenges to 15 food allergens and 10 environmental 
allergens was correlated with in vitro histamine release from leukocytes in 
30% of RAS patients thus investigated but none of the patients experienced 
complete resolution upon avoidance. This indicated that both food allergens 
and histamine do have minor roles to play in the pathogenesis of RAS 
(Wray, Vlagopolous, & Siraganian 1982).
However some authors found no link between RAS and foods that patients 
thought were instrumental in precipitating lesions; walnuts, strawberries and 
tomatoes (Eversole, Shopper, & Chambers 1982). It was likely that the 
acidic and astringent nature of these foods caused pain in subjects already 
with RAS lesions rather than causing the ulcer formation itself.
A prospective study of 21 RAS patients utilised patch testing to identify 
allergens and 20 of these had one or more positive results. Of these, eight 
experienced compete remission on allergen avoidance and many others 
reported an 80% improvement (Nolan et al. 1991). This study clearly 
indicated that allergy testing and skilled allergen avoidance advice was
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clinically efficacious in many patients with RAS though there was no 
control group tested. Another study found that one out of five RAS patients 
patch tested had a clinically relevant positive reaction (to menthol) and 
resolution upon allergen avoidance though again no healthy control group 
was studied (Shah, Lewis, & Gawkrodger 1996).
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1.3.6. Management and Treatment
Clinical management of the patient with RAS involves history, examination 
and investigations (usually haematological) to check for the possibilities of 
underlying systemic disease and patients may require correction of 
haematinic deficiencies.
A total of 23 out of 47 patients identified as having one or more nutritional 
deficiencies experienced complete remission on replacement therapy (Wray 
etal. 1978). Peripheral blood examination (haemoglobin concentration, 
mean corpuscular volume, mean corpuscular haemoglobin and examination 
of blood film) alone would have missed 16 patients in this study and it was 
recommended that estimation of serum iron content, total iron binding 
capacity, whole blood folate and vitamin B 12 assay should also be carried 
out in RAS patients (Hutcheon et al. 1978). The value of haematological 
screening in children aged 7-16 with RAS, was shown in a retrospective 
study of 100 children, 21 of whom were found to have a deficiency of one 
of the above mentioned nutritional factors (Field et al. 1987). Nolan et al 
suggested including vitamins Bi, B2 and B6 in the haematological screening 
as 28% of 60 RAS patients were found to be deficient in one or more of 
these vitamins and in a controlled but not blinded study, patients with a 
deficiency improved after replacement therapy (Nolan, McIntosh, & Lamey 
1991). In a further study of a group of 47 RAS patients each having a single 
haematinic deficiency, 70% showed considerable subjective improvement in 
their symptoms when replacement regimes were instituted (Porter et al.
Avoidance of relevant allergens is efficacious in a proportion of patients. 
Treatment is generally focussed on controlling symptoms and preventing 
secondary infection and includes the types listed in Table 5. A placebo 
effect has been noted by some authors and few medicines actually reduce 
the recurrences of the lesions without notable side effects (Porter, Scully, & 
Pedersen 1998). The use of corticosteroids is of benefit in many cases, 
where they are thought to inhibit effector B and T cells and T helper cells 
(Pedersen & Klausen 1984) though a recent publication calls for more 
rigorous scientific study in this area (Kalmar 2000). The immunomodulator 
levamisole has been shown to have a number of effects in both humoral and 
cellular immune mechanisms of RAS patients. These include normalisation 
of the CD4+/CD8+ ratio, IgM and IgA levels, and the disappearance of 
serum antinuclear antibodies, giving rise to both subjective and objective 
clinical improvement in symptoms though long term (1-22 months) 
treatment was required (Sun et al. 1994).
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Table 5. Some Reported Therapies of RAS
Preparation Types Medicament
Mouthrinses Chlorhexidine gluconate 
Benzydamine hydrochloride 
Carbenoxolon disodium 
Betadine
Topical corticosteroids Hydrocortisone hemisuccinate 
Triamcinalone acetonide (in 
adhesive paste)
Fluocinonide (cream) 
Betamethasone valerate 
(mouthrinse)
Betamethasone-17-benzoate 
(mouthrinse)
Flumethasone pivolate (spray) 
Beclomathasone dipropionate 
(spray)
Antibiotics Topical tetracyclines
Immunomodulators Levamisole
Transfer factor
Colchicine
Gammaglobulins
Aza thioprine
Dapsone
Thalidomide
Pentoxifylline
Prednisolone
Azelastine
Alpha-2-interferon
Cyclosporin
Amlexanox
5-amino salicylic acid
Others Systemic zinc sulphate
Monoamine-oxidase inhibitors
Sodium cromoglycate
Deglycirrhizinated liquorice
Sucralphate
Etreninate
Low-energy laser
Based on the table reproduced in (Porter, Scully, & Pedersen 1998).
1.4. Angioedema
1.4.1. Introduction
Quinke oedema was described by Dr Heinrich Quinke in 1881 and the 
hereditary version of this was reported seven years later (Mattingly, Rodu,
& Ailing 1993; Oltivai et al. 1991).
Hereditary (Ruddy 1988), acquired (Oltivaiet al. 1991; Postlethwaite & 
Parry 1988) and idiopathic forms of angioedema have been well 
documented in the literature in recent years. Patients with angioedema (AE) 
often experience orofacial symptoms such as tongue and lip swelling and 
thus may present first to their dental surgeon, though due to the sudden 
onset and severity of symptoms especially if pharyngeal and laryngeal 
swelling are present, patients often present to accident and emergency 
facilities (Guo & Dick 1999; Ruddy 1988). The condition was formerly 
known as angioneurotic oedema, due to patients complaining of a choking 
sensation and being labelled as neurotic, prior to the nature of the condition 
being fully known. The “neurotic” component has since been dropped as 
there is no marked contributing psychological overlay to this condition (Sim 
& Grant 1990). Dental treatment procedures, particularly surgical 
procedures, may aggravate or precipitate an angioedematous response 
(Degroote, Smith, & Huttula 1985; Ruddy 1988).
AE refers to localised swelling of skin or mucous membranes often 
associated with urticaria. It may occur as part of an IgE-mediated reaction 
(Sussman, Yang, & Steinberg 1992). AE is characterised by recurrent, non-
pruritic oedema of the subepithelium or submucosa (Wong 1990). The face, 
tongue, pharynx and larynx are commonly affected as are the small bowel . 
and extremities. As well as being distressing to the patient, tongue, 
pharyngeal and laryngeal swelling can lead to respiratory embarrassment 
(Thompson & Frable 1993) and can be fatal (Ulmer & Garvey 1992). Small 
bowel involvement can give rise to acute abdominal pain and other 
symptoms which may mimic inflammatory bowel disease (Eck et al. 1993; 
Jacobs, Hoberman, & Goldstein 1993).
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1.4.2. Classification
1.4.2.1.Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, autosomal dominant genetic 
disorder affecting 1:50,000 of the population in the UK (Postlethwaite & 
Parry 1988). The genetic abnormality affects the coding for Ci esterase 
inhibitor (Cl-INH) which results in the formation of a null allele (Ishi, 
Kawaguchi, & Nakajima 1996; Ruddy 1988; Verpy et al. 1996). Two types 
have been recognised (Oltivai et al. 1991), type 1 which makes up 85% of 
cases and type 2 making up the other 15%. In type 1, affected patients have 
a biochemical deficiency of C\ esterase inhibitor (Cl-INH) which results in 
low circulating levels of this important regulator of the complement 
cascade. In type 2, affected patients have normal circulating levels of C 1 - 
INH but the protein is dysfunctional, causing a decrease in its activity. 
Without the regulating influence of Cl-INH, patients are susceptible to a 
massive, escalating inflammatory response due to the unimpeded action of 
C l, C2 and C4 (Oltivai et al. 1991). Such a response may be triggered by a 
number of precipitants such as stress, oestrogen containing drugs, allergy or 
trauma (Degroote, Smith, & Huttula 1985; Ruddy 1988; Seidman et al. 
1990; Sim & Grant 1990; Wilson 1996) and has considerable morbidity and 
may even be fatal. HAE is indeed the most severe form of AE (Ruddy 
1988). Clinical features of hereditary AE are the absence of accompanied 
urticaria with the AE which suggests a minor role for histamine in its
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pathogenesis (Sim & Grant 1990) and a positive family history though this 
is only found in 75-85% of cases (Ruddy 1988).
1.4.2.2.Acquired Angioedema - (1) Acquired Cl-INH Deficiency
The acquired form of AE was first described in 1972 (Caldwell et al. 1972) 
and is recognised in patients presenting at a later age, a negative family 
history and low serum Clq (Clq levels are normal in HAE). Affected 
patients have a normal Cl-INH gene and normal amount of functioning C l- 
INH protein secreted into the plasma. However, once in the plasma, C l- 
INH is bound by circulating antibodies and consequently its functioning 
capacity is reduced (Markovic et al. 2000). Two types have been 
recognised according to the types of antibodies involved.
In most cases, there is an associated benign or malignant 
lymphoproliferative disorder such as large cell lymphoma, chronic 
lymphocytic leukaemia, or monoclonal gammopathy (Eck et al. 1993; 
Markovic et al. 2000). Hodgkins disease and primary systemic amyloidosis 
have also been associated (Markovic et al. 2000). Antibodies against the 
monoclonal B-cell immunoglobulins cross react with the Cl-INH protein 
and the resulting antigen-antibody complex is eliminated. C lq components 
are also affected by a similar mechanism.
Rarer forms of C 1 -INH deficiency arise in patients suffering from 
autoimmune diseases. These patients have autoantibodies that react with the 
Cl-INH molecule and decrease the levels of Cl-INH (Markovic et al.
2000).
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1.4.2.3.Acquired Angioedema - (2) Drug and Allergy Related 
Angioedema and Idiopathic Angioedema
AE may occur in patients with no demonstrable decrease in the quantity or 
function of Cl-INH. There is considerable debate regarding the aetiology 
of both urticaria and AE as evidenced by the correspondence between some 
authors (Dolovich 1992; Knight 1993; Singh 1992). These reactions may be 
induced by drugs, food, or contact allergies; stress; physical factors such as 
trauma, heat and cold; infections; systemic diseases such as systemic lupus 
erythematosus or be idiopathic (Kao & Zeitz 1993). The precipitating 
factors may operate together, for example trauma in a patient taking drugs 
that have been known to cause angioedema (Kharesh 1992). Some physical 
causes are found in combination as in cases where food intake together with 
a rise in body temperature results in AE (Zuberbier, Bohm, & Czametzki
1993). A helpful classification by mechanism has been tabled by Miller and 
Zeiss and is reproduced in Table 6 (Miller & Zeiss 1993). Urticaria is 
closely related to AE and the most common clinical finding is urticaria 
without AE. The next most common is urticaria and AE together and the 
least common
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Table 6. Classification o f Urticaria and Angioedema
I. Immunologic
n . Direct 
histamine release 
and/or uncertain 
mechanisms
HI.
Nonimmunologic
IV. Idiopathic
(Miller & Zeiss 1993)
IgE mediated Foods
Chemicals and therapeutic 
agents
Foreign proteins (venom, 
latex, insulin)
Immune 
complex and 
complement 
mediated
Blood and blood products, 
cuprophane haemodialysis 
membranes
Opiates, radiographic 
contrast media, vancomycin, 
pentamidine, dextran, 
aspirin, other NSAIDs
Physical stimuli
Underlying 
medical disease
Cold, cholinergic, solar 
urticarias, pressure and 
exercise urticaria/AE and 
dermatographism
Urticaria pigmentosa 
(systemic mastocytosis), 
cutaneous vasculitis, serum 
sickness, malignancy, 
infections (viral, parasitic), 
acquired Cl inhibitor 
deficiency
Hereditary Hereditary AE, hereditary
vibratory AE, familial cold 
urticaria, C3b complement 
deficiency,
Papular urticaria
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is AE alone. Urticaria is characterised by cutaneous wheals and symptoms 
of intense pruritus and is designated acute or chronic if the lesions last less, 
or more than six weeks (Kao & Zeitz 1993). Urticaria involves the 
superficial portion of the dermis while AE affects primarily the deeper 
dermal layers and the subcutaneous tissues with the most likely symptom 
being pain rather that pruritus (Cooper 1991). Urticaria and AE have a peak 
incidence in the third and fourth decades (Kao & Zeitz 1993).
The agents causing AE may be those acting directly with blood vessels such 
as circulating immune complexes (found in autoimmune diseases and in 
Type III hypersensitivity), chemicals (e.g. cocaine), systemic diseases and 
microorganisms, or on the mast cells. Those acting on mast cells may 
utilise an IgE mediated mechanism as in anaphylactic reactions or be 
mediated through substances such as vasoactive proteins e.g. histamine, 
bradykinin, prostaglandin D, leukotriene C and D and platelet activating 
factor. These mediators of the inflammatory response cause an increase in 
vascular permeability which gives rise to an increase in plasma kinin 
production which in turn leads to a further increase in vascular permeability 
and so starts a positive feedback mechanism (Davidson et al. 1992). 
Complement components play a major role as promoters of histamine 
release from basophils and mast cells as well as being chemotactic for 
components of the inflammatory response (Davidson et al. 1992).
Various substances have been reported as precipitating angioedema by 
allergic mechanisms and some of these are shown in Table 7. Contact 
urticaria has been reported after the use of a formaldehyde containing dental
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Table 7. Allergens Implicated In Angioedema and Urticaria
Allergen Reference
Tomato (Thompson & Frable 1993)
Hazel nut (Mattingly, Rodu, &
Ailing1993)
Peanut (Sicherer, Burks, & Sampson
1998; Tariq et al. 1996)
Monosodium (Squire 1987)
glutamate
Food additives* (de Martino et al. 1992)
Food additives# (Malanin & Kalimo 1989)
P-lactam antibiotics (Thompson & Frable 1993)
Bovine fibrin in (Wuthrich, Bianchi-Kusch, &
haemostatic sponge Johansson 1996)
Black rubber in (Grattan & Kennedy 1985)
dental dam
Latex (Rosen et al. 1993)
* The following food additives resulted in positive reactions following oral challenge in 56 
children with urticaria/AE: sunset yellow (El 10), annatto (El60b), sodium benzoate
(E211), tartrazine (E l02), aspartamine, erythrosine (E l27) and acetyl-salicylic acid.
# The following food additives gave positive, reproducible reactions on skin prick testing: 
benzoic acid, propionic acid and patent blue
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root canal paste (el Sayed et al. 1995). Recurrent facial swelling has been 
rarely reported as the clinical feature of a Type IV hypersensitivity reaction 
to rubber chemicals and formaldehyde (Lamey & Forsyth 1986).
The most common drugs associated with angioedema are the angiotensin 
converting enzyme (ACE) inhibitors which are used in the treatment of 
hypertension ("Medicines Resource Centre" 1994). All types of ACE 
inhibitors have the potential to cause AE although they may have different 
molecular configurations (Slater, Merrill, & Guess 1988). The most 
common types reported as precipitating AE, in order of frequency are 
lisinopril, enalapril and captopril, and reactions to these have been well 
documented (Giannoccaro et al. 1989; Rees, Bergman, & Ramirez- 
Alexander 1992; Thompson & Frable 1993; Ulmer & Garvey 1992). Most 
cases of AE occur in the first seven days of treatment with ACE inhibitors 
though late onset AE has been described occurring sometimes years after 
commencement of therapy (Guo & Dick 1999; Slater, Merrill, & Guess
1988). The precipitation of AE by ACE inhibitors is a mechanism based 
side effect of the drug involving the inhibition of ACE, which is the same 
substance as kininase 2, which may cause blockade of bradykinin 
metabolism which in turn leads to increased action of this vasoactive 
peptide. The conversion of angiotensin I to angiotensin II (a potent 
vasoconstrictor) is also blocked which significantly decreases peripheral 
vascular resistance (Gannon & Eby 1990). There may also be increased 
synthesis of bradykinin or related kinins. Some other pharmacological drug 
reactions may also contribute towards this phenomenon as some patients 
react to one type of ACE inhibitor but not to another. However, if a patient
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has had a reaction to a particular ACE inhibitor they are more likely to have 
a reaction to another and so all ACE inhibitors should henceforth be avoided 
in these patients (Slater, Merrill, & Guess 1988). The incidence of ACE 
inhibitor-induced AE is estimated to be 0.1% - 0.2% of the population 
taking ACE inhibitor drugs (Gannon & Eby 1990).
The black population in America has been identified as being at increased 
(4.5 times) risk of ACE inhibitor induced AE than white Americans (Brown 
et al. 1996), and this may be due to increased sensitivity to bradykinin in 
black Americans (Gainer et al. 1996).
Other precipitating drugs include NSAIDs such as ketorolac (Shapiro 1994) 
and aspirin (Davidson et al. 1992) (NSAIDs are thought to cause allergy­
like reactions mediated by vasoactive mediator release rather that true Type 
I allergic reactions (Anderson 1997a)), and angiotensin II receptor 
antagonists such as Cozaar (Boxer 1996).
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1.4.3. Treatment
The treatment and management of angioedema can be divided into three 
stages :
(1) management of the acute attack;
(2) chronic prevention; and
(3) prophylaxis prior to surgery
In all types of angioedema, management of the acute attack centres around 
maintenance of the airway with in-patient care often being required.
1.4.3.1.Hereditary Angioedema and Acquired Deficiency of Cl INH
(1) Any patient with a history of HAE or with an acquired deficiency of Cl 
INH showing any signs of an angioedematous episode should be transferred 
as a matter of urgency to hospital for further management and observation 
as either endotracheal intubation or a surgical airway may be required 
(Thompson & Frable 1993). Episodes of angioedema may last 24-48 hours, 
often with increasing severity and so during significant episodes in-patient 
care is usually required (Giannoccaro et al. 1989). Patients who have bowel 
involvement may require re-hydration and narcotic analgesics as the bowel 
symptoms may be severe (Sim & Grant 1990).
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(2) In the long term, prevention of attacks is of prime importance as, once an 
attack has started, it can be extremely difficult to control despite intensive 
medical management with antihistamines, corticosteroids and adrenaline 
(Sim & Grant 1990). Prophylaxis is usually achieved by attenuated 
androgens such as danazol or stanozolol (Madanes & Farber 1982). Patients 
can be maintained on low doses of these steroids for long periods of time 
with little or no side effects (Cicardi et al. 1991). These anabolic steroids 
increase the plasma levels of Cl-INH as well as some other proteins 
(Cicardi et al. 1991). Pregnancy and menstruation increase HAE activity 
and prophylaxis with fresh frozen plasma and/or careful use of androgens 
during pregnancy has been useful (Hawthorne 1996; Sim & Grant 1990).
In patients with acquired Cl-INH, the most effective treatment is diagnosis 
and treatment of the underlying disorder, however the AE often precedes the 
discovery of the underlying disease by up to seven years so anabolic 
steroids may have to be used for a period of time (Markovic et al. 2000).
(3) Prophylaxis prior to surgical procedures involving the oral cavity is 
necessary in patients who have HAE or acquired Cl-INH deficiency. In 
some patients, the administration of a local anaesthetic may cause sufficient 
trauma to trigger an attack while in others, the stress of dental treatment 
contributes to their angioedema (Degroote, Smith, & Huttula 1985). The 
use of intravenous sedation is prudent to avoid further anxiety in these 
patients as the trauma of endotracheal intubation during a general
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anaesthetic has been shown to precipitate attacks (Kharesh 1992). Fresh 
frozen plasma can be administered to increase the levels of Cl-INH. Two 
units given 8 hours prior to treatment ensures adequate tissue distribution of 
the protein. Preparations of purified Cl-INH can also be used which 
reduces the risk of cross infection from plasma transfusions. These 
preparations have been shown to significantly reduce the number and 
severity of attacks (Atkinson & Frank 1991; Degroote, Smith, & Huttula 
1985).
1.4.3.2.Acquired Angioedema - Drug and Allergy-Related and 
Idiopathic Angioedema
(1) Although a patient with respiratory embarrassment secondary to AE 
would be unlikely to present to the dental surgeon, there is always the 
possibility that this could develop during a consultation or treatment in 
susceptible individuals (Grattan & Kennedy 1985). If there is respiratory 
distress or severe facial or lingual swelling, the patient should be transferred 
to hospital for further management as above. Administration of 
hydrocortisone and antihistamines such as chlorpheniramine, either 
intravenously or intramuscularly, is useful in the management of these cases 
as is the intramuscular administration of adrenaline (Wong 1990).
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(2) Patients who are likely to suffer from severe or recurrent episodes 
are instructed on the use of a self-administration system of intramuscular 
adrenaline, Epipen®, which delivers 300 micrograms of adrenaline (British 
Medical Association & Royal Pharmaceutical Society of Great Britain 
2000b).
Identification of the causative factor in the angioedema often provides the 
treatment regimen. This may require changing the drug regime or 
avoidance of identified allergens or physical factors . If food or 
environmental allergens are suspected, circulating IgE levels to putative 
allergens (RAST test) (Wuthrich, Bianchi-Kusch, & Johansson 1996) 
should be assessed and skin testing such as prick or patch tests should be 
carried out in a specialist centre (Lamey & Forsyth 1986; Tariq et al. 1996). 
In some cases, patients have been controlled on long term antihistamine 
therapy, while anticholinergics such as Pirenzepine have been useful in AE 
precipitated by physical factors (Ciprandi et al. 1989; Zuberbier, Bohm, & 
Czametzki 1993). An empirical, additive free diet was suggested by 
Malanin and Kalimo who found that skin testing was beneficial in 
predicting good responders to avoidance diets (Malanin & Kalimo 1989).
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(3) In severe cases, steroid or antihistamine cover should be considered 
prior to undertaking dental surgery. Patients with a history of severe 
reactions may require referral for hospital management of certain dental 
procedures (Atkinson & Frank 1991).
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1.5. Erythema Multiforme
1.5.1. Introduction
Erythema multiforme (EM) is thus named after its various clinical 
presentations which include macular, papular, vesiculo-bullous and 
ulcerative lesions and which may affect the skin, mucous membranes and 
conjunctiva (Schofield, Tatnall, & Leigh 1993). The disease is an 
uncommon mucocutaneous disorder that may represent a transient 
autoimmune defect (Lozada-Nur, Gorsky, & Silverman 1989). The age at 
onset is usually in the second and third decade (Farthing et al. 1995) and 
most initial presentations affect either the skin alone or the skin and the oral 
cavity though subsequent attacks were more likely to involve other sites as 
well (Farthing et al. 1995). The frequency of recurrence was 1-3 times per 
year in 34% of 82 EM patients investigated (Farthing et al. 1995) and a 
mean of 6 times per year in another study of 65 patients (Schofield, Tatnall, 
& Leigh 1993).
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1.5.2. Classification and Features
The clinical spectrum of EM can be classified by the severity into EM minor 
- one mucous membrane affected with or without cutaneous manifestations 
and major - more than one mucous membrane involved with severe 
generalised skin lesions (Huff, Weston, & Tonnesen 1983). Major EM is 
also termed Stevens-Johnson syndrome (SJS) (Anderson 1997a; Eversole
1994). Some authors consider that toxic epidermal necrolysis (TEN, Lyell’s 
disease, toxic epidermolysis), a rare, life threatening disorder characterised 
by widespread desquamation of skin and mucosa and multi organ-system 
failure, is part of the EM spectrum of diseases (Anderson 1997a).
EM may also be classified by its periodicity, either recurrent and self 
limiting or chronic and continuous (Eversole 1994; Manganaro 1996). The 
recurrent pattern lasts for usually 21 days while the chronic form if 
untreated may persist for years (Lozada-Nur, Gorsky, & Silverman 1989).
A characteristic feature of EM is vermilion haemorrhagic ulceration 
(Eversole 1994). Other clinical features include oral lesions in 25-50% of 
EM cases, and the classical target lesions of the skin which are found in 25- 
38% of cases (Lozada-Nur, Gorsky, & Silverman 1989; Lozada &
Silverman 1978). More severe types may also be accompanied by 
headaches and elevated temperatures (Lozada-Nur, Gorsky, & Silverman
1989).
Diagnosis is by exclusion together with the clinical features and history as 
the features of EM are characteristic rather than pathognomic (Manganaro
1996). Clinically especially in the absence of cutaneous or ocular
involvement, the lesions may mimic those of RAS and primary herpes 
(Farthing et al. 1995). EM may be differentiated from minor RAS by the 
fact that EM lesions more often affect keratinised mucosa and areas of 
confluent ulceration can often be seen, major RAS by the predilection of the 
fauces in this case, from herpetiform ulceration by the size of the ulcers, and 
from primary herpes by the fact that this is not recurrent and typically 
affects the hard palate and gingivae (Farthing et al. 1995). Microscopic 
examination aids in eliminating other diseases that may present a similar 
clinical appearance such as pemphigus vulgaris, benign mucous membrane 
pemphigoid and erosive lichen planus (Manganaro 1996). The histological 
appearance of EM is fairly non-specific and consists of intracellular oedema 
of the stratum spinosum, intra and subepithelial vesicle formation and a 
primarily chronic inflammatory cell infiltrate of varying intensity (Staretz & 
DeBoom 1990).
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1.5.3. Aetiology And Pathogenesis
EM is an acute dermatitis of unknown aetiology (Lombardi, Hauser, & 
Budtz Jorgensen 1993), nevertheless pharmacologic involvement is thought 
to be responsible for half of all cases, with circulating immune complexes 
consisting of antibody and drug antigenic component (Eversole 1994). The 
sulpha group of drugs have been implicated as causative agents in the 
majority of drug related EM (Eversole 1994) but many others have been 
recorded as precipitating the disease, such as the pharmacological 
preparations shown in Table 8.
Herpes simplex virus (HSV) infection accounts for many of the other cases 
particularly in recurrent EM and, though only one third of patients had 
detectable HSV by the polymerase chain reaction in this study, perhaps in 
most EM cases (Darragh et al. 1991). EM was preceded by HSV infection 
in 61% of 82 EM patients with the delay between HSV infection and EM 
being between 1 and 15 days in 97% of cases (Farthing et al. 1995).
EM can develop after a cutaneous delayed hypersensitivity reaction (Gil 
Mateo et al. 1995).
EM has also been associated with inflammatory bowel diseases such as 
ulcerative colitis and Crohn’s disease and the mechanism for this is thought 
to be a Type III or IV hypersensitivity reaction (Chapman, Forsyth, & 
MacQueen 1977).
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Table 8. Drugs Suspected In the Aetiology OF Erythema Multiforme
Antimalarials NSAIDs
Barbituates Penicillin
Bisulphan Phenylbutasone
Carbamazepine Phenytoin
Chlorpromide Salicylates
Clindamycin Sulphonamides
Codeine Tetracyclines
(Staretz & DeBoom 1990; Wolkenstein et al. 1996; Wright 1984; Yusin, 
Crawford, & Klaustermeyer 1999)
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T lymphocytes are the dominant part of the cell infiltrate and many bear the 
CD8+ phenotype (Lombardi, Hauser, & Budtz Jorgensen 1993), with CD4+ 
T cells being predominant in the peripheral tissues of a typical cutaneous 
target lesion (Puig et al. 1995). Langerhan’s cells are found to be increased 
in size and number in the early stages of the lesions (Lombardi, Hauser, & 
Budtz Jorgensen 1993). Anderson however states that no immune reaction 
has been identified in EM and refers to the disease as an ‘allergic-like 
reaction’ though he doesn’t state the mechanism of this response (Anderson 
1997a). Many reactions to topically applied agents have been termed EM- 
like reactions rather than EM though the histological picture, and more 
importantly the immunohistochemical characterisations of the two are very 
similar (Puig et al. 1995).
Eversole postulates that the mechanism behind EM involves immune 
complex vasculitis or the direct action of immunologic factors on the 
keratinocytes themselves resulting in necrosis (Eversole 1994). Puig et al 
consider that the epidermal expression of ICAM-1 and HLA-DR might be 
involved in the regulation of an immunologic process mediated by CD4+ 
lymphocytes which would give rise to the EM clinical and histological 
picture regardless of aetiology (Puig et al. 1995). In cases where HSV is 
suspected, the mechanism is likely to be an immune reaction to HSV rather 
than a pathologic effect of HSV itself (Scully 1993).
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1.5.4. Role of Allergy
As has already been stated, the immune pathogenesis of EM involves 
reaction to an antigen be it viral, drug or other type (Eversole 1994). Indeed 
EM has been described as a possible morphological pattern of ACD 
(Rietschel 1989), as a sequelae of ACD in some patients (Gil Mateo et al. 
1995) and others have suggested that EM may be a manifestation of an 
allergic contact sensitivity giving rise to a Type III reaction (Friedman & 
Perry 1985). Some however have been unable to identity any regularly 
associated factors with the onset of EM, drug, HSV or food/environmental 
hypersensitivities (Lozada-Nur, Gorsky, & Silverman 1989).
Other substances that have been reported as eliciting EM as a result of 
cutaneous or mucosal contact include: primula (Hjorth 1966), vitamin E 
(Saperstein, Rapaport, & Rietschel 1984), nickel (Friedman & Perry 1985), 
benzoic acid (Lewis et al. 1989), colophony and fragrance mix (O'Donnell 
& Tan 1997), sesquiterpene lactones (Gil Mateo et al. 1995) and bufexamac 
(Kurumaji 1998). It is most likely that a Type III hypersensitivity reaction 
is mainly responsible for the clinical features of EM though the close 
relationship with ACD suggests some role for a cell mediated role (Pedersen 
& Klausen 1984).
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1.5.5. Management and Treatment
Testing for HSV is usually carried out by attempting to culture the virus 
though this is often unsuccessful (Scully 1993) and questioning the patient 
may elicit information about previous episodes of herpes labialis (Farthing 
et al. 1995). However, in cases where the history of the disease includes 
recent HSV infection, continuous treatment with aciclovir 400mg twice 
daily has been shown to be more effective than short courses of the drug 
(Schofield, Tatnall, & Leigh 1993).
A careful history will indicate what, if any drugs were being used at the time 
of and prior to the initial eruption. Patch testing to drugs implicated in EM 
were useful in testing a topical preparation (Kurumaji 1998) but showed 
weak sensitivity to systemically administered drugs thought to precipitate 
SJS (Wolkenstein et al. 1996). Treatment of the lesions is largely 
symptomatic and involves pain relief, fluid replacement (Wright 984) 
(intravenously if required) (Farthing et al. 1995) and antimicrobial therapy 
to prevent or treat secondary infections (Roleau 1999). Corticosteroids are 
used to both prevent, and modulate the severity of lesions in minor EM but 
have been shown to be deleterious in severe SJS and TEN (Roleau 1999). 
Levamisole may be used as a steroid potentiator or as treatment in its own 
right and both regimes have shown good results in a double blind cross over 
trial in 14 patients (Lozada 1982). Dapsone and antimalarials have also 
been utilised with a small degree of success (Schofield, Tatnall, & Leigh
1993). Azathioprine is recommended by some authors (Farthing et al.
Early withdrawal of the offending medication in drug-induced SJS/TEN is 
vital as this may save lives (Roleau 1999) and treatment of these severe 
cases is thought to be best undertaken in either specialised intensive care 
units or bums units and the symptomatic therapy should be the same as for 
major bums (warming of the environment, correction of fluid and 
electrolyte losses, high calorie intake and the prevention of sepsis) (Roleau 
1999).
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1.6. Orofacial Granulomatosis
1.6.1. Introduction
Oral granulomatous lesions were identified as part of the clinical picture of 
Crohn’s disease in 1969 (Dudeney 1969). In 1985, Wiesenfield introduced 
the term orofacial granulomatosis (OFG) as an umbrella term for diseases of, 
the oral cavity that are characterised by persistent oedema of the lips and/or 
orofacial regions, and that present a granulomatous histological appearance 
(Wiesenfeld et al. 1985).
The term ‘granulomatous’ implies that a histological examination has been 
performed and that granulomas have been identified. However, some 
authors use the term to describe a clinical picture as well, whether 
granulomas were found on biopsy or not (Wiesenfeld et al. 1985). Gibson 
recommends the use of the term orofacial lymphoedema to describe the 
clinical picture as granulomas are not always identified in specimens from 
these patients (Gibson 1998).
OFG includes Melkersson Rosenthal Syndrome (MRS), oral Crohn’s 
disease (OCD), cheilitis granulomatosis (CG), sarcoidosis and Miescher’s 
granulomatous cheilitis. Unfortunately some of the definitions of these 
diseases have been applied very loosely in some publications (Sussman, 
Yang, & Steinberg 1992) for instance CG is regarded by some as an 
oligosymptomatic form of MRS (Worsaae et al. 1982). Clinically, some 
cases of angioedema have been confused with OFG (Rees 1999).
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1.6.2. Classification and Features
1.6.2.1.Orofacial Granulomatosis
The clinical feature of OFG as described by Wiesenfield are: facial 
swelling, lip swelling, mucosal oedema (lobulated or cobblestone 
appearance), mucosal tags, gingival lesions (full thickness erythema and 
swelling), angular cheilitis, oral ulceration (usually irregular or linear in 
shape and affects 30-40% of patients with OFG (Armstrong & Burrows
1995)), geographic tongue, fissured tongue and unilateral facial nerve palsy 
(Wiesenfeld et al. 1985). The observed histological features were: oedema 
of the superficial corium with prominent dilated lymphatic vessels, 
granuloma formation in 47/57 patients and occasional intracellular 
birefringent material observed in some granulomas (which was not 
considered to be of aetiological significance). The granulomas varied 
considerably consisting of cells such as epithelioid histiocytes, 
multinucleated cells, lymphocytes and macrophages (Wiesenfeld et al.
1985). Six out of 60 OFG patients were diagnosed with definite Crohn’s 
disease while two patients were diagnosed with sarcoidosis (Wiesenfeld et 
al. 1985).
OFG is a disease of primarily young adults and children, younger subjects 
being more likely to have, or to develop, CD (Sainsbury et al. 1987) and the 
distribution among the sexes is equal (James et al. 1986).
OFG patients with pyostomatitis vegetans are more likely to have OCD as it 
is associated with inflammatory bowel diseases and thus they should be
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referred for gastrointestinal investigation (Rees 1999). Sanderson et al 
(1996) found a much higher incidence of OCD in patients manifesting signs 
of OFG. Ten patients who had no gastrointestinal symptoms were 
investigated for CD by colonoscopy, and eight of then had macroscopic or 
microscopic evidence of inflammation with seven showing granuloma 
formation (Sanderson et al. 1996).
1.6.2.2.Melkersson-Rosenthal Syndrome
The earliest references to this disorder were in 1859 by Mart (Wiesenfeld et 
al. 1985). Melkersson described the association of facial paralysis with 
facial oedema in 1928 and in 1931 Rosenthal added the finding of lingua 
plicata (also termed ‘fissured’, ‘scrotal’ or preferably ‘furrowed’ tongue 
(Fisher 1990)) as another associated sign and the triad was termed MRS in 
1949 (Sussman, Yang, & Steinberg 1992). Many authors have since 
attempted to describe ‘mono-symptomatic’ MRS (Sussman, Yang, & 
Steinberg 1992). It is considered that lip swelling occurs in 66% of MRS 
patients (Hernandez, Hernandez, & Lucas 1986), though Homstein includes 
this as by far the predominant feature (Homstein 1997) and Sussman et al 
states the definitive diagnosis of MRS is only possible after a lip biopsy 
which suggests that they consider the diagnosis to stand even if no other 
symptoms are present (Sussman, Yang, & Steinberg 1992). Facial palsy 
occurs in 30% of cases and fissured tongue occurs in 20-40% of cases 
(Podmore & Burrows 1986). Some authors found that facial oedema was
present in 50% of MRS patients (Zimmer et al. 1992). This variation in 
presenting signs and symptoms makes the strict diagnosis of MRS as a triad 
of symptoms, tenuous at best in the majority of patients thus labelled 
however some of the difficulty in diagnosis is due to the fact that there may 
be a delay in the appearance of some of the symptoms for months or years 
(Homstein 1997). Some authors include other clinical signs that are often 
found in MRS such as sclerosing macroglossitis, palsies of other cranial 
nerves, transitory encephalopathic disturbances and eyelid, facial or 
intraoral swelling (Homstein 1997). As well as the intraoral swelling that 
may affect the labial, buccal, gingival, sublingual and palatal mucosa 
(Worsaae et al. 1982) and the tongue (Zimmer et al. 1992), further signs that 
have been reported are gingivitis, gingival and buccal erosions and buccal 
erythema (Zimmer et al. 1992). The signs of Assuring of the lips, angular 
cheilitis and excoriation of the lips are direct consequences of the lip 
oedema (Vistnes & Kemahan 1971). Several authors include a wide variety 
of ‘minor’ accompanying signs as part of the clinical picture of MRS such 
as the extensive list of nineteen neurological signs described by Homstein 
(Homstein 1997). The systemic or more generalised symptoms that have 
been associated with MRS are pyrexia, chills, migraine headaches, 
premenstrual tension, nausea, vomiting, epiglottic dysphagia, 
bronchospasm, acrocyanosis of hands and feet and factitious urticaria 
(Alexander & James 1972; Homstein 1997; Ingram 1993; Worsaae et al. 
1982).
There is an equal sex distribution and MRS commonly occurs in the second 
and third decades (Worsaae et al. 1982).
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Histological examination shows the presence of noncaseating granulomas in 
many cases though it is not considered an obligatory characteristic by some 
authors (Homstein 1997). The granulomas often consist of epithelioid giant 
cells and are perivascularly situated (Podmore & Burrows 1986). Other 
common features are non specific inflammation, the presence of 
lymphocytes and plasma cells in the granulomas and oedematous connective 
tissue (Worsaae & Pindborg 1980).
Cheilitis granulomatosa (CG) has been described as mono-symptomatic 
MRS as patients present with only swelling affecting one or both lips 
(Podmore & Burrows 1986). CG also usually affects young adults and is 
also called Miescher’s granulomatous cheilitis. Clinically, the picture is of 
diffuse, non-tender swelling of one or both lips and the histological features 
are of non-necrotising granulomas and oedema, lymphangiectasia and 
perivascular infiltration (Allen et al. 1990). CG is probably identical to 
what is termed OFG (Field & Tyldesley 1989).
Rees considers that the diagnosis of classic (triad present) or mono- 
symptomatic MRS should be considered as a default diagnosis once Crohn’s 
disease, sarcoidosis and allergic stomatitis have been ruled out, with OFG 
being the running diagnosis while investigations are going on (Rees 1999).
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1.6.2.3,Oral Crohn’s Disease
OCD and OFG have been shown to be closely linked and many authors 
have use the terms synonymously as the difference between them is still 
considered to be controversial (Ivanyi, Kirby, & Zakrzewska 1993). It is 
estimated that oral lesions have been found in 0-20% of patients with CD 
(Rees 1999), while among OFG patients, 6% (n=6) (Gibson, Forsyth, & 
Milligan 1995), 10% (n=6) (Wiesenfeld et al. 1985), 17% (n=13) (James et 
al. 1986), 37% (n=7) (Scully et al. 1982) and 48% (n= 14) (Williams, Wray, 
& Ferguson 1991) have later developed CD.
Early OCD is held to be difficult to distinguish from oligosymptomatic 
MRS (Homstein 1997).
1.6.2.4.Sarcoidosis
Sarcoidosis is a chronic multisystem disease of unknown origin whose onset 
is in young adulthood and which may be life-threatening if the lungs or 
other vital organs are involved (Rees 1999). It has clinical and histological 
features as in the facial/lip swelling of OFG but the swelling is also 
associated with evidence of more systemic involvement (Armstrong & 
Burrows 1995). Rarely, a patient with sarcoidosis may initially present with 
tongue swelling alone (Mendelsohn, Field, & Woolgar 1992). Symptoms 
may include weight loss, fatigue, cough and bone or joint pain (Frieden et
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al. 1989). It has been estimated that up to 3% of OFG patients also have 
signs and symptoms of sarcoidosis (Wiesenfeld et al. 1985).
125
1.6.3. Aetiology
The histological features of granulomas have prompted some to consider 
that the lip swelling may be composed of lymphoedema due to blockage of 
the lymphatics by the granulomas (Hernandez, Hernandez, & Lucas 1986).
1.6.3.1.0rofacial granulomatosis
No hereditary predisposition was found in 60 cases (Wiesenfeld et al. 1985) 
and hereditary factors are not considered to be of much importance by other 
authors (Armstrong & Burrows 1995).
The presence of mycobacterial infection has been investigated in 60 cases of 
OFG with entirely negative results after Ziehl-Neelson staining of lesional 
tissue samples (Wiesenfeld et al. 1985). One patient presented with cervical 
lymphadenopathy that had granulomas on histological examination that was 
diagnosed and treated as tuberculosis though Zeehl-Neelson stains showed 
no acid-alcohol-fast bacilli and a chest radiograph was normal. Three years 
later the patient represented with lip swelling and classical OFG features 
demonstrating that granulomatous cervical lymphadenopathy may be an 
early sign of OFG (James & Ferguson 1986).
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1.6.3.2.Melkersson-Rosenthal Syndrome
The three most likely aetiologies are hereditary, allergic or infectious factors 
(Alexander & James 1972) and Meisel-Stosiek et al suggest a multifactorial 
origin including a genetic basis (Meisel-Stosiek, Homstein, & Stosiek
1990).
MRS is held to be inherited as an incomplete, autosomal dominant trait 
with variable penetrance (Alexander & James 1972). Lygidakis identified 
MRS in seven family members spanning four generations (Lygidakis, 
Tsakamarakas, & Illias 1979). 42 patients with MRS and 171 of their 
relatives were examined in another study and were found to have an 
increased incidence of furrowed tongue (62% compared to the 15% 
incidence in the German population). This was the most striking inherited 
pattern as, precluding the tongue lesions the relative risk for MRS in first 
degree relatives was only 7% (estimated). It is therefore doubtful that the 
known hereditary anomaly of furrowed tongue can be extended to include 
all the symptoms of MRS. Nevertheless, the close association of furrowed 
tongue as part of MRS does suggest some genetic factors (Meisel-Stosiek, 
Homstein, & Stosiek 1990). A possible location of the responsible gene is 
at 9pl 1 (Smeets, Fryns, & van den 1994).
Allergy to food additives (Pachor, Urbani, & Cortina 1989), flavourings 
(McKenna, Walsh, & Burrows 1994) and food stuffs (nuts) (Hernandez, 
Hernandez, & Lucas 1986) have been advocated, (see section 1.6.4.).
Viral aetiologies as herpetiform eruptions have preceded the lip swelling 
(Alexander & James 1972) and mycobacterial infection produces a similar 
histological picture (Sussman, Yang, & Steinberg 1992).
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Stress, emotional turmoil, cold and trauma have all been proposed as 
precipitating factors (Nally 1970).
The generally held suggested pathogenesis of MRS is that of an abnormal 
reactivity of the cranial neurovascular system which causes intermittent 
orofacial oedema (the palsy is caused by nerve compression of the facial 
nerve or by direct granulomatous infiltration of the nerve sheath (Henry
1994)). The regional mucocutaneous tissues are therefore more susceptible 
to inflammatory reactions to noxious (allergic/infectious) stimuli (Meisel- 
Stosiek, Homstein, & Stosiek 1990).
1.6.3.3.0ral Crohn’s disease
Mycobacterial infection has been suspected to be involved in the aetiology 
of CD for some time and IgG antibodies to mycobacterial stress protein 
(mSP65) have been shown to be raised in some CD patients (Elsaghier et al. 
1992) though certain epitopes of stress proteins are shared by several 
bacterial genera so other bacteria may be responsible. The mSP65 levels 
were measured in ten patients with OFG and were found to be significantly 
elevated in four of them who had OCD, and in three (these three had no CD 
at the time ) out of the remaining six patients, compared to a control group 
(Ivanyi, Kirby, & Zakrzewska 1993). Mycobacterium paratuberculosis has 
been identified as the causative factor in provoking a delayed 
hypersensitivity reaction in Johne’s disease, the ruminant equivalent of 
human CD (Morgan 1987). IgG antibodies to M. paratuberculosis were 
measured prior to and after dapsone therapy of CD and were significantly
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higher in those patients that responded well to the treatment suggesting that 
either mycobacteria or a cross reacting species, sensitive to dapsone, are 
responsible for the development of CD (Prantera et al. 1989). The 
polymerase chain reaction technique was used to identify M  
paratuberculosis in fresh frozen tissue from CD patients and was successful 
in two thirds of CD cases and 12.5% of normal controls (Sanderson et al. 
1992). A further study using similar techniques in OCD and OFG lesional 
tissue (paraffin wax embedded) samples failed to isolate M. 
paratuberculosis in either of the disease groups though the use of paraffin 
wax embedded tissue may have been a factor in the negative results (Riggio 
et al. 1997).
The granulomatous reactions seen in CD has been postulated to be a result 
of a foreign body reaction against the silicates ingested through using 
toothpaste (Sullivan 1990).
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1.6.4. Role of Allergy
Atopy has been suggested to coincide with OFG in 12% (n=l), 20%(n=29) 
and 60% (n=45) of cases in various studies (James et al. 1986; Sainsbury et 
al. 1987; Williams, Wray, & Ferguson 1991).
A Type IV allergic response to either an unidentified, non-degradable, 
particulate dental allergen or to an infectious agent was considered to be a 
possibility in some patients (Sussman, Yang, & Steinberg 1992). Analysis 
of T cell receptor V gene usage in an OFG patient suggested that delayed 
hypersensitivity was involved in the pathogenesis of the disease (Lim et al.
1997) and cellular immunity was also supported by a case with a decreased 
CD4:CD8 ratio (Henry 1994). Allen et al considered that the presence of 
the perivascular infiltrate and the granulomatous reaction in CG suggested 
that an immune response to some antigen/pathogen was involved (Allen et 
al. 1990).
Alexander and James consider that the possible role of allergy in OGD is 
inconsistent with the localised nature of the lesions (Alexander & James 
1972) though they do not state what type of allergy they mean here.
One patient with CG who had extensive dental restorations was patch tested 
to dental materials with negative results (Sussman, Yang, & Steinberg 
1992). Pachor et al described a case of MRS without the neurological 
involvement of the facial nerves (Pachor, Urbani, & Cortina 1989). This 
patient had positive reactions on double blind food challenge after 
elimination diet therapy to sodium benzoate and tartrazine and experienced 
complete remission of his facial swelling upon avoidance of these additives.
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In a report of a case, Hernandez et al found that the patient with CG tested 
positive to almonds, hazelnuts, lactalbumin and rye on allergy testing 
(Hernandez, Hernandez, & Lucas 1986); on allergen avoidance of these 
foods, the patient experienced resolution of the lip swelling. In other 
isolated case reports, several authors had demonstrated the allergic nature of 
OFG to various allergens such as cobalt (Pryce & King 1990), monosodium 
glutamate (Oliver et al. 1991) carmosine and sunset yellow (Sweatman et al.
1986).
Several series of OFG patients most of whom who underwent patch testing 
with various allergens have been presented. 14 of 80 OFG patients (18%) 
were deemed to have an allergic response to foods or food additives though 
it was not stated how many of the 80 were patch tested and a very limited 
range of allergens were tested (cocoa, cinnamaldehyde, cinnamon and 
piperitone) (Patton et al. 1985). In another study 100 OFG patients were all 
tested to the Standard European Series and to food additives (FA), 
flavourings and dental materials. Immediate contact urticaria testing (20 
minutes) was also carried out with the FA and flavourings. Overall 93 were 
positive to one or more allergens with the most common allergens being; 
benzoates (45), cinnamon (45), chocolate (19) and nickel (14) (Gibson, 
Forsyth, & Milligan 1995). Armstrong et al reported a series of 48 OFG 
patients who were all patch tested to a similar battery of allergens (with 
immediate contact urticaria testing as well) as the previous series of 100 
patients. However only 20 (42%) had positive reactions to the standard 
patch tests with the most common allergens being nickel (4 patients) and 
fragrance mix (3). Ten patients had 14 positive responses to the FA and
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flavouring allergens and out of this group, seven reported improvement on 
allergen avoidance. A further 18 (38%) had positives to the contact urticaria 
tests; benzoic acid (18), sorbic acid (15) and cinnamaldehyde (15) 
(Armstrong et al. 1997). It was not stated whether there was any crossover 
between the three groups listed and how many (if any) were negative, or if 
the contact urticaria reaction was read at the end of the 20 minutes only or 
evaluated after six hours. This could have a marked effect on the number of 
false positives reported as benzoic acid in particular can give rise to 
transient irritant reactions (Lahti 1980).
In all of these reports, no control groups were patch tested and this lack has 
been noted by others who have called for control populations particularly in 
relation to reactions to cinnamaldehyde (Challacombe 1997).
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1.6.5. Management and Treatment
Appropriate treatment of OFG involves primarily investigations leading to a 
more specific diagnosis if possible (AE, OCD, sarcoidosis). Once these 
diseases have been excluded, appropriate allergy testing may identify a 
further section who can be treated effectively by allergen avoidance. This 
leaves patients with MRS on which a multiplicity of treatments have been 
tried with various results.
Investigations include questioning the patient for a history of 
gastrointestinal disturbance, symptoms of sarcoidosis or precipitating 
allergens. The nutritional status of patients should be checked at regular 
intervals to pick up asymptomatic gastrointestinal disease (Field & 
Tyldesley 1989; Scully et al. 1982). Radiographic examination (chest and 
barium meal series of the intestine) will assist in the diagnosis of sarcoidosis 
and CD (Field & Tyldesley 1989). Haematological and biochemical 
parameters such as serum ACE, Cl esterase inhibitor, complement, liver 
function tests, urea and electrolytes, serum calcium, phosphate, zinc, 
magnesium and immunoglobulin concentrations and erythrocyte 
sedimentation rate should also be measured (Scully etal. 1982). A biopsy 
of affected tissues should include the deep subcutaneous layers as some 
granulomas are located next to minor salivary glands and even into the 
facial musculature (Wiesenfeld et al. 1985). If CD or sarcoidosis are 
suspected, the patient should also be referred for further evaluation and
treatment as required. Some have proposed that serum IgA may prove to be 
a marker of OFG and/or OCD as this immunoglobulin has been found in 
increased quantities in these diseases (Challacombe et al. 1997). Patch 
testing to include food additives, flavourings and constituents of dental 
prophylactic preparations are appropriate allergy tests as it is a Type IV 
reaction that is suspected (Rees 1999).
Swelling of the lips has been treated with intralesional steroid injections, 
oral prednisolone, oral hydroxychloroquine and surgical reduction (Allen et 
al. 1990). Surgical reduction has yielded good initial results in some cases 
but recurrence is common and scar tissue formation may require further 
surgical intervention (Henry 1994) and is thought overall to be not 
warranted in most cases (Editorial 1991). As well as anti-malarial drugs, 
the anti-leprous drug clofazimine has been reported to have been clinically 
effective in one case of classic MRS and three cases of CG. The mechanism 
of action in these cases was thought to be of increased macrophage 
phagocytosis (Podmore & Burrows 1986). The intralesional steroids seem 
to be the most efficacious but spontaneous remission has been reported 
(Allen et al. 1990; Sakuntabhai, Macleod, & Lawrence 1992; Worsaae et al.
1982) and it is hard to know what brought about the resolution especially 
when some have claimed that intralesional injection of boiled water has 
given good results (Vistnes & Kemahan 1971). Removal of dental foci of 
infection has improved the lip swelling in some cases (Nally 1970) and laser 
beam acupuncture has been described as a promising treatment by others 
(Homstein 1997). Many authors have tried various treatments, including
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glucocorticoids, antihistamines, radiotherapy, sulphasalazine, co- 
trimoxazole, metronidazole, azathioprine all to no avail (Editorial 1991; 
Morales et al. 1995; Vistnes & Kemahan 1971; Wiesenfeld et al. 1985; 
Worsaae et al. 1982). Fisher found that a combination of tetracycline and 
prednisolone reduced lip swelling and prevented further recurrences of 
facial palsy (Fisher 1990).
The facial nerve palsy of MRS is considered to be self limiting, usually 
lasting about eight weeks and thus no treatment is offered in the majority of 
cases (Alexander & James 1972) though some advocate the use of systemic 
steroids (Zimmer et al. 1992). Though electrical stimulation of the nerve 
during the period of palsy has been suggested, its efficacy is debatable 
(Vistnes & Kemahan 1971). However, complete resolution does not occur 
in a small number (Zimmer et al. 1992) and residual weakness can be 
markedly disfiguring (Alexander & James 1972). Treatment that can then 
be offered consists of surgical decompression of the affected nerve (Vistnes 
& Kemahan 1971).
Where allergy is suspected, and an allergen identified by appropriate testing, 
allergen avoidance has been shown to give resolution in 55% (complete) 
and 37% (partial) patients (Gibson, Forsyth, & Milligan 1995). One patient 
improved only after commencing on an elemental diet with staggered 
introduction of different foods though she had shown positive reactions to 
some food additives, it was considered that other food stuffs not included in 
the allergy testing procedure must also be provoking her immune system to 
respond (Sweatman et al. 1986).
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Compliance with dietary advice is improved when it is given by a dietitian 
or senior clinician (Gibson, Forsyth, & Milligan 1995).
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1.7. Other Oral Diseases And Allergy
1.7.1. Plasma Cell Gingivitis
Plasma cell gingivitis has been described as a syndrome consisting of a triad 
of signs; gingivitis, cheilitis and glossitis, with early reports attributing the 
signs to a hypersensitivity reaction to micro-organisms or constituents of 
toothpastes or chewing gum (Silverman & Lozada 1977). It is now termed 
allergic gingivostomatitis (Wray et al. 1999). The pathognomonic histology 
consists of diffuse sheets of plasma cells replacing normal connective tissue 
structure. Silverman and Lozada in 1977 on review of the literature and 
from their own experience concluded that this syndrome was a transient 
disease occurring between approximately 1966 andl973 and affecting few 
persons and titled their publication ‘An epilogue to plasma-cell gingivitis’ 
accordingly. As a total of 12 patient’s lesions resolved on systemic 
prednisolone therapy and two responded to discontinued use of chewing 
gum or toothpaste, they postulated that it was caused by allergy to an 
unidentified allergen present in substances such as chewing gums and 
toothpastes, though no allergy testing or oral rechallenge with the suspected 
agents were carried out. In all patients, the cheilitis component completely 
resolved with an antifungal cream (Silverman & Lozada 1977). 
Unfortunately for the title, further cases of plasma cell gingivitis have been 
described in the subsequent years. Palmer and Eveson found no evidence of 
allergy in two cases with full thickness gingivitis which histologically 
contained a predominantly plasma cell infiltrate but there were no signs of
glossitis or cheilitis. Again there were no allergy tests done and the 
immunogenic component was discounted merely because the patients did 
not chew gum and had no resolution on discontinuance of their toothpaste. 
Interestingly one of the patients was treated with triamcinalone in orabase 
with a resultant slight improvement, but this was not followed with a 
stronger steroid and in both patients, the lesions persisted (Palmer & Eveson 
1981). Further case reports have described one case related to use of a 
herbal toothpaste despite a negative patch test to the suspected paste 
(Macleod & Ellis 1989). In two cases reported in 1992 no causative 
allergen was discovered despite one patient reporting her symptoms starting 
with the use of a mouth wash preparation and undergoing no allergy tests, 
and the other’s (what the authors refer to as) ‘extensive allergy testing’ 
being confined to selected inhaled allergens and eight foods all of which 
have been associated with IgE mediated reactions. No allergens associated 
with delayed type hypersensitivity reactions were tested (Sollecito & 
Greenberg 1992). Other case reports have related plasma cell gingivitis to 
the use of a mint flavoured confectionery and to spices though no allergy 
tests were carried out (Lubow et al. 1984; Reed et al. 1993).
A few authors have noted the psoriasiform appearance to the histological 
appearance of the affected epithelium, and the fact that two patients 
concomitantly suffered from psoriasis (Lubow et al. 1984; Palmer & Eveson 
1981).
138
1.7.2. Desquamative Gingivitis
Desquamative gingivitis is a term that has been used for many years to 
describe erythematous, desquamating appearance of the marginal and 
attached gingivae that bleeds upon mild trauma. The condition is sore if not 
painful and as a result of this often has superimposed marginal gingivitis 
due to the pain and bleeding on tooth brushing (Jandinski & Shklar 1976). 
Desquamative gingivitis (DG) is a clinical description rather than a 
diagnosis. In a study of 453 patients attending a dermatology clinic, the 
percentages of each of the disease groups with which DG was associated 
were; mucous membrane pemphigoid (MMP) 63.6%, lichen planus (LP) 
25%, pemphigus vulgaris (PV) 18.4% and bullous pemphigoid (BP) 3.2%. 
The definitive diagnosis was made from a biopsy of non-lesional mucosa 
with both histological and immunological examination (Sklavounou & 
Laskaris 1983). Markopoulos 13 years later found that the percentages of 
patients in different disease groups presenting with DG were slightly 
different: MMP 41.6%, PV 9.1% and OLP 6.8% (Markopoulos et al. 1996). 
In a study of 49 cases of DG they found that two had no histological 
evidence of MMP, PV or OLP and classed this group as idiopathic 
(Markopoulos et al. 1996). Recently Staines et al (1998) described a case of 
idiopathic DG that was related to an allergic response to formaldehyde in 
nail vamish (the patient was a habitual nail biter). No biopsy was taken but 
indirect immunofluorescence was carried out to exclude some 
immunological diseases before the patient was referred for cutaneous patch 
testing. The authors suggest that idiopathic DG is the same condition as
plasma cell gingivitis, which is more often associated with allergic 
mechanisms (Staines, Felix, & Forsyth 1998). The same year, Yih et al 
widened the collection of diseases that may present as DG to comprise: 
erosive OLP, lichenoid mucositis, MMP, PV, paraneoplastic pemphigus, 
linear IgA disease and BP, as an immunological group and an idiopathic 
group consisting of chronic bacterial, fungal or viral infections and other 
factors of a non autoimmune nature capable of causing irritation or 
inflammation (Yih et al. 1998). In 72 patients with DG Yih et al found that 
the most common underlying disease was erosive OLP and lichenoid 
mucositis, together comprising 42% of patients. They describe lichenoid 
mucositis as possibly being a result of a hypersensitivity reaction to drugs, 
dental materials or foods (Yih et al. 1998).
Treatment of DG not due to pemphigus is often difficult and involves oral 
hygiene measures, topical steroid preparations held against the gingivae 
with a Wenvac splint, and systemic steroids in persistent cases (Scully & 
Porter 1997). Some authors found that dapsone therapy met with some 
success (Matthews, Pinkney, & Scully 1981).
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1.7.3. Oral Dysaesthesia
Also termed burning mouth syndrome and glossodynia, oral dysaesthesia 
(OD) is a complex issue in that a wide variety of aetiological factors have 
been implicated. This state of affairs stems in part from the fact that in OD, 
no clinical or histological evidence of disease can be observed and the 
disorder is based on the subjective symptoms experienced by the patient. 
Three types have been described by Lamey and Lamb: in type 1, the 
burning is not present on waking and appears and worsens as the day 
progresses; in type 2, the burning sensation is constant and unremitting and 
in type 3 the symptoms are intermittent (Lamey et al. 1994). OD primarily 
affects post climacteric females and the age of onset is usually in the fifth 
decade (Helton & Storrs 1994). The symptoms of patients who experienced 
burning sensations intraorally were noted in a prospective study of 25 
patients (eight of whom who also had visible oral mucosal lesions so not all 
had OD) (Bergdahl, Anneroth, & Anneroth 1994). Most (24) complained of 
a wide variety of extraoral symptoms as well such as musculo-skeletal 
disorders, headache, dizziness, skin problems, insomnia, stress, fatigue and 
anxiety (Bergdahl, Anneroth, & Anneroth 1994).
The aetiology of OD is thought to reside in three main groups: local factors 
such as xerostomia, candidiasis, tongue dysfunction and hypersensitivity 
reactions; systemic factors such as anaemia, drug side effects and hormonal 
disturbances and psychogenic factors such as depression, anxiety and 
phobias (Bergdahl, Anneroth, & Anneroth 1994). Type 1 OD is thought to 
be often related to systemic factors, type 2 to psychogenic factors and type 3
to local factors particularly hypersensitivity (Lamey et al. 1994). In patients 
with type 3 OD who had no demonstrable allergy on patch testing, 
significantly higher levels of psychiatric illness were found compared to 
those with an identifiable allergen when using the General Health 
Questionnaire but this was not confirmed by using the Hospital Anxiety and 
Depression scale (Lamey et al. 1994). Treatment for those identified as 
having a psychogenic basis for the burning sensations includes reassurance, 
anxiolytic and antidepressant medication, and cognitive-behaviour therapy 
(Humphris, Longman, & Field 1996).
I.7.3.I. Role of allergy
A wide variety of allergens have been implicated in causing a 
hypersensitivity response giving rise to OD. These include: acrylic 
monomer, benzoyl peroxide, butyl methacrylate, cobalt chloride, N,N- 
dimethyl-4-toluidine, formaldehyde, glycol dimethacrylate, gold chloride, 
nickel sulphate, oligoacrylate, /7-phenylenediamine, polyethyl methacrylate, 
potassium bichromate, 4-tolydiethanolamine, and food additives such as 
sorbic acid and propylene glycol (de Groot, Weyland, & Nater 1994).
21 patients in a different study were patch tested to a dental series and two 
(9.5%) showed a positive response to mercury with resolution of the 
burning sensation after their amalgam fillings were removed (one of these 
had a positive result to patch testing with gold also and this restorative 
material was also replaced). This was higher than the previously reported
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prevalence of 0% of 24 Swedish patients though the numbers were small in 
both studies (Skoglund & Egelrud 1991).
In this group, 30% of patients had a deficiency of iron though no patients 
with iron deficiency alone were cured with replacement therapy (one patient 
with vitamin B12 and iron deficiency had complete resolution of the burning 
symptoms after replacement therapy) (Bergdahl, Anneroth, & Anneroth 
1994). In a further study of 33 OD patients, 23 (65%) were found to have 
positive results to patch testing and of these 10 patients experienced 
complete symptomatic resolution upon allergen avoidance (Lamey et al.
1994). The allergens implicated were acrylics, epoxy resin, benzoic acid, 
propylene glycol, cinnamon, cinnamaldehyde, cinnamyl alcohol, fragrances, 
sorbic acid, cobalt and nickel and in nine patients, the burning recommenced 
on rechallenge (Lamey, Lamb, et al. 1994)}. Nickel allergy was found to be 
more prevalent in OD patients (21%) than OLP patients (3%) in a study in 
which 24 patients in each disease group were patch tested (Skoglund & 
Egelrud 1991). In a Finnish study, four patients with OD had positive 
results on patch testing with a dental series of allergens, three to gold and 
one to mercury; however none of these reactions were considered clinically 
relevant to their oral symptoms (Alanko et al. 1996). 22 patients with OD 
(though the authors stated that some had a mild erythematous appearance to 
the oral mucosa) were investigated by patch testing to a routine, dental and a 
spice series of allergens and a high proportion had relevant, positive 
reactions to materials used in the manufacture of acrylic dentures (27%) and 
to metals used in dentistry (27%) (Dutree-Meulenberg, Kozel, & van Joosst 
1992). Other positive reactions were elicited to carba mix,
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phenylenediamine, formaldehyde, fragrance mix, balsam of peru, wood tar 
mix, primin, nutmeg, coriander, cinnamon, celery and curry (Dutree- 
Meulenberg, Kozel, & van Joosst 1992).
Of 53 other OD patients, 23% had relevant positive patch test reactions to 
materials used in the manufacture of denture bases (Kaaber & Nielsen 1979) 
and van Joost described a further four patients all with positive reactions to 
denture materials (van Joosst, van Ulsen, & van Loon 1988).
Peanut sensitivity has been implicated in a patient with OD (Whitley, 
Shepherd, & Ferguson 1991) though food additives and flavourings have 
been reported more frequently (Lamey et al. 1994; Lamey, Lamb, & Forsyth 
1987).
An American study found none of eight OD patients had positive reactions 
to patch tests using dental allergens though two had a non-immunologic 
contact urticaria reaction to cinnamic aldehyde and also had decreased 
symptoms after avoiding the agent (Helton & Storrs 1994).
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CHAPTER 2 AIMS AND HYPOTHESES
2.1. Aims
Reactions to food additives and flavourings have been documented in OLE, 
(Todd et al. 1990; Yiannias et al. 2000), RAS (Wray, Vlagopolous, & 
Siraganian 1982; Wright et al. 1986), AE (de Martino et al. 1992; Squire
1987), EM (Lewis et al. 1989; O’Donnell & Tan 1997) and OFG (Gibson, 
Forsyth, & Milligan 1995; Oliver et al. 1991; Pachor, Urbani, & Cortina 
1989). In none of the above publications were healthy controls also tested. 
It was therefore deemed of importance to patch test a healthy (without any 
of the oral mucosal diseases mentioned above) group of control subjects. 
From 1980 to 1996, patients from Glasgow Dental Hospital & School were 
referred to the Contact Dermatitis Investigation Unit (CDIU) at Belvidere 
Hospital (until 1994) and then at Glasgow Royal Infirmary, in order to 
investigate the role that allergy played in the oral mucosal diseases from 
which they suffered. The results of these tests were entered into a computer 
database.
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A total of 1252 patients were tested (patch testing or delayed 
hypersensitivity testing, and contact urticaria testing) over the 16 year 
period and though various case reports and some larger studies utilised some 
of these results10, no comprehensive or total analysis had been carried out to 
investigate this large group of patients. It was considered to be of good 
clinical and economical sense to categorically state the clinical benefit, if 
any of these referrals.
To this end, investigation into subjective clinical improvement experienced 
by the patients themselves, following the utilisation of avoidance diets (in 
cases of allergy to food substances), was considered important.
For some years it had been considered that there were differences in the 
histological appearance of sections from patients with OLE who had lesions 
and who also had amalgam dental restorations, and those who had OLE 
lesions in amalgam-free mouths. The differences that had been subjectively 
noted to be associated with amalgam related OLE were an increased number 
of apoptotic cells, an increase in the disruption of the basal cell layers of the 
epithelium, and an increased thickness and density of the inflammatory 
infiltrate. Likewise, the microscopic appearance of OLE lesions that were
10 The results of studies on some of these patients have been published in previous papers 
(Garioch et al. 1990; Gibson, Forsyth, & Milligan 1995; James et al. 1987; Lamey et al. 
1990; Lamey et al. 1994; Lamey & Forsyth 1986; Lamey, Lamb, & Forsyth 1987; Lamey 
& Lewis 1990; Lewis et al. 1989; McCartan & Lamey 1998; Nolan etal. 1991; Nolan, 
McIntosh, & Lamey 1991; Patton et al. 1985; Petrucci et al. 1995; Rees et al. 1998; Rees & 
Gibson 1997; Riggio et al. 1997; Riggio et al. 1999; Staines, Felix, & Forsyth 1998; Todd 
et al. 1990; Wiesenfeld et al. 1985).
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associated with other topical allergens such as food additives and 
flavourings were also considered to have a particularly florid inflammatory 
cell infiltrate and marked degeneration of the basal cell layers of the 
epithelium.
It had also been noted that OLE lesions that were associated with systemic 
medications, drug induced lichenoid reactions (DILR), commonly presented 
one of two alternate histological appearances. Some were associated with a 
sparse inflammatory infiltrate together with a florid epithelial reaction, 
while others were associated with a florid inflammatory infiltrate with a 
relatively unaffected epithelium.
During the investigation, some other areas of interest were also explored 
such as the prevalence of allergy to mercurials in OLE patients.
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The aims are summarized below;
1. Analyse computer data from the Contact Dermatitis Investigation 
Unit.
2. Test a group of healthy controls.
3. Ascertain the clinical results from the patients point of view.
4. Investigate the histological differences between sections of oral 
lichen planus and lichenoid reactions secondary to 
hypersensitivity responses.
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2.2. Hypotheses
1. That the prevalence of positive patch test reactions in patients with 
recurrent aphthous stomatitis (RAS), oral lichenoid eruptions (OLE), 
orofacial granulomatosis (OFG), erythema multiforme (EM), and 
angioedema (AE) will be different from the normal population.
The null hypothesis is stated: there are no differences in the prevalence 
of contact allergic reactions to food additives and flavourings and to 
environmental allergens between healthy subjects and those with OLE, 
RAS, AE, EM and OFG.
2. That these patient groups: OLE, RAS, AE, EM and OFG will have 
different allergy profiles in terms of the amount of positive reactions and 
what the test substances are that elicit these reactions.
The null hypothesis is stated: there are no differences in the ‘allergic 
profiles’ of patients with OLE, RAS, AE, EM and OFG.
3. That the patients with positive reactions to food additives and 
flavourings upon patch testing will experience improvement in 
symptoms after following an allergen avoidance diet.
The null hypothesis is stated: there is no symptomatic improvement 
upon following an allergen free diet in those with positive patch test 
reactions to food additives and flavourings.
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4. That there are histological differences between specimens from patients 
with OLE lesions in patients with amalgam restorations and those with, 
no amalgam present, and between those with positive and negative patch 
test results. More specifically, that in the amalgam related and patch test 
positive related lesions, the number of apoptotic cells will be increased, 
the inflammatory cell infiltrate will be thicker and denser and that the 
amount of basal cell disruption will be increased compared to the 
appearance of the lesions with no amalgam relationship or with negative 
patch test results.
The null hypotheses are stated:-
There are no differences in the number of apoptotic cells between OLE 
lesions related to amalgam and those that are not, and between OLE 
lesions that are associated with positive or negative results to patch 
testing.
There is no difference in the amount of inflammatory infiltrate as 
determined by thickness (distance extending into the lamina propria 
from the epithelium) and density between OLE lesions related to 
amalgam and those that are not, and between OLE lesions that are 
associated with positive or negative results to patch testing.
There is no difference in the amount of disruption of the basal layer 
between OLE lesions related to amalgam and those that are not, and 
between OLE lesions that are associated with positive or negative 
results to patch testing.
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In regard to DILR, the null hypothesis is stated: that there are no 
distinguishing patterns in the histological appearance of specimens from 
patients that may have a drug related aetiology to their OLE. 
Specifically, there is not an increase among histological appearances of 
specimens showing a mild inflammatory infiltrate together with a florid 
epithelial reaction (increased epithelial tropism, increased numbers of 
apoptotic cells and increased basal cell disruption), or specimens 
showing an increased thickness and density of the inflammatory 
infiltrate together with a mild epithelial reaction (determined by none or 
small amounts of apoptotic cells, epithelial tropism and basal cell layer 
disruption).
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CHAPTER 3 CLINICAL ALLERGY STUDIES
3.1. Introduction
Since 1980, patients from Glasgow Dental Hospital & School were referred 
to the Contact Dermatitis Investigation Unit (CDIU) at Belvidere Hospital 
(until 1994) and then at Glasgow Royal Infirmary, in order to investigate the 
role that allergy played in the oral diseases from which they suffered. As 
patients who tested positive to food additives began experiencing relief from 
their symptoms after following dietary advice on avoidance of the 
appropriate allergens, more patients were sent for testing. It became 
apparent that patients with some diseases affecting the oral cavity seemed to 
yield more positive reactions to these tests and to gain greater benefit from 
the dietary avoidance than others. However, during this time, little was 
known about the prevalence of allergy to food additives and food substances 
in the normal population. It was therefore decided to patch test a healthy 
group of control subjects to the same allergens that the group with oral 
diseases were exposed.
The patients who had been sent for patch testing as part of the investigation 
into their oral disease were then contacted to ascertain the outcome of any 
dietary modifications that they had carried out as a consequence of the patch 
test results.
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3.2. Subjects
3.2.1. Disease population
The patients were all referred from the Oral Medicine Department at 
Glasgow Dental Hospital & School and were patch tested between 1980 and 
1996 at the Contact Dermatitis Investigation Unit (CDIU) in Glasgow which 
is a regional referral centre covering the West of Scotland. The computer 
database at the CDIU in Glasgow Royal Infirmary was an old program 
(Delta 4 software based on an Apricot system) and was accessed by Digby 
James of MAPEJ (PCD)11 and converted into a ASCII format. The file was 
then converted into Microsoft Access. The patient records at the CDIU and 
in some cases at GDH also, were referred to for further information. All 
referred patients were included in the study but particular attention was paid 
to those patients with: oral lichenoid eruption (OLE), recurrent aphthous 
stomatitis (RAS), orofacial granulomatosis (OFG), erythema multiforme 
(EM) and angioedema (AE). The criteria for the above diagnoses were as 
follows;
OLE -  White papules or striae, forming reticular, linear or annular patterns; 
white plaque-like lesions with papules or striae at the margins; some 
patients also had areas of atrophy, erosions or bullae (Kramer, Lucas, 
Pindborg, & Sobin 1978), see Figs 2-5, and if a biopsy was carried out (as it 
was on most patients) a histological appearance consistent with OLE.
11 MAPEJ (PCD), Digby James, Quinta Cres, Oswestry, Shropshire, SY10 7RN
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Fig. 2. Photograph O f Reticular OLE Affecting Left Buccal Mucosa
Fig. 3. Photograph O f Papular OLE Affecting Right Buccal Mucosa
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Fig. 4, Photograph O f Erosive OLE Affecting Left Buccal Mucosa
Fig. 5. Photograph O f Severe Erosive OLE Affecting Left Buccal 
Mucosa
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RAS -  Episodes of oral ulceration which recurred more that twice per year 
and that were not overtly traumatic in origin (Graykowski et al. 1966). See 
Figs 6-8.
AE -  One or more episodes of sudden and rapid facial, laryngeal or oral 
swelling. See fig 9.
EM -  A history of persistent or recurrent oral ulcerations with or without lip 
and skin lesions; clinically, diffuse oral erythema and irregular ulcerations 
frequently covered by pseudomembranes, ulceration and crusting of the lips, 
skin macules and papules (characteristically ‘target’ lesions) often with 
crusting, and a histological appearance consistent with EM, i.e. ruled out 
other oral mucocutaneous ulcerative diseases and often showed a 
perivascular lymphocytic cellular infiltrate (Lozada & Silverman 1978).
See figs 10 and 11
OFG -  Patients had at least two major criteria or had one major criterion 
plus three minor criteria. Major criteria were defined as chronic upper or 
lower lip swelling, mucosal oedema and cobblestoning, aphthous ulceration, 
mucosal tags and full thickness gingivitis. Minor criteria were defined as 
chronic facial swelling, angular cheilitis, fissured tongue, non-aphthous 
ulceration and papillary hyperplasia (Gibson 1998). See figs 12 and 13.
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Fig. 6. Photograph o f  Minor RAS Lesion
Fig. 7. Photograph o f  Major RAS Lesion
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FigJS, Photograph o f Herpetiform RAS Lesions
- i • f1 I
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Fig. 9. Photograph O f Localised AE/Urticaria
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Fig. 10. Photograph O f EM Target Lesions And Lip Crusting
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F i g . i l .  Photograph O f Intraoral EM
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Fig. 12. Photograph O f Extraorai Appearance O f OFG
Fig. 13. Photograph O f Intraoral Appearance O f OFG
3.2.2. Control population
Permission from the local Area Dental Ethics Committee was sought and 
gained prior to this part of the study commencing. 100 people made up of 
volunteers from the following groups were patch tested: staff working at 
Glasgow Dental Hospital & School, students studying at Glasgow Dental 
Hospital & School and friends/family of the above. All were patch tested at ' 
Glasgow Dental Hospital from July to December 1996. A short series of 
questions were asked of all the control subjects and informed consent 
obtained prior to the tests commencing. The questions sought information 
on age, sex, geographical area, occupation, medical history and what type of 
milk (breast or formula) they were fed on as infants. See appendix A-E for 
the information sheets that all control subjects were given, questionnaire, 
consent form and working sheets.
Exclusion criteria:
Control subjects who had been patch tested for any reason previously or 
who had been referred for patch testing.
Control subjects who had a history or clinical evidence of any of the 
diseases outlined in section 3.2.1. according to the diagnostic criteria as 
previously outlined.
Exclusion From The Study:
114 people volunteered for the study. Six were excluded on the grounds 
that they had previously been patch tested and two had clinical evidence of a
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mild oral lichenoid reaction. A further five gave a history of recurrent 
aphthous stomatitis and one had a history of angioedema. There remained. 
100 who were included in the control group.
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3.3. Methods
3.3.1. Reading Of Patch Tests
3.3.1.1. Grading Systems
It is generally accepted that patch test sites should be viewed both at 48 hrs 
and at a later date (between 3 and 7 days on), which reduces the number of 
both false positive and false negative results (Brasch, Geier, & Henseler 
1995; Rietschel et al. 1988).
There are a number of well used and accepted grading systems: the 
International Contact Dermatitis Research Group (ICDRG) original system, 
the ICDRG modified system, the North American Contact Dermatitis Group 
(NCDG) system and the Swedish Multicenter Study (SMCS) system.
These scoring systems require various morphological features to be present 
at any one test site in order for a diagnosis of a positive allergic reaction to 
be made. All the systems require erythema and infiltration of the test site 
for a grade 1 allergic reaction and most require the presence of at least a few 
papules as well. All require the presence of papules in addition to the 
erythema and infiltration for a grade 2 reaction, and for a grade 3 reaction 
all require the presence of vesicles or bullae or both. The scoring system 
chosen for both the disease patients and the control subjects was the SMCS 
system which doesn’t rely so heavily on the presence of papules which are 
the most difficult to assess (Bruze et al. 1995). This system, uses scores of 
0, E, and 4 to indicate negative, equivocal, and irritant reactions and 1, 2,
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and 3, to indicate allergic responses: 1 with erythema, 2 plus oedema and 
papules and 3, plus vesicles. Irritant reactions were defined as having a 
morphology composed of a) a smooth glazed appearance or slight erythema, 
or b) sharp borders confined to the patch test site, or c) a ‘cracked’ 
superficial surface, or d) minimal or no induration (Klas et al. 1996).
3.5.I.2. Irritant Responses
Irritant reactions to cutaneous patch tests can confuse the observer into 
treating these reactions as allergic in nature (Nater & Hoedemaker 1976). 
Grading patch test reactions by visual inspection and palpation is a 
subjective process and techniques to help objectively decide if a reaction is 
allergic or irritant are available. They include laser Doppler flowmetry 
(Gowkrodger, McDonagh, & Wright 1991; Staberg, Klemp, & Serup 1984) 
and skin reflectance measurements (Mendelow et al. 1986) to quantify the 
amount of erythema involved in a positive reaction, infra-red thermography 
to quantify the changing temperature of an allergic response (Baillie et al.
1990), measuring changes in skin-barrier function by transepidermal water 
loss measurements (Serup & Staberg 1987a; van der Valk et al. 1985) and 
measuring the associated oedema by ultrasonic methods (Serup & Staberg 
1987b). Although these methods are more objective, good correlation has 
been shown to exist between many of the objective and visual/palpation 
methods (Berardesca & Maibach 1988; Willis, Stephens, & Wilkinson 
1988) and the visual/palpation scoring of reactions takes far less time to 
complete so is generally used in clinical practice.
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3.3.I.3. Other Techniques Used In Patch Testing
Due to differences between oral mucosal and cutaneous anatomy, it may be 
supposed that food substances and other materials ingested orally, may 
affect the mouth and not show positive results on cutaneous patch testing. 
However, Fisher believes that if the oral mucosa is sensitised, the skin is too 
(Fisher 1995) and other authors also believe that a positive patch test 
reaction is a fairly reliable sign of generalised sensitivity reaction (Skoglund 
& Egelrud 1991). It is also possible that the chemicals could have no effect 
on oral mucosa but after being absorbed from the gastro-intestinal tract may 
give rise to an allergic reaction that manifests itself in the skin. Materials 
used in the manufacture of dental appliances, used during dental treatment 
or used by the patient for dental home care purposes may also produce these 
phenomena. The techniques of intraoral patch testing are more complicated 
than cutaneous methods as the adherence of the suspected allergen to the 
mucosal surface is difficult to maintain and because of the presence of 
saliva, the histological differences of the epidermal surfaces and the 
differences in the microflora of the different areas, the results are not 
directly comparable to cutaneous patch testing (Axell et al. 1986).
However, methods that have been used are useful in a number of cases 
where cutaneous patch tests have given negative results and a reaction to a 
dental material is strongly suspected. The methods of attachment require 
either adhesive pastes and bandages or the use of suction cups to hold the 
allergen in place, all of which can only be used for a very short time. 
Alternatively, individual intraoral appliances can be constructed which hold
the allergen in a solid form next to the mucosa for longer periods of time 
(Fisher 1974; Fisher 1995; von Nielsen & Klaschka 1971). Positive test 
reactions on oral mucosa are only elicited when the test concentration of the 
allergen is 5-10 times greater than that of the test concentration used for skin 
(Kaaber 1990).
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3.3.2. Factors To Consider When Patch Testing
3.3.2.1. Angry Back Syndrome
A single strong positive reaction at a test site can lead to a series of false 
positives elsewhere in the testing area due to a state of hypersensitivity 
(Mitchell 1975). The patch test chemical is absorbed into the blood stream 
and may be carried to any part of the skin. It is also absorbed by lymphatics 
which may carry the chemical to local parts of the skin, often to other patch 
test sites. The presence of a strong positive reaction may exaggerate 
adjacent weak irritant and allergic responses (Mitchell 1977).
3.3.2.2. Sensitisation
Sensitisation to allergens applied during the patch testing process has been a 
cause for concern. The risk is negligible (Meneghini, Rantuccio, & Lomuto 
1972) and is minimised by using non-irritant vehicles for the test substances 
(Mendelow et al. 1985), avoiding placement of test strips on eczematous or 
otherwise compromised skin and by using the correct concentration of test 
substance (Kligman & Epstein 1975) in preparations that have been 
thoroughly mixed (Sulzberger 1975). The avoidance of patch testing during 
acutely active phases of disease states, no matter which part of the body is 
affected also minimises the risk of sensitisation.
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3.3.2.3. Adverse Reactions
Systemic reactions to the applications of allergens in patch tests are rare but 
erythema multiforme has been reported after patch testing with colophony 
and fragrance mix (O'Donnell & Tan 1997), and nickel (Friedman & Perry 
1985). Strong patch test reactions may last for up to three weeks especially 
in atopic individuals (Mancuso, Berdondini, & Cavrini 1999).
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3.3.3. Patient variance
3.3.3.I. Age
Differences in the incidence of positive patch test results exist between 
populations of differing ages. Most studies detect the highest prevalence in 
the second to fifth decades (Husain 1977) with some showing a bimodal 
pattern giving a decrease in the forth decade, in both male and females 
according to some authors (Sugai et al. 1979) and in females only according 
to others (Walton, Nayagam, & Keczkes 1986). When tested with 
multivariate statistical analysis, the differences in positive reactions between 
the ages vary as to which allergen is being tested e.g. nickel cause positive 
reactions among younger people in the first to third decades, while 
fragrances tend to cause more positives among those in the seventh decade 
(Christophersen et al. 1989). However, among a normal population, while 
doing sensitisation studies with dinitrochlorobenzene, no significant 
differences were found between 165 subjects in the age range 23- 69 years 
(Friedmann et al. 1983).
Patch testing in young children has been shown to be effective giving a high 
incidence of positive and relevant reactions (Rademaker & Forsyth 1989; 
Wantke et al. 1996). There are however, inherent problems in patch testing 
in children. Their size can make application of tests difficult and their 
excessive mobility can affect the adherence of the tests. The skin of infants 
and young children is more likely to exhibit non specific irritant reactions 
which may manifest as false-positives. To avoid this many substances
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should be tested in children in reduced concentrations (Fisher 1994; Fisher 
1995).
The elderly skin has been said to be less able to mount an inflammatory 
response (Giannini & Sloan 1957). This may be due to a decrease in both 
epidermal Langerhan’s cells (Gilchrest, Murphy, & Soter 1982), circulating 
T-lymphocytes (Augener et al. 1974) and in the function of different subsets 
of T-lymphocytes (Weksler 1982). However, there is considerable 
conflicting evidence for the incidence of the susceptibility of the elderly to 
contact sensitisation and to the ability to elicit a reaction via patch testing 
once sensitised (Kwangsukstith & Maibach 1995). One study found a 
steadily increasing prevalence of contact sensitivity with age (Goh 1986). It 
may be that with the increased dryness of the skin, together with an often 
increased exposure to toiletries and topical medications, that the decreased 
reactivity of the skin is compensated for in part (Fisher 1995). Despite the 
conflicting data, it is generally accepted that the elderly have a decreased 
incidence of delayed hypersensitivity, a decrease in sensitisation to new 
allergens and are less likely to react to substances to which they were 
previously sensitised.
3.3.3.2. Sex
Again there is controversy as to what influence gender has on the induction 
and elicitation of allergic contact dermatitis (ACD). The induction of 
sensitivity to dinitrochlorobenzene showed no differences between the sexes 
when carried out on 165 healthy subjects. However, in one study, sex
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hormones were shown to have an effect on the induction of sensitivity with 
progesterone increasing the sensitisation and oestrogen decreasing it 
(Gerretsen et al. 1975). The differences in positive reactions between the 
sexes do however vary depending on what allergen is being tested e.g. 
testing with nickel sulphate yields a higher rate of positive reactions 
whereas there were no significant differences between the sexes with 
neomycin (Edman & Moller 1982). Most authors would agree however that 
the differences in induction of ACD can be accounted for by differing 
occupations, exposure to cosmetics and jewellery, culture and hormonal 
influence by the sexes (Kwangsukstith & Maibach 1995). Most studies 
conclude that females are patch tested for suspected allergens more often 
than males and that they have a higher incidence of positive results.
3.3.3.3. Atopy
The decision whether or not to patch test those with cutaneous or respiratory 
atopy has aroused interest because of a number of factors. The immune 
system of atopies is altered in that the local cell mediated immunity in the 
skin is suppressed due to a functional decrease in T-cells (Bos et al. 1992). 
However, this is not a severe systemic suppression as atopies are not 
predisposed to opportunistic infections (Bos et al. 1992). As a result of this, 
there has been a reported decrease in contact sensitivity among this group 
(Uehara & Sawai 1989). In some studies this has been shown to mainly 
exist in atopies with severe atopic dermatitis, with normal sensitisation rates 
occurring among those with mild or moderate atopic disease (Uehara &
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Sawai 1989), while in others the rate of inducing sensitisation to 
dinitrochlorobenzene was decreased in patients with only minimal atopic . 
dermatitis (Rees, Friedmann, & Matthews 1990). There is evidence of an 
increased irritant response in those with atopic dermatitis and this may be 
due to impaired skin barrier function (Klas et al. 1996). This defective 
cutaneous barrier together with an increased exposure to chemicals through 
skin care preparations offsets the mild immunological suppression so atopic 
patients may have a greater, equal or lesser incidence of allergic contact 
dermatitis which depends both on the severity of their atopic disease and on 
the activity of their atopic dermatitis at the time of testing (Mitchell 1975; 
Whitmore 1994).
3.3.3.4. Race
The effect of race on the elicitation of positive patch test results is 
complicated by the difficulty in visually reading the amount of erythema on 
the skin of people whose skin is very dark in colour (Fisher 1995).
Possibly, partly due to this difficulty, it has often been concluded that the 
skin of blacks is more resistant to contact sensitivity and to irritants than that 
of Caucasians (Kligman & Epstein 1975). This has been further backed up 
by studies showing that black skin has more layers of stratum comeum than 
Caucasoid skin and that these layers are also more compact, as shown in 
density experiments (Weigand, Haygood, & Gaylor 1974). However, many 
studies have shown an equal ratio of allergic contact dermatitis between 
blacks and whites (Berardesca & Maibach 1988).
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When studied in Singapore, no difference was found in the prevalence of 
contact sensitivity between Indian, Chinese and Malaysian subpopulations. 
(Goh 1986).
3.3.3.5. UV Radiation Exposure
Exposure to strong sunlight diminishes the numbers of Langerhan’s cells 
present in the epidermis (Fyad, Masmoudi, & Lachapelle 1987; Zelickson & 
Mottaz 1970). This loss of antigen presenting ability consequently has an 
effect on both the induction and the elicitation of allergic responses during 
patch testing (Toews et al. 1980). To minimise this effect, patients and 
control subjects were not tested within four weeks of a prolonged period of 
UV radiation exposure by which time the Langerhan’s cells would have 
returned to a normal state both qualitatively and quantitatively (Toews et al. 
1980).
3.3.3.6. Observation Time
The period in history in which a patient is tested may be crucial in affecting 
the results of that patient’s sensitivities (Aberer & Holub 1992). Humans 
can develop sensitivities to various new allergens at any time in their lives 
and by the same token, lose contact sensitivity to substances, though most 
will retain contact sensitivities for long periods of time if not for life (Ayala 
et al. 1996; Keczkes, Basheer, & Wyatt 1982; Meneghini & Angelini 1977).
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Particular allergens may evolve as especially problematic during one period 
or another due to changing environmental conditions and industrial working 
practices (Edman & Moller 1982).
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3.3.4. Patch Testing Procedure
For patch testing to be effective both in the diagnosis of contact sensitivity 
and in the treatment of such patients, the patch testing procedure should take 
the form of three parts: a) history and examination; b) application of the 
patch tests and, c) advising the patients on how to avoid the relevant 
allergens.
The words ‘patch test’ refer in relation to the patient groups and the control 
group in this investigation, to both delayed hypersensitivity testing (DHT) 
and to contact urticaria testing (CUT).
All patients when attending for patch testing were asked detailed questions 
about their symptoms and exposure to various food and environmental 
allergens. They were asked questions about their general medical history 
with particular attention paid to any skin or mucosal problems that they may 
have had. Their age, sex, where they lived, occupation, and whether they 
considered that their disease was related to their occupation was ascertained. 
An examination of any signs of the disease present at the time was carried 
out. Informed consent was given by each subject prior to the tests 
beginning.
The selection and application of appropriate test substances to the patient’s 
requirements was then done.
Upon receiving a positive result, patients were given skilled advice, both 
verbal and written, on the steps they should take to avoid the causative 
allergens in their environment. This sometimes necessitated a visit to the
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patient’s home and/or workplace to aid in the education of the patient with 
regard to their environment.
3.3.4.I. 48 Hour Patch Test
Immunologically mediated reactions can be classified by the Gell and 
Coombs method (Gell & Coombs 1968). The type IV or delayed 
hypersensitivity reaction is mediated by T lymphocytes and classically 
takes 2 days to develop (Rietschel 1989).
Petrolatum was used as the carrying medium of choice where possible as 
this facilitates ease of handling and avoids the “edge effect” that can 
complicate the reading of patch tests carried out with solutions (Fyad, 
Masmoudi, & Lachapelle 1987). The test substances that were suspended in 
petrolatum were dispensed from plastic disposable syringes and placed in 
Finn chambers ™ 12 (8mm aluminium wells) arranged on Scanpor13 surgical 
tape. A 4mm length of the test substance carried in petrolatum from the 
containing syringe was expressed into the aluminium well (Antoine & 
Lachapelle 1988; Hjorth 1989; Rietschel 1989). Those carried in an 
aqueous solution were dispensed from plastic dropper bottles and placed on 
a 5mm disc of filter paper14 that was sitting in the aluminium well. One 
drop was used to wet the filter paper immediately prior to the placement of 
the tests. On day 1, the tapes were applied to the upper back, avoiding the
12 Epitest, Hyryla, Finland.
13 Scanpor, Norgesplaster, Oslo, Norway
14 Filter paper discs supplied by Bio Diagnostics Ltd.
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vertebral column, and a hypoallergenic skin marker15 was used to denote the 
test sites. See Figs 14 and 15. The tapes remained in place for 48 hours. . 
On day 3, approximately 1 hour after removal, the test sites were examined 
by the clinician and given a score as outlined below. The test sites were re­
examined and scored on day 5, a total of 96 hours after initial exposure to 
the allergen via the test sites, see Figs 16 and 17.
A total of 48 different allergens were placed on the backs of control subjects 
on day 1 of the study and the results read on days 3 and 5. The allergens 
were suspended in petrolatum (n=46) or in an aqueous solution (n=2) and 
were the same as the basic 48 used on most of the disease population 
(modified European Standard Series, food additives, perfumes and 
flavourings, and chocolate). The patch testing procedure was carried out 
with the patients and with the control subjects in as similar a way possible to 
minimise any variance in the results due to differing patch testing and 
examining techniques.
15 Supplied by Crawford Pharmaceuticals.
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Fig. 14. Photograph O f Allergens Arranged On Tape Prior To Applying
lo  The Volunteer's Back
Fig. 15. Photograph O f Tapes With Allergens Applied To The Upper 
Back
180
Fig. 16. Photograph O f Day 5 Results
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3.3.4.2. Contact Urticaria Test
Epicutaneous testing can also be used to elicit Type I hypersensitivity 
reactions and non-immunologic contact urticaria (NICU) reactions in 
sensitised patients.
On day 1, the test substances (food additives, chocolate and all the perfumes 
and flavourings bar sorbitan sesquiolate) were placed on the subjects 
forearms where they were clearly visible to the subject. See Figs 18 and 19. 
On the skin next to each site, a number was clearly marked with a pen to 
identify each individual test. After 20 minutes, the Scanpor tapes with the 
test substances were removed and the test sites examined by the clinician.
A score of 0 (no reaction) or 1 (reaction clearly visible, ie palpable, pruritic 
erythema) was given for each test site. See Fig 20. The subject was 
instructed to observe the test sites at hourly intervals over the subsequent 6 
hours and record any changes or sensations of pruritus associated with any 
of the sites. At the following visit, the subjects records of the test were 
examined and a further score given.
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Fig. 18. Photograph o f  allergens ready for contact urticaria testing
Fig. 19. Photograph o f  allergens in situ on flexor surfaces o f  forearms
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Fig. 20. Photograph O f Positive Result After 20 Minutes
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3.3.5. Observer Calibration
It has been said that the preparing and placement of patch tests can be done 
by an amateur but the reading and interpretation requires an expert (Hjorth 
1989; Sulzberger 1975). In order to gain the necessary training and 
experience, the research observer spent 3 months training in patch test 
techniques and in the reading of patch test reactions alongside the expert 
dermatologist. Most of the patients involved in the study were examined by 
the same clinician (consultant dermatologist) when attending for patch 
testing at the CDIU Dept. The control subjects were all examined by the 
research clinician at Glasgow Dental Hospital and School. In order to 
minimise inter-rater variation, a study was carried out to test the accordance 
in reading patch test reactions between the two observers. At the end of the 
training period and prior to the research project commencing, consecutive 
patients attending for their 96 hour delayed hypersensitivity reading were 
examined by both observers and the results compared. Patch test reactions 
were graded as outlined previously. This process was repeated during the 
period of patch testing the normal population sample, with both patients and 
healthy control subjects examined by both observers at the two different test 
locations. Each patient was examined individually by each observer in turn 
and there was no communication between the observers during the reading 
period. Both observers had access to the identity of the allergens on each 
patch and to the results of the 48 hour readings.
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The disease subjects had between 48 and 111 patches to be read (all of 
which had been placed on their upper back), which averaged at 72.5 per 
subject.
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3.3.6. Outcome Of Dietary Avoidance Of Relevant Allergens
Avoidance of allergens to which the patient is sensitive, minimises the 
immune response of the patient to that allergen and may enable the immune 
system to lose its sensitivity or at least its detectable sensitivity entirely 
(Keczkes, Basheer, & Wyatt 1982; Meneghini & Angelini 1977).
Patients who attended the CDIU for patch testing and who had a positive 
skin sensitivity to a dietary allergen were given diet avoidance advice with 
respect to the particular allergen. This was both verbally given usually by a 
senior dietician and in the form of written instructions. Examples of the 
dietary advice sheets for patients sensitive to benzoic acid and 
cinnamaldehyde are given in Appendix F. These were prepared by the 
senior dietician K.A. Milligan at Glasgow Royal Infirmary. These patients 
were contacted by means of a postal questionnaire with an accompanying 
letter and a post paid reply envelope. The letter and questionnaire are 
shown in Appendices G and H. The purpose was to ascertain the following:
• did they understand the diet advice
• how successful were they in maintaining the dietary changes/ 
restrictions
• whether their symptoms had changed in any way since receiving the 
advice
• whether they knew of any other contributing factors to their 
improvement or otherwise
Linear analogue scales were used to ascertain the levels of compliance with 
the dietary avoidance advice and the pre and post testing symptoms
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(Huskisson 1974). The patients were asked to mark a cross on a 10cm line. 
The results were calculated by measuring with a ruler the distance along the 
line that the mark had been placed. A score of 0 was given if the score was 
at the beginning of the line, a score of 1 if the measurement was between 0 
and 0.9cm from the beginning, 2 if the measurement was between 1 and 
1.9cm, etc. A score of 10 was given when the cross was marked at the end 
of the line.
A total of 476 patients were sent a letter enclosing a questionnaire and a 
reply paid envelope with which to return it. The patients receiving the letter 
were selected by taking the disease group and selecting only patients with 
any of the 5 diseases under consideration and who also had a positive 
reaction to a food substance. 50 further patients’ addresses were not 
available so letters were not sent. The letter and questionnaire can be found 
in Appendices F and G.
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3.3.7. Statistical Analysis
Inter-rater agreement was calculated using the chance-corrected measure of 
agreement, known as Kappa (Campbell & Machin 1999) and this was 
carried out using SPSS computer software16.
1 7The statistics computer package, Minitab version 12 was used to compute 
the rest of the statistical analysis. Statistical significance was conceded at 
the 5% level. For age comparisons between different groups, the two 
sample t test was utilised and two proportions test was used in comparing 
the sex of different groups.
Categorical data were analysed by the Chi Squared test. The number of 
patients positive to the patch testing and contact urticaria testing was 
compared to the control group using the two proportions test, except where 
indicated.
The paired t test was used in the comparison between the pre post testing 
symptom scores in the analysis of the questionnaire results. The difference 
in symptom improvement between patients with different dietary 
compliance levels was calculated using one way analysis of variance.
16 SPSS Science Software UK Ltd., The Research Park, Vincent Drive, Birmingham, B15 
2SQ. UK T e l: (0121)471 4199. Fax:(0121)471 5169.
17 Minitab Inc., 3081 Enterprise Drive, State College, PA 16801-3008
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3.4. Materials
The patients attending the CDIU were tested to allergens that were likely to 
be contributing to their disease process in some way. The selection of 
allergens was based on the patients’ signs, symptoms and history of 
exposure to various materials. Nearly all were tested with the modified 
European Standard Series and most of the patients were tested to food 
additives, perfumes and flavourings and to chocolate. As the testing period 
was over a long time period, some of the allergens or concentrations 
changed in the different series over the years and these changes have been 
explained in the text or taken into account in the computing of results, i.e. 
the percentages of positive results have been calculated from the number of 
patients who were tested to each allergen. Most patients were also tested to 
other allergens as well e.g. series of dental materials, cosmetic and 
pharmaceutical vehicles, rubber chemicals, medicaments or other foods 
thought to play a part in the patients’ disease process. These other allergens 
are not included in this study except where specifically mentioned. The 
control subjects were tested to the same basic sets of allergens to which 
patients referred from the dental hospital were exposed, i.e. the modified 
European Standard Series of environmental allergens, food additives, 
perfumes and flavourings and to chocolate.
All the allergens were mixed with petrolatum as the carrying vehicle, except 
for formaldehyde and one of the chocolate essence preparations which were 
carried in aqueous solution. Both the carrying vehicles have low irritant and
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sensitisation potential and a petrolatum test site was included on all subjects 
as a control (Mendelow et al. 1985).
191
3.4.1. Food Additives
The food additives that were used as test allergens for both the control 
subjects and the patients were: benzoic acid, salicylic acid, tartrazine, 
glutamic acid, butylated hydroxytoluene, butylated hydroxyanisole, 
propylene glycol, sorbic acid and sodium metabisulphite. These substances 
were tested in the delayed hypersensitivity reaction and in the contact 
urticaria tests. See Table 9 for the concentrations, carrying media and 
manufacturers of the various allergens.
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Table 9. Concentration And Carrying Media Of The Food Related
Allergens Used
Food Additives \
Benzoic Acid 5 Petrolatum Crawford16
Salicylic Acid 1 Petrolatum GRI19
Tartrazine 0.1 Petrolatum GRI
Glutamic Acid 2 Petrolatum GRI
Butylated
Hydroxytoluene
2 Petrolatum Trolab ®20
Butylated
Hydroxyanisole
2 Petrolatum Trolab ®
Propylene Glycol 5 Petrolatum Crawford
Sorbic Acid 2 Petrolatum Trolab ®
Sodium
Metabisulphite
1 Petrolatum Trolab ®
Perfumes and 
Flavourings
Cinnamyl Alcohol 1 Petrolatum Trolab ®
C innamaldehy de 1 Petrolatum Trolab ®
Eugenol 1 Petrolatum Trolab ®
Amylcinnamaldehyde 1 Petrolatum Trolab ®
Hydroxycitraonellal 1 Petrolatum Trolab ®
Geraniol 1 Petrolatum Trolab ®
Isoeugenol 1 Petrolatum Trolab ®
Oak Moss Absolute 1 Petrolatum Trolab ®
Benzyl Alcohol 1 Petrolatum Crawford
Musk Ambrette 5 Petrolatum Trolab ®
Sorbitan Sesquiolate 20 Petrolatum Trolab ®
ChocolateA |
Essence of Chocolate 5 Aqueous GRI
Essence of Chocolate 5 Petrolatum GRI
The chocolate allergen used between 1980-1985 was ‘creamy chocolate
colour’, 5% and 10%.
Crawford Pharmaceuticals, 71a High Street, Stony Stratford, Milton 
Keynes, MK11 1BA 
Glasgow Royal Infirmary 
84 Castle Street, Glasgow, G4 OSF 
Allergens prepared by the hospital pharmacy.
Trolab Patch Test Allergens
HERMAL Diagnostics Dept., D-21462 Reinbek, Germany
18 Crawford 
l9GRI
20TroIab®
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3.4.2. Perfumes And Flavourings
The perfumes and flavourings that were tested were: cinnamyl alcohol, 
cinnamaldehyde, eugenol, amylcinnamaldehyde, hydroxycitraonellal, 
geraniol, isoeugenol, oak moss absolute, benzyl alcohol, and musk ambrette, 
(see Table 9). Sorbitan sesquiolate being added as an emulsifier to the 
fragrance mix in the European Standard Series, was included in the testing 
(Frosch et al. 1995). All were tested in the delayed hypersensitivity test and 
all but sorbitan sesquiolate were tested in the contact urticaria test.
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3.4.3. Chocolate
Essence of chocolate was tested with the two different carrying media 
(petrolatum and water) in both the delayed hypersensitivity test and contact 
urticaria test, (see Table 9).
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3.4.4. European Standard Series
The control subjects were tested to a series of common environmental 
allergens, which was the same as that of the disease patients. A modified 
European Standard Series was used consisting of 23 test allergens and a 
control (PMF). See Tables 10 and 11 for details of the concentrations, 
carrying media and manufacturers of these allergens.
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Table 10. Concentrations And Carrying M edia O f The Environmental
Allergens Used (Modified European Standard Series)
Nickel Sulphate 5 ............. Petrolatum Tfolab®5^ ^
Colophony 20 Petrolatum Trolab ®
Cobalt Chloride 1 Petrolatum Trolab ®
Formaldehyde 1B Aqueous Trolab ®
Potassium Dichromate 0.5 Petrolatum Trolab ®
PPD* l c Petrolatum Trolab ®
Mercapto-mixa 2C Petrolatum See page 198
Neomycin 20 Petrolatum Trolab ®
Paraben mixb 16 Petrolatum See page 198
Balsam of Peru 25 Petrolatum Trolab ®
Thiuram-mixc 1 Petrolatum See page 198
PPD-mixd 0.6 Petrolatum See page 198
Fragrance-mixe 8° Petrolatum See page 199
Primin 0.01 Petrolatum Trolab ®
Quatemium 15 1 Petrolatum Trolab ®
Carba-mixf 3 Petrolatum See page 199
Wool Alcohols 30 Petrolatum Trolab ®
PTBP# Formaldehyde Resin 1 Petrolatum Trolab ®
Caine-mixg 5e Petrolatum See page 199
Epoxy Resin 1 Petrolatum Trolab ®
Quinoline 6 Petrolatum Trolab ®
Ethylene Diamine 1 Petrolatum Trolab ®
Thiomersal 0.1 Petrolatum Trolab ®
Control (Petrolatum) 100 DePuy22
Concentrations prior to August 1984:
A 2.5%
B 2% 
c 0.5%
D 16%
E 8%
Abbreviations: * Paraphenylenediamine, Paratertiarybutyl phenol
Suppliers and Manufacturers:
21 Trolab® Trolab Patch Test Allergens
HERMAL Diagnostics Dept., D-21462 Reinbek, Germany.
22 DePuy DePuy Healthcare, Leeds LS25 2JY, England.
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Table 11. Mix Constituents:
All mixes prepared using equal quantities of each of the individual
ingredients.
a Mercapto-mix supplied by Trolab ® ready mixed.
Dibenzothiazyl disulphide 1 Petrolatum Trolab ®
N-Cyclohexylbenzothiazyl
Sulphenamide
1 Petrolatum Trolab ®
Morpholinylmercatobenzothi
azole
0.5 Petrolatum Trolab ®
b Paraben mix supplied by Trolab ® ready mixed.
Methyl Parahydroxybenzoate 3 Petrolatum Trolab ®
Ethyl Parahydroxybenzoate 3 Petrolatum Trolab ®
Propyl Parahydroxbenzoate 3 Petrolatum Trolab ®
Butyl Parahydroxbenzoate 3 Petrolatum Trolab ®
c Thiuram-mix supplied by Trolab ® ready mixed.
T etramethy lthiuram 
Disulphide
0.25 Petrolatum Trolab ®
Tetraethylthiuram Disulphide 0.25 Petrolatum Trolab ®
T etramethylthiuram 
Monosulphide
0.25 Petrolatum Trolab ®
Dipentamethylenethiuram
Disulphide
0.25 Petrolatum Trolab ®
d PPD-mix prepared by GRI23 pharmacy.
Cyclohexlyphenyl PPD 1 Petrolatum Crawford
Diphenyl PPD 0.25 Petrolatum Trolab ®
Isopropylphenyl PPD 1 Petrolatum Trolab ®
23 GRI Glasgow Royal Infirmary
84 Castle Street, Glasgow, G4 OSF 
Allergens prepared by the hospital pharmacy.
24 Crawford Crawford Pharmaceuticals, 71a High Street, Stony Stratford, Milton
Keynes, MK11 1BA
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Table 11 Continued
e Fragrance-mix supplied by Trolab ® ready mixed.
Allergen Concentra- Medium Manufacturer 
tion [%]
Cinnamyl Alcohol 1 Petrolatum Trolab ®
Cinnamonaldehyde 1 Petrolatum Trolab ®
Eugenol 1 Petrolatum Trolab ®
Amylcinnamaldehyde 1 Petrolatum Trolab ®
Hydroxycitraonellal 1 Petrolatum Trolab ®
Geraniol 1 Petrolatum Trolab ®
Isoeugenol 1 Petrolatum Trolab ®
Oak Moss Absolute 1 Petrolatum Trolab ®
Sorbitan sesquiolate 20 Petrolatum Trolab ®
r
Carba-mix prepared by GRI pharmacy.
Diphenylguanidine 1 Petrolatum Trolab ®
Diethyldithiocarbamol 1 Petrolatum Trolab ®
Dibutyldithiocarbamol 1 Petrolatum Trolab ®
g Caine-mix prepared by GRI pharmacy.
Lignocaine 15 Petrolatum Trolab ®
Cinchocaine 5 Petrolatum Trolab ®
Benzocaine 5 Petrolatum Trolab ®
Tetracaine 1 Petrolatum Trolab ®
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3.4.5. Mercurials
There is a well established link in some patients with OLE to a positive 
reaction to mercurials (Laine, Kalimo, & Happonen 1997). An example of 
the improvement in the OLE in a patient sensitive to mercurials following 
amalgam replacement with non metal restorations is shown in Figs 21 and 
22. To investigate this further, the results of all patients who had been 
tested with various mercurials were analysed.
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Fig. 21. Photograph O f OLE Related To Old Corroded Amalgam
Restoration
Fig. 22. Photograph O f OLE Following Replacement O f Amalgam 
Restorations (same patient as in Fig 2)
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3.5. Results
3.5.1. Observer Calibration
The kappa statistic for the inter-rater agreement assessment prior to the 
commencement of the patch testing of the control sample was 0.60. The 
figure for the assessment obtained in the middle of the testing procedure 
was 0.73. These figures correlate well with inter-rater agreements when 
examining other subjectively determined parameters such as caries 
incidence in teeth (Fyffe et al. 2000).
3.5.2. Demographics Of Patients And Controls
A total of 1,252 patients were referred to the CDIU from Glasgow Dental 
Hospital in the time from 5th December 1980 to the 14th October 1996 and 
all were included in the study. One hundred controls were examined.
3.5.2.I. Diagnosis
A total of 889 of the patients were diagnosed as having one of the five main 
categories of disease under consideration, i.e. angioedema (AE), erythema 
multiforme (EM), oral lichenoid reactions (OLE), orofacial granulomatosis 
(OFG) and recurrent aphthous stomatitis (RAS). The categories and the 
number of patients in each are as shown in Table 12.
Among the rest of the patients, 162 were referred for oral dysaesthesia 
(OD), 17 were referred with desquamative gingivitis and two were referred 
with plasma cell gingivitis. The remainder (n=182), were referred for other
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reasons such as: lip swelling which was not thought to be OFG or AE, facial 
eczema, suspected allergy to local anaesthetics, geographic tongue, 
gingivitis related to porcelain bonded crown, migraine, Sjogrens syndrome, 
median rhomboid glossitis, nasal congestion, dry mouth and suspected 
allergy to denture materials.
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Table 12. Main D isease Categories o f  Patients Referred to the CDIU
OLE 261
RAS 277
AE 45
EM 42
OFG 264
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3.5.2.2. Age
The age of the total number of patients by decade is listed for every year in 
Table 13. A large proportion of the patients were tested in the years 
1991,1992,1994 and 1995. The normality of the age distribution is shown 
in Fig. 23 and the ages of the patients in each of the disease categories is 
shown in Fig. 24.
The average age of patients at the time of patch testing was 39 years (mean 
was 39.46, S.D. = 19.25) and the range was from 2 (n=l) to 94 (n=l) years. 
The average age of OLE patients at the time of patch testing was 52 years 
(mean was 51.5, S.D. = 12.9) and the range was from 2 (n=l) to 79 (n=l) 
years.
The average age of RAS patients at the time of patch testing was 31 years 
(mean was 31.3, S.D. = 16.6) and the range was from 3 (n=l) to 83 (n=l) 
years.
The number of patients in the AE group was 45. The average age of 
patients at the time of patch testing was 48 years (mean was 47.8, S.D. = 
18.25) and the range was from 13 (n=2) to 73 (n=2) years.
The number of patients in the EM group was 42. The average age of 
patients at the time of patch testing was 33 years (mean was 32.5, S.D. 
=14.31) and the range was from 12 (n=l) to 65 (n=l) years.
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Table 13. A ge bv Year o f  Examination
DECADE
1 2 3 4 5 6 7 8 9 10 Total
1 1 2
5 2 2 3 0 2 13
1 4 6 4 2 5 2 1 25
2 2 1 6 16 1 4 42
5 3 8 3 9 8 6 42
5 5 8 3 9 10 5 45
2 4 7 8 7 8 9 1 46
6 10 8 11 10 14 5 2 66
3 14 15 7 12 12 9 2 1 75
3 10 23 14 14 15 16 1 96
5 16 11 14 8 13 5 3 1 76
9 26 15 21 15 23 11 5 1 126
10 41 23 31 17 20 18 6 166
5 5 10 15 8 12 11 3 1 70
7 22 16 33 24 26
21
6 1 156
5 16 12 32 29 19 18 9 1 141
1 9 6 9 18 10 9 3 65
57 194 163 218 180 211 166 57 5 1 1252
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Fig. 23. Histogram o f  the A ge o f  Total Number o f  Patients at the Time o f
Examination
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Fig. 24. Histograms o f  the Age o f  Patients and Controls
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The average age of OFG patients at the time of patch testing was 24 years . 
(mean was 24.3, S.D. = 16.13) and the range was from 3 (n=l) to 94 (n=l) 
years.
The ages of control subjects ranged from 19 (n=3) to 60 (n=l) with the 
mean at 33.33 years, S.D. = 10.57. However the most common age band 
that the control subjects were included in, was the third decade, 20-29 
(n=45). The control group was comparable with the RAS and EM groups of 
patients, significantly younger than the OLE and AE groups and 
significantly older than the OFG group. See Table 14. and Fig. 25.
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Table 14. Comparison O f The Age O f Controls And Disease Groups
[Statistically significant results in bold italics]
OLE 51.5
(12.9)
75.5, 20.8
RAS 31.3
(16.6)
-4.9, 0.8
AE 47.8
(18.3)
8.6, 20.3
EM 32.5
(14.3)
-5.8, 4.0
OFG 24.3
(16.1)
-11.84, -6.1
CONTROL 33.3
(10.6)
* 95% confidence interval for the ages of the patients (disease group minus the age of the 
control group).
2 1 0
Fig. 25. Boxplot o f Age o f Subjects at the Time o f  Examination: by 
Disease Group
[Width o f  box corresponds to sample size.]
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3.5.2.3. Sex
Of all the patients that were sent for patch testing, 33.6% were male (n=420) 
and 66.4% were female (n=832).
When observed by disease category, 24.1% (n=63) of the patients with OLE 
were male and 75.9% (n=198) were female. Of the patients with RAS, 
33.9% (n=94) were male and 66.1% (n=183) were female. The male : 
female ratio of those patients with AE was close to equal being 49% (n=22)
: 51% (n=23). 45% (n=19) of the patients with EM who were referred for 
patch testing were male and 55% (n=23) were female. Of the patients with 
OFG who were referred for patch testing, 57% (n=151) were male and 43% 
(n=l 13) were female.
29% of the control subjects were male and 71% were female.
The numbers of males in each of the disease groups was compared with the 
number of males in the control group. The results are shown in Table 15. 
and in Fig. 26. There was a statistically significant higher proportion of 
males in the AE and OFG groups of patients when compared to the controls.
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Table 15. Comparison Between Sex Of Controls And Disease Groups
[Statistically significant results in bold italics]
OLE 24.1 75.9 -15.1,5.4
RAS 33.9 66.1 -56.0, 15.4
AE 48.9 51.1 2.8, 37.0
EM 45.2 54.8 -1.2, 33.7
OFG 57.2 42.8 17.5,38.9
CONTROL 29.0 71.0 -
* 95% confidence interval for the percentage difference of the number of males (disease 
group minus the control group).
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3.5.2.4. Geographical Area
840 patients came from either Glasgow itself (n=501) or the central belt of 
Scotland. One patient came from the north of Scotland and one other from 
the north of England. The addresses of the other 5 patients were not known. 
All the control subjects lived within commuting distance of Glasgow as they 
all worked or studied at Glasgow Dental Hospital & School.
3.5.2.5. Ethnic Origin
The ethnic origin of the patients referred for patch testing was not known as 
it had not been recorded at the time of examination either in the CDIU or 
GDH.
The majority of control subjects were of Caucasian origin (n=94 ), four were 
Asian, and two were African. The numbers of Asian and African subjects 
were too small to warrant separate analysis of the patch test results.
3.5.2.6. Occupation
A wide variety of occupations were represented in this group. See figs 27- 
29. The most common types of occupational status were; school pupils 
(n=186), housewives (n=139), secretarial/clerk (n=79) and retired (n=59).
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In 21 (1.7%) of the 1,252 patients, the allergic reaction was considered to be 
of occupational significance. In a further 20 (1.6%) patients, the 
occupational relevance was possible but questionable.
70.4% (n=882) of the patients had no occupational relevance to their disease 
and in 26.3% (n=329) cases this was not recorded.
The main occupations among control subjects were dental surgeons (n=35), 
dental students (n=13) and nursing staff and dental surgery assistants 
(n=13). The proportions of these and the other occupations among the 
control group are shown in Fig. 30.
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Fig. 27. Bar Chart o f  the M ost Common Types o f  Occupation Am ong
Patients
200 —
100 —Z3z
o —1
13 20 21 22 26 29 341 2 3
Types of Occupation
Key to Types of Occupation:
1 T eacher/Lecturer 21 School pupil
2 Shop Assistant 22 Student
3 Secretarial 26 Unemployed
13 Manager 29 Retired
20 Housewife 34 Miscellaneous
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Fig. 28. Bar Chart o f  Types o f  Occupation Am ong Patients
2D -
15 -
10  -
5 — U U U a G U U a a a
i — r
5 7 10 11 12 17 25 30 31 32 33 35 39
Type of Occupation
Key to Types of Occupation:
5 Nurse/Dental Nurse
7 Factory worker
10 Domestic
11 Catering
12 Mechanic
17 Engineer
25 Driver
30 Paramedical worker
31 Auxiliary Nurse
32 Welder/Tool maker
33 Salesman
35 Dentist/Doctor
39 Architect/Surveyor
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Fig. 29. Bar Chart o f  The Least Common Types o f  Occupation Among
Patients
4 -
2 -
1 -
1 — I— I—I— I I I I I I I I I I I I I I I I I T"
4 6 8 9 141516182324283740424344454647485052
Type of Occupation
Key to Types of Occupation:
4 Hairdresser
6 Waiter
8 Building trade
9 Technician
14 Electrician
15 Plumber
16 Joiner
18 Painter/Decorator
23 Porter
24 Labourer
28 Steel worker
37 Laundrette assistant
40 F armer/Gardener
42 Postman
43 Storeman
44 Printer
45 Tailor
46 Carpet fitter
47 Journalist
48 Foreman
50 Pre school age child
52 Civil servant
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Fig. 30 . Types o f  Occupation Among Control Subjects
30 -
20 -
10 -
cn □
1 3 5 9 10 13 15 17 22 30 34 35 38
Occupation
Key to occupations:
1 Lecturer 17 Engineer
3 Secretary 22 Dental Student
5 Nurse/Dental Nurse 30 Medical photographer
9 Dental Technician 34 Miscellaneous
10 Cleaner 35 Dentist/Doctor
13 Manager 38 Science Officer
15 Plumber
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3.5.2.7. Further Characterisations of the Control Group
Skin Disease
Ten control subjects gave a history of past skin disease, which 
included childhood eczema (n=3), fungal infections (n=3), psoriasis 
(n=2) and itchy rashes on exposure to the sun (n=2).
Twenty eight gave a history of skin problems that had recently or 
currently affected them. Of these, eight gave a history of eczema (2 
with their hands affected), another 11 described an itchy rash to 
unknown stimulus (3 of whom had their hands involved), four gave a 
history of irritation of the skin or rash produced by wearing 
examination gloves (3 dentists, 1 dental technician), two described 
an itchy rash to some soap powders, two had urticaria and one had 
dermatitis.
Known Intolerances
Medications - 11 control subjects gave a history of allergy to 
medications; six were allergic to penicillin, one to septrin, one to 
chloroquine, one to tetracycline, one to aspirin and one to ‘Difflam’ 
cream.
Elastoplasts -  11 control subjects gave a history of a skin reaction to 
elastoplasts.
Jewellery -  29 gave a history of skin reactions to this, with 28 
reporting reactions to costume jewellery and one to gold. Of the 28
reacting to costume jewellery, five only had problems while wearing 
earrings in pierced ears.
Cosmetics/Toiletries -  13 control subjects experienced problems 
with these; five had skin reactions to perfumes and two to other 
cosmetic products.
Chemicals -  five including two reporting skin problems with soap 
powders and one with detergents.
Fifty control subjects gave no history of skin reactions to any of the 
above categories.
Atopy
A total of 23 control subjects gave a history of atopy (criteria being 
asthma, severe childhood or adult eczema, or hay fever severe 
enough to warrant the use of antihistamine therapy). A further 14 
control subjects had an atopic tendency (criteria being mild 
childhood or adult eczema, mild hay fever or migraine).
Infant Feeding Status
Forty nine control subjects had been fed from birth on infant formula 
and 49 were fed breast milk for a varying period of time; five for 
under one month, 35 for 1-6 months and nine for an unknown period 
of time. The remaining two control subjects were unsure of their 
infant feeding status.
3.5.3. Patch Test Results
The irritant reactions were not considered in this thesis, and 
“positive” refers to a positive allergic reaction. All positive 
reactions, graded 1, 2 or 3 according to the accepted scoring for 
patch tests as outlined earlier, were combined together in analysing 
the results. Equivocal test sites were considered a negative result. 
The percentage of positive reactions were calculated out of the 
number of patients tested for each allergen in each disease group. 
When calculating the percentages of positive reactions to the whole 
of a series of allergens, the maximum number of patients tested to at 
least one of the allergens in the series was used to avoid artificially 
inflating the number of positive results.
3.5.3.I. Atopy And Infant Feeding In The Control Group
There were no significant differences in the patch test results 
between subjects who had been bottle fed and those who had been 
breast fed from birth.
There were no significant differences in the patch test results 
between those who were atopies or had an atopic tendency and those 
who did not.
However, the proportion of subjects who had been bottle fed from 
birth was increased in the atopic group (23 out of 37 were bottle fed,
p=0.04, the 95% confidence interval for the difference in the 
proportions of those who were bottle fed minus the proportion of 
those who were breast fed was 0.011, 0.407).
3.5.3.2. Patch Test Results In The Total Number Of Referred 
Patients
The total number of patients who had one or more positive allergic 
reaction during the testing was 988 (78.9%) out of the group of 
1,252. Most of these reactions (n=891, 71.2%) were to the modified 
European Standard Series or to the food additives, perfumes and 
flavourings or chocolate.
The total number of patients with OLE who had one or more positive 
allergic reactions during the testing was 212 (81.2%) out of the 261 
patients in this group.
The total number of patients with RAS who had one or more positive 
allergic reactions during the testing was 230 (83.0%) out of 277 in 
this group.
The total number of patients with AE who had one or more positive 
allergic reactions during the testing was 36 (80.0%) out of the 45 
patients in this group.
The total number of patients with EM who had one or more positive 
allergic reactions during the testing was 33 (78.6%) out of the 42 in 
this group.
The total number of patients with OFG who had one or more 
positive allergic reactions during the testing was 203 (76.7%) out of 
the 264 patients in this group.
Seventy out of the control group reacted positively to one or more of 
the allergens tested.
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3.5.3.3. Notes on abbreviations, formatting and symbols used in 
Tables 5-14.
Abbreviations: DHT -  delayed hypersensitivity test.
CUT -  contact urticaria test.
95% Cl -  the 95% confidence interval for the 
difference in the number of positive reactions (disease 
group minus control group).
Total no. +ve -  the total number of patients that had a 
positive reaction to the allergen.
Formatting: Bold italics indicate a significant result (p=<0.05).
Results in italics indicate borderline significance 
(p=>0.05 and <0.085).
Symbols: * indicates that the statistical results may be invalid
due to the small sizes of some of the results.
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3.5.3.4. Food Additives
The results of the patch tests for patients and controls for all the food 
additives are shown in Tables 16-18. Thirty three control subjects 
had one or more reactions to food additives (section 3.4.1 lists the 
food additives in this category). Of these, 11 had reactions to the 
delayed hypersensitivity tests (DHT) only and 20 reacted only to the 
contact urticaria tests (CUT). The other two control subjects had 
reactions to both types of tests but in each case to different food 
additives. No-one had a reaction to the same substance in both types 
of test.
Only three of the nine food additives elicited responses in the control 
subjects. These were benzoic acid, sorbic acid and sodium 
metabisulphite. The reaction rate between the two types of tests was 
28%, 3% and 6% respectively.
Most of the positive reactions in the disease groups were also to 
benzoic acid (n=446), sorbic acid (n=87) and sodium metabisulphite 
(n=38).
Of the 222 patients with OLE who were tested to benzoic acid (in 
one or both of the DH and CU tests), 29.7% (n=66) had a positive 
reaction but this was not significantly different from the controls. 
7.1% (n=15) reacted to sorbic acid in the CUT which was significant 
though the numbers were small enough to cast doubt on the validity 
of the statistical analysis.
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The significant results in the RAS group of patients when compared 
to the 100 controls were, that there were many more reactions to 
CUT and to both CUT and DHT, with benzoic acid. 46.2% (n=126) 
had positive reactions out of a maximum of 273 tested to this 
allergen, compared to 28% controls. There was also a significant 
difference in the number of positive reactions to RAS patients tested 
to sorbic acid in the CUT when compared to controls though the 
small amount of positive reactions in the control group may have 
affected the validity of the statistical analysis.
Amongst the AE patients 25.0% (n=9) reacted positively to benzoic 
acid in the DHT which was significant compared to controls (7%). 
Nearly half of the EM patients reacted to benzoic acid and this was 
significant in the CUT when compared to controls. The numbers of 
patients in this group 12.5% (5) reacting to sorbic acid yielded a 
result of borderline significance (p=0.052) though again the size of 
the positive group in the controls (2) was small which may invalidate 
the result.
Of the 240 patients with OFG, 47.2% (n=l 10) had a positive reaction 
to CUT with benzoic acid which was highly significant when 
compared to the controls. A significant number also reacted to 
sorbic acid.
The percentage of positive reactions to the food additives and 
benzoic acid in particular, across all disease groups are shown in 
Figs 31 and 32.
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Fig. 31. Bar Chart o f Positive Reactions to Food Additive Series
OFG Control
Fig. 32. Bar Chart o f  Positive Reactions to Benzoic Acid
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As some of the patients who tested positive to some allergens in this 
series, also tested positive to others the total number of patients who 
had one or more reactions to one or more of the allergens in this 
series was calculated and are shown in Table 19.
In all patients, over one third had a positive reaction to one or more 
of the food additives tested in the CUT and nearly half when both 
tests were taken into account. These results were significantly 
higher than controls though it should be borne in mind that the 
control group size of 100 was small compared to the 1,082 patients 
who were tested to these allergens.
The RAS and OFG groups of patients had significantly more 
positives to the CUT compared to the control group, and the AE 
group had a significantly greater number of positives to the DHT.
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3.5.3.5. Perfumes And Flavourings
See Tables 20-23 for the results of the patch testing to these 
allergens. In the control group, only three out of the 11 substances 
elicited a response (see section 3.4.2 for listing of perfumes and 
flavourings in this category). Seven of the control subjects reacted 
to cinnamaldehyde. Of these, five had a positive reaction to the 
CUT only, one only to the DHT and one reacted to both. Two 
further patients had a positive reaction, one to geraniol and the other 
to oak moss absolute.
Of all the patients tested to these allergens (maximum number tested 
was 1161), 28.6% (n=327) reacted to cinnamaldehyde ( nearly all in 
the CUT) and 4.2% (n=49) reacted to oak moss absolute (mostly in 
the DHT). As only one of the control group had a positive reaction 
to oak moss absolute, formal statistical analysis was not possible.
Of the 234 OLE patients tested to these allergens, 16.2% (n=38) 
reacted to cinnamaldehyde in the CUT which was significant when 
compared to the control group. 6% (n=14) reacted to oak moss 
absolute though for the reasons outlined above, formal statistical 
comparison was not possible.
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The only significant result in the other four disease groups was to 
cinnamaldehyde in the CUT, with the results from the RAS and OFG 
patients being highly significant.
The percentage of positive reactions to the perfumes and flavourings 
and to cinnamaldehyde in particular, across the disease groups are 
shown in Figs 33 and 34.
The reactions to the whole series of perfume and flavouring 
allergens (shown in Table 19) were significantly higher in all disease 
groups compared to controls in both types of tests (except for the 
DHT in the OFG group). The number of positives in the control 
group to the DHT in this series was small (n=4), and this should be 
borne in mind when considering the validity of the statistical 
analysis.
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Fig. 33. Bar Chart o f  Positive Reactions to the Perfume and
Flavouring Series
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Fig. 34. Bar Chart o f  Positive Reactions to Cinnamaldehyde
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3.5.3.6. Chocolate
The results of patch testing with the chocolate allergens are shown in 
Table 19. together with the results to the food additive and perfumes 
and flavourings series as a whole.
Because of the small number of positive reactions to chocolate in the 
control group (one volunteer reacted to chocolate essence (in 
petrolatum) in the delayed hypersensitivity test), the validity of the 
statistical analysis must be questioned. However, of the total 
number of 49 who tested positive to chocolate (42 to the DHT), 
about 40% were in the OFG group.
The percentage of positive reactions in each group to the chocolate 
allergens are shown in Fig. 35.
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Fig. 35. Bar Chart o f  Positive Reactions to Chocolate
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3.5.3.7. All food substances
Table 24 shows the combined result of testing with all food 
substances in all the disease groups and controls.
Twenty three control subjects reacted positively to only benzoic 
acid, one reacted only to sorbic acid and three reacted only to sodium 
metabisulphite. Only two control subjects reacted only to 
cinnamaldehyde and the volunteer who reacted to chocolate only had 
that positive result. Of those who reacted to benzoic acid, most had 
only that reaction, whereas of those who reacted to cinnamaldehyde, 
most reacted to one of the food additives as well.
In total, 37 of the control subjects had a reaction to one or more food 
substances.
The results for the food substance (FS) allergens (food additive 
series, perfume and flavouring series and chocolate allergens) as a 
whole were significantly higher than the number of positives found 
among the controls. The 95% confidence interval for the difference 
in the percentage of positives in the disease minus the controls was 
over 20% in all the disease groups.
The percentage of positive reactions all of the food substances tested, 
are shown in Fig. 36.
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Fig. 36. Bar Chart o f Positive Reactions to All Food Allergens
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3.5.3.8. Modified European Standard Series
The results are summarised in Table 24 and Fig. 37 and are tabulated 
in detail in Tables 25-30. The proportion of controls reacting to this 
series was significantly greater than the proportion of the RAS, EM 
and OFG patients and was similar to the proportion of the OLE 
group.
Fig. 38. shows the distribution between the disease groups of those 
who tested positive to the modified European Standard Series and/or 
the food substances.
When taken together with the FS allergens, there were no significant 
differences between the disease and control groups.
Seventy out of the control group reacted positively to one or more of 
the allergens tested. One had only an irritant reaction (to cobalt) and 
only 26 of the control subjects had no reactions at all.
The petrolatum test was negative in all 1,252 patients and controls.
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Fig. 37. Bar Chart o f Positive Reactions to the Modified Standard
Series
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Fig. 38. Bar Chart o f  the Number o f  Patients with Positive
Reactions to the Modified Standard Series and/or to Food 
Allergens
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Table 25. Reactions o f  the Total Number o f  Patients to the
Modified European Standard Series
Nickel Sulphate 1247 195 15.6
Colophony 1244 39 3.1
Cobalt Chloride 1245 40 3.2
Formaldehyde 1246 18 1.4
Potassium Dichromate 1245 16 1.3
PPD* 1244 16 1.3
Mercapto-mix 1245 7 0.6
Neomycin 1245 30 2.4
Paraben mix 1245 14 1.1
Balsam of Peru 1245 56 4.5
Thiuram-mix 1242 22 1.8
PPD+-mix 1244 1 0.08
Fragrance-mix 1230 128 10.4
Primin 1138 3 0.3
Quaternium 15 1138 7 0.6
Carba-mix 1244 8 0.6
Wool Alcohols 1246 16 1.3
PTPB# Formaldehyde Resin 1138 7 0.6
Caine-mix 1240 9 7.2
Epoxy Resin 1245 8 0.6
Quinoline 1138 8 0.7
Ethylene Diamine 1245 4 0.3
Thiomersal 1245 44 3.5
Control (Petrolatum) 1252 0 0
All of the above 1247* 470 37.7
f Paraphenylenediamine
# Paratertiarybutylphenol
* Some of these patients were not tested to all of the allergens in the series.
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Table 26. Reactions O f OLE Patients And Controls To The
Modified European Standard Series
[See notes in section 3.5.3.3.]
Nickel Sulphate 260 34 13.1 23 0.035 -0.191, -0.007
Colophony 259 1 0.4 5 0.037* -0.90, -0.003
C obalt C hloride 260 8 3.1 3 0.97* ,
Form aldehyde 260 6 2.3 0
Potassium
D ichrom ate
260 3 1.2 2 0.585*
PPD f 260 4 1.5 1 0.668*
M ercapto-m ix 260 1 0.4 0
Neomycin 260 7 2.7 1 0.231*
Paraben  mix 260 3 1.2 0
Balsam of Peru 260 19 7.3 4 0.25
Thiuram -m ix 260 2 0.8 1 0.839*
PPD T-mix 260 1 0.4 0
Fragrance-m ix 260 35 13.5 6 0.019 0.012, 0.137
Prim in 235 0 0.0 0
Q uaternium  15 235 0 0.0 0
C arba-m ix 260 0 0.0 0
Wool Alcohols 260 6 2.3 0
PTPB resin" 235 1 0.4 0
Caine-mix 260 2 0.8 0
Epoxy Resin 260 0 0.0 1
Quinoline 235 1 0.4 0
Ethylene Diamine 260 1 0.4 0
Thiom ersal 260 20 7.7 21 0.002 -0.219, -0.047
Control
(Petrolatum )
261 0 0.0 0
All 260s 109 41.9 49 0.227
+ Paraphenylenediamine
# Paratertiarybutylphenol formaldehyde resin
§ Some of these patients were not tested to all of the allergens in the series. 
Chi Squared Test used.
* Small numbers may make test invalid.
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Table 27. Reactions O f RAS Patients And Controls To The
Modified European Standard Series
[See notes in section 3.5.3.3.]
Nickel Sulphate 276 54 19.6 23 0.478
Colophony 276 9 3.3 5 0.474
C obalt C hloride 276 10 3.6 3 0.76
Form aldehyde 276 5 1.8 0
Potassium
D ichrom ate
276 4 1.45 2 0.726*
PPD T 276 0 0 1
M ercapto-m ix 276 0 0 0
Neomycin 276 5 1.8 1 0.526*
Paraben  mix 276 6 1.2 0
Balsam of Peru 276 11 4.0 4 0.995
Thiuram -m ix 276 3 1.1 1 0.941*
PPD T-mix 276 0 0 0
Fragrance-m ix 276 25 9.1 6 0.298
Prim in 273 0 0 0
Q uatern ium  15 273 3 1.1 0
C arba-m ix 276 0 0 0
Wool Alcohols 276 2 0.72 0
PTPB* Resin 273 1 3.7 0
Caine-mix 276 2 0.72 0
Epoxy Resin 276 1 3.6 1 0.547*
Quinoline 273 2 0.73 0
Ethylene Diamine 276 2 0.72 0
Thiom ersal 276 10 3.6 21 0.000 -0.257, -0.091
C ontrol
(Petro latum )
277 0 0 0
All 276§ 88 31.9 49 0.005 -0.284, -0.059
f Paraphenylenediamine 
u Paratertiarybutylphenol formaldehyde resin
51 Some of these patients were not tested to all of the allergens in the series.
Chi Squared Test used.
* Small numbers may make test invalid.
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Table 28. Reactions O f AE Patients And Controls To The
Modified European Standard Series
[See notes in section 3.5.3.3.]
Nickel Sulphate 45 9 20.0 23 0.681
Colophony 45 1 2.2 5 0.369
C obalt C hloride 45 2 4.4 3 0.681
Form aldehyde 45 0 0.0 0
Potassium
D ichrom ate
45 0 0.0 2
PPD T 44 2 4.5 1 0.282*
M ercapto-m ix 45 0 0.0 0
Neomycin 45 0 0.0 1
Paraben  mix 45 0 0.0 0
Balsam of Peru 45 2 4.4 4 0.903*
Thiuram -m ix 45 1 2.2 1 0.612*
PPD T-mix 45 0 0.0 0
Fragrance-m ix 44 5 11.4 6 0.264
Prim in 37 0 0.0 0
Q uaternium  15 37 0 0.0 0
Carba-m ix 45 0 0.0 0
Wool Alcohols 45 0 0.0 0
PTPB* Resin 37 1 2.7 0
Caine-mix 44 0 0.0 0
Epoxy Resin 45 0 0.0 1
Quinoline 45 0 0.0 0
Ethylene Diamine 45 5 0.0 0
Thiom ersal 45 0 0.0 21
Control
(Petro latum )
45 0 0.0 0
All 45s 15 33.3 49 0.069 -0.326, 0.012
+ Paraphenylenediamine
# Paratertiarybutylphenol formaldehyde resin
§ Some of these patients were not tested to all of the allergens in the series. 
Chi Squared Test used.
* Small numbers may make test invalid.
252
Table 29. Reactions O f EM Patients And Controls To The
Modified European Standard Series
[See notes in section 3.5.3.3.]
Nickel Sulphate 41 5 12.2 23 0.103
Colophony 41 1 2.4 5 0.431*
C obalt C hloride 41 1 2.4 3 0.849*
Form aldehyde 41 0 0.0 0
Potassium
D ichrom ate
41 0 0.0 2
PPD T 41 0 0.0 1
M ercapto-m ix 41 0 0.0 0
Neomycin 41 1 2.4 1 0.581*
P araben  mix 41 0 0.0 0
Balsam of Peru 41 0 0.0 4
Thiuram -m ix 41 2 4.9 1 0.269*
PPD T-mix 41 0 0.0 0
Fragrance-m ix 41 2 4.9 6 0.785*
Prim in 41 0 0.0 0
Q uaternium  15 41 1 2.4 0
C arba-m ix 41 0 0.0 0
Wool Alcohols 41 0 0.0 0
PTPB" Resin 41 0 0.0 0
Caine-mix 41 1 2.4 0
Epoxy Resin 41 0 0.0 1
Quinoline 41 0 0.0 0
Ethylene Diamine 41 0 0.0 0
Thiom ersal 41 0 0.0 21
C ontrol
(Petrolatum )
42 0 0.0 0
All 41 10 24.4 49 0.003 -i0.410, -0.082
+ Paraphenylenediamine
* Paratertiarybutylphenol formaldehyde resin
* Small numbers may make test invalid.
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Table 30. Reactions O f OFG Patients And Controls To The
Modified European Standard Series
[See notes in section 3.5.3.3.]
Nickel Sulphate 263 28 10.6 23 0.007 -0.214, -0.033
Colophony 261 7 2.7 5 0.337
C obalt Chloride 261 1 0.4 3 0.134* ,
Form aldehyde 262 4 1.5 0
Potassium
D ichrom ate
261 1 0.4 2 0.265*
PPD T 261 4 1.5 1 0.671*
M ercapto-m ix 261 1 0.4 0
Neomycin 261 4 1.5 1 0.671*
P araben mix 261 2 0.8 0
Balsam of Peru 261 9 3.4 4 0.807*
Thiuram -m ix 261 4 1.5 1 0.671*
PPD T-mix 261 0 0.0 0
Fragrance-m ix 254 7 2.8 6 0.13
Prim in 232 0 0.0 0
Q uaternium  15 232 2 0.9 0
C arba-m ix 261 2 0.8 0
Wool Alcohols 262 5 1.9 0
PTPB* Resin 232 1 0.4 0
Caine-mix 261 1 0.4 0
Epoxy Resin 261 4 1.5 1 0.671*
Quinoline 232 0 0.0 0
Ethylene Diamine 261 0 0.0 0
Thiom ersal 261 7 2.7 21 0.000 -0.265, -0.101
C ontrol
(Petrolatum )
264 0 0.0 0
All 263 68 25.9 49 0.000 -0.343, -0.120
f Paraphenylenediamine
# Paratertiarybutylphenol formaldehyde resin 
Chi Squared Test used.
* Small numbers may make test invalid.
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Out of the total number of patients, 195 reacted positively to nickel, 
12 (6.2%) were male and 183 (93.8%) were female. The sex 
distribution of those patients who had a positive reaction to nickel 
according to diagnosis is shown in Table 31, and the percentages of 
each disease group with positive reactions to nickel are shown in Fig 
39.
Significantly more control subjects than patients in the OLE group 
reacted to nickel, colophony and to thiomersal, though the numbers 
were small to colophony and valid statistical comparison was 
impossible. The proportion of positive reactions to the fragrance 
mix was in the opposite direction with 13.5% of OLE patients to 6% 
of controls. Positives to thiomersal were significantly more 
prevalent in controls than in RAS and OFG patients, see Fig 40. 
Because of the high incidence of thiomersal allergy in the control 
sample group (21%) which skewed the totals, these totals were 
calculated without the thiomersal results being considered. The 
results of these are shown in Table 32. This changed the results 
considerably, in that only the OFG group had more positives to the 
modified European Standard Series compared to the control group 
(p=0.043). When the results of the tests to the modified European 
Standard Series and FS allergens were combined, RAS, AE and 
OFG patients all showed a significantly greater proportion of 
positive reactions than control subjects with the 95% confidence 
interval being greater than 20% in each case.
There were no significant differences between the numbers of 
positive reactions to individual allergens in AE or EM patients when 
compared to controls, though the total number of positives in the EM 
group was significantly less than the total in the control group.
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Table 31. Sex Distribution o f  Patients With Positive Reactions to
Nickel
OLE 2 (5.9) 32 (94.1)
RAS 5 (9.3) 49 (90.7)
AE 0 8(100)
EM 0 5(100)
OFG 4(14.3) 24 (85.7)
All patients 12(6.2) 183 (93.8)
Controls 1 (4.3) 22 (95.7)
Fig. 39. Bar Chart O f Positive Reactions To Nickel
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Fig. 40. Bar Chart O f Positive Reactions To Thiomersal
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3.5.3.9. Results of Testing With Mercurials
Of the total number of patients (n=l,252), 1,244 were tested to thiomersal in 
the modified European Standard Series. A total of 241 were tested to the 
organic mercurials series which included mercury 0.5%, ammoniated 
mercury 1%, phenyl mercuric nitrate 0.05% and thiosalicylic acid 0.1%. 
Sixty of these and 226 further patients were tested to crushed amalgam 30% 
and ammoniated mercury 2%. These two series are referred to as the 
mercury and amalgam series. Phenyl mercuric acetate 0.05% was included 
in a number of different allergen series and out of 1,114 patients tested, 16 
(1.4%) had a positive reaction to it. A total of 1,166 patients were tested to 
one or more other (not including thiomersal) mercurial allergens though 
most of these were only tested with thiomersal and phenyl mercuric acetate. 
Because of the different mercurials that patients were tested to, the results 
are differentiated into two groups of mercurials: those mercurials that act as 
preservatives, thiomersal and phenyl mercuric acetate, and those more 
closely related to amalgam restorations (the rest). The results are shown in 
Table 33 (thiomersal, phenyl mercuric acetate and the total all mercurials) 
and Table 34 (mercury and amalgam series). The OLE patients were 
statistically more likely to have a positive patch test to thiomersal or to 
allergens in the mercury and amalgam series than RAS and OFG patients 
(the numbers of positives in AE and EM patients were too small to analyse).
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Table 33. Positive Reactions to Thiomersal and Phenyl Mercuric Acetate
[significant results indicated by bold italics (p<0.05)]
OLE 20 (7.7) 10(4.2) 99 (8.0)
RAS
10 (3.6) 
p=0.042a
2 (0.80) 22(1.8)
AE 0 0 0
EM 0 0 4(0.3)
OFG
7(2.7)
p=0.01b
2(1.0) 14(1.1)
ALL
PATIENTS
44 (3.2) 16(1.4) 166(13.3)
Of those tested
Statistical analysis compared RAS, AE, EM and OFG groups to the OLE group 
a 95% confidence interval for the difference in the proportion (%) of positive reactions 
(OLE group minus RAS group) (0.2, 8.0%).
b 95% confidence interval for the difference in the proportion (%) of positive reactions 
(OLE group minus OFG group) (1.2, 8.8%).
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Table 34. Positive Reactions to Mercury and Am algam  Series’
[significant results indicated by bold italics (p<0.05)]
OLE 201 91 (45.3)
RAS
80
15 (18.8)“
p=<0.000
AE 7 0
EM
15
4 (26.7)
p=0.12*
OFG
53
8 (15.1)b
p=<0.000
ALL PATIENTS 467 140 (30.0)
To one or more of these allergens.
Statistical analysis compared RAS, AE, EM and OFG groups to the OLE group 
* The normal approximation may be inaccurate for small samples. 
a 95% confidence interval for the difference in the proportion (%) of positive reactions 
(OLE group minus RAS group) (15.5, 37.5%).
b 95% confidence interval for the difference in the proportion (%) of positive reactions 
(OLE group minus OFG group) (18.3,42.0%).
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There was also a statistically significant difference in the number of 
positives in the OLE group when compared to all other patients (p=002, 
95% confidence interval for the difference in the proportion (%) of positive 
reactions (OLE group minus the ‘all other patients’ group) was (1.9, 8.6))
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3.5.4. Outcome Of Dietary Avoidance Of Relevant Allergens.
3.5.4.I. Analysis Of Responses
Number Of Responses
Of the 476 questionnaires that were sent out to patients, 275 (57.8%) 
questionnaires were returned to the department. Of these, 44 were returned 
by the postal service marked “not at this address”, one couldn’t remember 
much of the details of the clinic attendances and results as she had attended 
over 7 years previously, and one patient had died in the intervening period 
since patch testing. There were no significant differences between the age 
(p=0.53) and sex (p=0.396) of those who responded and those who did not 
respond to the questionnaire.
Number Filled Out Correctly
Of the 229 patients that did fill out the form, 214 (83.6%) completed the 
form correctly. Three patients only filled out one side of the questionnaire 
and a further 43 had incorrectly completed one or more of the linear 
analogue scales. However some of these (n=18) had indicated their answer 
by writing at the side of the scale and these were allocated an estimate based 
on that information.
Diet Advice
A total of 24 patients responded that they had never received written diet 
advice from the dietician at the CDIU department though they all would
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have received verbal advice by a trained nurse at the clinic on their last visit. 
Fourteen of these patients went on to claim that they attempted to follow the 
advice given, presumably the verbally given diet advice, to a greater or 
lesser extent. The other 10 patients indicated that the question was not 
applicable to them or left it blank.
Estimate Of Cooperation With Diet Advice
Fifiteen patients left this blank. Of the 204 that answered this part, the 
scores were graded into 5 categories according to how well they complied 
with the diet advice;
0 = Not at all,
1 -3 = Poor,
4-6 = Moderate,
7-9 = Good 
10 = Fully.
The results were that most patients considered that they had shown good or 
full compliance with the diet advice and are shown in Table 35. There were 
no significant differences in the ages or sex of patients that indicated poor, 
moderate or full -  good compliance with the diet advice (95% confidence 
intervals not shown).
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Table 35. The Dietary Advice Compliance Scores For A ll Patients
OLE 67 6 0 6 9 24 22
RAS 87 4 2 6 19 29 27
AE 5 0 2 0 1 0 2
EM 6 1 0 0 2 2 1
OFG 64 4 0 3 5 20 32
TOTAL 229 15 4 15 36 75 84
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Estimate Of Pre-Testing Symptoms
A total of 231 patients completed this part correctly and again the scores 
were divided into 5 categories according to their symptoms:
0 = None,
1-3 = mild,
4-6 = moderate,
7-9 = severe 
10 = most severe.
Most patients recorded scores of severe symptoms or above for their pre 
patch testing score with the median score being 8.21. The results are shown 
in more detail in Table 36.
Estimate Of Post-Testing Symptoms
A total of 224 patients answered this part and the scores were divided into 5 
categories according to their symptoms as described above. The majority of 
patients recorded a lower score for their symptoms after their patch testing 
and subsequent dietary changes. The results are shown in Table 37.
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Table 36. The Pre Patch Testing Symptom Scores
OLE 3 0 8 6 25 25
RAS 1 0 3 5 24 54
AE 0 0 0 2 2 1
EM 0 0 0 0 1 5
OFG 2 0 2 8 20 32
TOTAL 6 0 13 21 72 117
Table 37. The Post Patch Testine Symptom Scores
OLE 3 2 27 12 15 8
RAS 4 1 32 26 15 9
AE 1 1 0 2 0 1
EM 1 0 1 1 1 2
OFG 3 3 32 13 6 7
TOTAL 12 7 92 54 37 27
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Change in symptoms
This was calculated by subtracting the post testing symptom score from the 
pre testing score and the results were divided into 8 categories;
-9 - -7 = symptoms much worse
-6 - -4 = symptoms moderately worse
-3 - -1 = symptoms slightly worse
0 = no change
1-3 = slight improvement
4-6 = moderate improvement
7-9 = marked improvement
10 = maximum improvement
In 44 patients, the change could not be calculated because there was not 
enough information. Most patients had an improvement in their symptoms 
after patch testing with the average symptom score improving by 4.31. The 
results are shown in Table 38.
44 patients were concurrently taking medication(s) that could have caused 
OLE reactions in the mouth. Only 22 of these had OLE and none of these 
patients attributed any of their improvement to changing their medications. 
In those who experienced marked to maximum improvement (n=63), some 
patients attributed other factors as well as the dietary change. These were: 
replacement of amalgam restorations (n=8), steroid therapy (n=2), 
replacement of denture (n=2), changing toothpaste brand (n=l), avoiding 
certain metals (n=l), iron replacement therapy (n=l) and taking 
antihistamine therapy (n=l).
269
Table 38. Change in Symptom Scores
■
ED DD1
OLE 5 2 3 2 13 15 11 14 2
RAS 4 0 0 4 12 17 29 20 1
AE 0 0 0 1 2 0 0 1 0
EM 1 0 0 0 2 1 1 1 0
OFG 3 0 2 0 10 11 14 22 2
TOTAL 14 2 5 7 39 34 55 58 5
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Results Of Dietary Avoidance Among Those Who Showed Good To 
Full Compliance With Advice.
A total of 159 patients indicated by a score of 7 -  10 that they had complied 
with the dietary avoidance advice given. The mean pre testing score of 
symptoms was 8.7 and the mean post testing score was 4.7. Thus the mean 
improvement in this motivated group was 4.0. The improvement scores by 
disease category are shown in Table 38, and these are illustrated by plotting 
the pre testing symptom scores against the post testing symptom scores in 
Fig 41.
The pre testing symptom scores were significantly higher than the symptom 
scores after dietary advice, p=0.04.
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Table 39. Response to avoidance therapy among patients with oral
mucosal disease who showed good compliance
OLE 52 46 (68.7) 7.8 5.0 2.8
RAS 85 56 (64.4) 9.4 4.9 4.5
AE 4 2 (40.0) 7.5 7.5 0
EM 6 3 (33.3) 9.7 7.3 2.4
OFG 61 52 (81.3) 8.8 3.9 4.9
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Fig. 41. Results O f Dietary Avoidance In Patients With Good
Compliance
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Results Of Dietary Avoidance Among Those Who Showed Poor 
And Moderate Compliance
The response to the dietary advice in those who had indicated poor 
compliance (scores 0 - 3 )  and those who had indicated moderate 
compliance (scores 4-6) to the dietary advice are shown in Table 39. 
Moderate compliance results are shown in square brackets. The pre testing 
symptom scores were higher than the post dietary advice symptoms in the 
moderate compliance group (p=0.021) and also higher in those with poor 
compliance to dietary advice though this was of borderline significance 
(p=0.068). The results of dietary avoidance are shown in Fig 42. Though 
the numbers of patients were small especially in the AE and EM categories, 
most improvement was in the region of a decrease of the symptom score of 
between 2-3.5.
There were no significant differences in the improvement scores between 
those with good, moderate or poor compliance, in the three patient groups 
with large enough numbers to analyse. The p values for the analysis of 
variance for each of the three groups were; OLE p=0.94, RAS p=0.473 and 
OFG p=0.172.
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Table 40. Response to avoidance therapy among patients with oral
mucosal disease who showed poor and [moderate! compliance
6 (9.0) 6.8 5.3 1.5
OLE 67 [9(13.4)] [7.6] [4.8] [2.8]
6 (6.9) 9.7 5.4 4.3
RAS 87 [19(21.8)] [7.6] [4.2] [3.4]
0 - - -
AE 5 [1 (20.0)] [4.0] [5.0] [-1.0]
0 - - -
EM 6 [2 (33.3)] [10.0] [6.5] [3.5]
3 (4.7) 8.3 5.3 3.0
OFG 64 [5 (7.8)] [6.6] [4.6] [2.0]
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Fig. 42. Results O f Dietary Avoidance In Patients With Poor Or
Moderate Compliance
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3.5.4.2. Analysis by disease category
Oral lichenoid eruption
Of those who experienced moderate to maximum symptomatic 
improvement (improvement score 4-10, n=25), 8 patients (50%) attributed 
the improvement to the removal of their amalgam restorations as well as to 
the diet. This figure was much higher than the only other disease group that 
had a patient attribute the improvement to amalgam replacement, one out of 
the RAS group (2.3%). The value for this difference was. p=0.002 (the 95% 
confidence interval for the difference in the percentage of OLE patients 
attributing amalgam minus the percentage of RAS patients attributing their 
improvement to amalgam was; 10.8%, 48.5%).
Of those who showed good to full compliance (score 7-10), the 
improvement is shown in Table 39 and Fig 43.
Recurrent aphthous stomatitis
Questionnaires were received back from 87 patients with RAS and 56 
(65.9%) showed good to full compliance. The average improvement in 
symptom scores for this group was of 4.3, with most of the patients starting 
with severe symptoms that after dietary modifications, were scored as mild 
symptoms. See Tables 39 and 40, and Fig 44.
277
Fig. 43. Results Of Dietary Avoidance In OLE Patients With Good 
Compliance
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Fig. 44. Results Of Dietary Avoidance In RAS Patients With Good 
Compliance
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Angioedema
Five questionnaires were received from patients with AE and of these, two 
indicated that they complied well with advice given (score 7-10). However 
their pre and post testing symptom scores showed no change (average of 
7.5) so no improvement was noted. However, the numbers of received 
questionnaires were so small as to question the meaning of any analysis.
Erythema multiforme
Of the six questionnaires received, three patients showed good to full 
compliance but only one indicated improvement and the other two reported 
no change in their symptoms. It should be noted here that 10 of the 42 EM 
patients were also taking medications that could cause EM eruptions. These 
drugs were: aspirin, indocid, feldine, naproxin, carbamazepine, phenytoin 
and dihydrocoedine. Two of the EM patients who replied to the 
questionnaire were in this category though none claimed that their 
improvements was due to drug change or avoidance. However, the numbers 
of questionnaires received from the patients in this group were so small that 
analysis is meaningless.
Oro-facial granulomatosis
A total of 64 questionnaires were received and 52 (81.3%) of these showed 
good to full compliance. The average pre and post testing scores were 8.5 
and 4.0 respectively and overall the average improvement was by a score of 
4.5, see Tables 39 and 40 and Fig 45.
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Fig. 45a Results O f Dietary Avoidance In OFG Patients W ith G ood
Compliance
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CHAPTER 4: HISTOPATHOLOGY STUDIES
4.1. Introduction
Histopathology is essentially a subjective art that is brought to excellence by 
years of experience and gain in knowledge of the microscopic findings of 
various diseases. While variation in classifications of various microscopic 
findings between examiners is expected due to the subjective nature of the 
discipline, variation in the findings of the same examiner looking at the 
same section is also common (Smith & Pindborg 1969). In order to 
minimise this and to assist in increasing the reproducibility of findings 
between different examiners and between repeated examinations of the 
same section by the same examiner, some authors have devised 
photographic standards of histological and cellular features that aid in both 
identifying and grading the features found (Smith & Pindborg 1969). The 
aim in using these is to focus attention on one microscopic feature at a time 
and using photographic standards, to visually assess which of the 
photographs (showing a range of different appearances of individual 
features that are ordered in severity) is most like the field in question.
A subgroup of the oral lichenoid eruption (OLE) patients investigated in 
Chapter 3 were also investigated by histological examination. Specimens 
obtained from OLE patients were examined to see if it was possible to 
assess by histological examination, whether there were any differences in 
the microscopic appearance of specimens from patients whose OLE could 
have been caused by a variety of factors. Those factors that were 
investigated were: the presence of amalgam dental restorations, taking
medications that are associated with the development of OLE, and 
hypersensitivity to food additives and flavourings, mercurials and other 
allergens. As iron deficiency anaemia results in atrophy of the oral 
epithelium (Ranasinghe et al. 1983), the ferritin levels were also assessed as 
an atrophic epithelium would increase the likelihood of antigen penetration 
of the epithelium and hence sensitisation. Normal ferritin levels are found 
between 25 and 300ng/ml and a level of under 25ng/ml was considered to 
indicate latent or actual iron deficiency.
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4.2. Patients
Consecutive patients from Glasgow Dental Hospital and School, Oral 
Medicine Clinic, who fulfilled the following criteria:
•  clinical diagnosis of an oral lichenoid reaction
•  biopsy from buccal mucosa, avoiding the occlusal line
•  histological diagnosis of an oral lichenoid eruption
•  attended CDIU at Belvidere/GRI for patch testing
The number of patients fulfilling the above criteria was 42. All pathological 
slides made from the specimens of buccal mucosa from each patient, were 
examined and the slide showing the most florid lichenoid reaction (as 
determined by disruption of normal histological appearance) was selected 
for histological grading. At the time of the histological grading the results 
of the patch tests were not known by the observer.
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4.3. Methods
All slides were stained with haematoxylin and eosin and where there was a 
suspicion of candidal species involvement, further sections (n=30) were 
stained with periodic acid Schiff following diastase digestion (PASD).
A pilot study of 15 haematoxylin and eosin stained histology sections, each 
from a different OLE patient, was carried out to enable standardisation of 
the grading methods and to provide reference views for the visual grading 
procedure. The histological characteristics that were examined and graded 
were keratin layer thickness, epithelial thickness, the thickness and density 
of the inflammatory cell infiltrate and the degree of basal cell layer 
disruption. The presence or absence of structures consistent with Candida, 
hypergranulomatosis, acanthosis, cellular tropism, germinal centres, 
perivascular infiltrate and marginating polymorphonuclear neutrophils was 
noted as was the number of mast cells, plasma cells and eosinophils present 
in each specimen.
From this, views of thin, medium and thick keratin layers, epidermal layers 
and inflammatory infiltrate layers were photographed along with views of 
sparse, medium and dense infiltrate layers. These reference views are 
shown in Figs. 45-50. The photographs served as a visual guide and the 
score was worked out by choosing the reference view that most closely 
resembled the section under scrutiny (Smith & Pindborg 1969). The grades 
for the other parameters were also worked out and standardised during the 
examination of the pilot study sections.
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As the results of the histological assessment were not being compared with 
those made by any other observer, no inter-observer calibration was 
necessary. However, an experienced senior pathologist gave training and 
advice during the grading proceedure.
The patch test results of the patients were obtained after the grading had 
been completed and the results analysed to discover whether there was any 
differences between the histological appearances of specimens from patients 
having amalgam restorations in their mouths (group A) and those without 
any amalgam restorations (group B), between patients on drugs known to 
have caused OLE (group C) and those not on any drugs known to have 
caused OLE (group D) and patients with positive (group E) or negative 
(group F) patch test results.
Each patient’s Dental Hospital records were examined to ascertain the 
ferritin levels from blood samples taken in the Oral Medicine Clinic, and 
dental information regarding the presence of amalgam restorations in the 
mouth. No ethical committee approval was required as the blood samples 
had all been collected prior to the study commencing and as part of the 
patients’ clinical investigations.
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4.3.1. Statistical Analysis
The categorical data were analysed using the Chi Squared test, combining 
some of the grades together where the expected values were less than two. 
Sets of (Bonferroni-corrected) 95% confidence intervals were computed for 
the difference between the proportions in each category of the two 
multinomial distributions. Multiple comparison analysis was not carried o u t' 
on the data because the sample size was too small for the results to be valid. 
The continuous data was analysed using the 2 sample t-test and the binary 
data, using the 2 proportions test.
The ages of the various groups were compared after normality was 
demonstrated by the use of plots.
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4.3.2. Histopathological Examination
Areas of ulceration in the specimens were not used in the assessment and a 
margin of one x20 microscope field adjacent to these areas was also 
avoided. Likewise areas of normal mucosa were excluded. No repeat 
examinations were made unless specified.
The different histological features of the specimens were graded as follows. '
4.3.2.1. Histological Parameters Arranged Into Ordered Categories
Keratin Layer Thickness
This was measured at a magnification of xlO using the reference figures 45- 
47. As the thickness of the keratin layer varied along the length of some 
specimens, the thickest area was used in any given section for the 
assessment.
Epithelial Thickness
This was assessed at xlO again using reference figs. 45-47, taking the 
assessment from the thickest area of the section but not including the rete 
ridges in the assessment.
Inflammatory Cell Infiltrate Layer Thickness
The sections were assessed at xlO and the field with the thickest layer 
chosen for the grading. The reference figs 45-47 were used as a guide and
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Fig. 46. Reference View O f Epidermis Showing Thin Keratin Epithelial
And Infiltrate Layers (xlO)
Fig. 47. Reference View O f Epidermis Showing Medium Thickness O f 
Keratin, Epithelial And Infiltrate Layers (xlO)
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Fig. 48. Reference View O f Epidermis Showing Thick Keratin, Epithelial 
and Infiltrate Layers (xlO)
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the scoring was as follows; a score of 1 indicated a thin infiltrate layer 
(approximately one fifth of the field width), 2 indicated a medium thickness 
of infiltrate layer (approximately one third of the field width) and a score of 
3 indicated a thick infiltrate layer (approximately one half of the field 
width).
Inflammatory Cell Infiltrate Layer Density
Reference figs. 48-50 were used to assess the density which was viewed at 
xl 0 and using the field with the densest area of infiltrate. This often but not 
necessarily corresponded with the thickest area of infiltrate on the section.
Basal Cell Layer Disruption
At a magnification of xlO, the field width with the most evidence of 
disruption of the basal cell layer on each specimen was assessed. A grade of 
1 was given if 0-33% of the length of the basal layer was affected by 
liquefaction, 2 if 33-66% was affected and 3 if over 66% of the area in the 
field was affected.
Cellular Tropism
This was assessed at xlO and graded 1-3 for mild, moderate and severe 
degrees of cellular tropism. The number of cells passing through the 
basement membrane was used rather that the height that they were seen to 
have reached in the epidermis. Again the field showing the most cells 
invading the epidermis was chosen for the assessment.
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Fig. 49. Reference View O f Epidermis Showing A Sparse Inflammatory
Cell Infiltrate Layer (xlO)
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Fig. 50. Reference V je^O f'E piderm is Showing An Inflammatory Cell
Infiltrate Layer With Moderate Density (xlO)
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Fig. 51. Reference View O f Epidermis Showing A Dense Inflammatory
Cell Infiltrate Laver (xlO)
»v
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The following three parameters were assessed in a similar manner to that of 
Firth and Reade (Firth & Reade 1990).
Mast Cells
This was assessed at x20 and the depth of section examined shown in fig 51. 
Three field widths closest to the lesion, or the most florid part of the lesion 
were examined and the mast cells counted. The score of the section was 
taken to be the average of these three scores. Each section was assigned a 
grade according to the numbers of mast cells found: none = 1, 1-10 = 2, >10 
= 3.
Plasma Cells
This was assessed at x20 and the depth of section examined shown in fig 52. 
Three field widths closest to the lesion or the most florid part of the lesion 
were examined and the mast cells counted. The score of the section was 
taken to be the average of these three scores. Each section was assigned a 
grade according to the numbers of plasma cells found: none = 1, 1-15 = 2, 
>15 = 3.
Eosinophils
This was assessed at x20 and the depth of section examined shown in fig 51. 
Three field widths closest to the lesion or the most florid part of the lesion 
were examined and the mast cells counted. The score of the section was 
taken to be the average of these three scores. Each section was assigned a 
grade according to the numbers of eosinophils found: none = 1, 1-10 = 2, 
>10 = 3.
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Fig. 52. Diagram O f Epithelium Showing Field Placement For
Assessment Of  Mast Cells And Eosinophils
Field diam eter 
includes 
approximately  
1/3 of the 
infiltrate layer.
Fig. 53. Diagram Of Epithelium Showing Field Placement For 
Assessment Of Plasma Cells
Field diam eter 
includes 
approximately  
1/2 of the 
infiltrate layer.
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4.3.2.2. Histological Parameters Arranged Into Binary Data
Acanthosis
Acanthosis was defined as a thickened spinous layer that was often but not 
always associated with rete ridge formation. The sections were assessed at 
xlO and the presence of acanthosis recorded.
Hypergranulomatosis
This was assessed at x 20. An increased thickness in the granular layer of 
the epidermis is usually found in specimens of patients with lichen planus 
(Ackerman 1978). This increased thickness was often arranged in regularly 
spaced clumps giving a ‘zig-zag’ appearance to the layer. The presence of 
hypergranulomatosis was taken as positive when the thickest point of the 
granular layer exceeded one third of the epidermal thickness.
Germinal Centres
This was assessed at xlO and was recorded positive if any germinal centres 
(focal concentration of inflammatory cells) were seen.
Marginating Polymorphonuclear Lymphocytes
The sections were examined at x20 and the three blood vessels that could be 
clearly seen closest to the most florid area were assessed for the presence of 
marginating polymorphonuclear leukocytes, i.e. neutrophils seen to be in 
contact with the vessel lumen walls.
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Perivascular Infiltrate
This was assessed at xlO and was recorded as positive if any of the dermal 
blood vessels had a distinct inflammatory infiltrate associated with them.
4.3.2.3. Histological Parameters - Continuous Data 
Apoptosis
Apoptosis was defined as cells with chromatin condensation at the periphery 
of the nucleus, a uniformly eosinophilic cytoplasm, nuclear fragmentation 
and pyknosis and nucleolar disintegration. The basal cell layer and the 
immediate suprabasal layers (3-4 cells thick) were assessed at a 
magnification of xlO for cells that were undergoing apoptosis and these 
were counted. The length of the basal cell layer was measured using a 
computer programme linked to a microscope. The basement membrane was 
traced, field by field on the computer monitor using a mouse and the length 
was returned by the computer in microns. From this, an estimate of the 
number of apoptotic cells per micron of basement membrane length could 
be determined.
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4.4. Results
All the sections from the biopsy specimens taken from 42 patients were 
examined and the section showing the most florid disease process chosen. 
Table 41 shows the patient demographics and ferritin levels and Table 42 
shows the possible aetiological factors which was the way in which the 
patients were divided up for further study. A total of 14 patients had low 
ferritin (<25mmol/l) but this did not correlate with atrophy of the 
epithelium, (p=0.166).
A total o f 28 patients had one or more amalgam dental restoration in their 
mouth (group A) and 14 had no amalgam restorations (group B).
The same group of patients were divided up according to whether they were 
on medications that could cause OLE, 12 were taking medication that may 
have caused the OLE (group C) and 30 were not (group D). The 
medications that may have caused OLE and that were being taken by this 
group of patients were aspirin, sulphasalazine, diclofenac, thyroxine, 
diuretics, (3-blockers and allopurinol.
The same group was again split up according to the results of the patch tests 
(delayed hypersensitivity (DHT) and contact urticaria tests (CUT)). A total 
of 28 patients had positive reactions to one or more patch tests (group E) 
and 14 patients were negative (group F).
Only two patients (patient number 5 and number 26) did not have any 
identified aetiological factor but this sample was too small to compare with 
the 40 that had identifiable possible aetiological factors. The age and sex
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Table 41. Patient Demographics and Relevant Dental Information
148
176
64'
NT
183
NT
138 
1 17
55
20 695
NT
23
110
118
112
43
294
136
49
25
27
28
42
47
NT
156
NT44
13242
3 Not tested
* Sample was not taken at the same time as the biopsy.
Table 42. Patients With OLE Lesions And Possible Aetiological Factors
[Y = Yes/positive, blank = no/negative]
1 i Y i J
2 [ Y r I
3 Y Y i ~  r
4 Y Y : ;j I
5
6 Y Y I  “  j
7 Y M
8 Y I Y 7 V 1 FS/M
9 ! Y 1 FS
10 Y Y ! Y ! M
11 Y Y Y ; M
12 Y Y ?
13 Y Y I
14 Y i Y j FS
15 Y j Y I FS
16 Y Y ! FS/M
17 Y Y Y ! FS/M
18 Y Y Y Y M
19 Y Y Y FS
20 Y
21 Y Y FS/M
22 Y Y
23 Y Y Y M
24 Y Y Y Y M
25 Y j FS
26
27 Y Y Y
28 Y Y FS
29 Y Y Y
30 Y j FS
31 Y Y Y
32 Y Y Y M
33 Y FS
34 Y Y Y M
35 Y Y Y ! M
36 Y Y : FS/M
37 Y Y M
38 Y Y M
39 Y Y
40 Y
41 Y Y M
42 Y Y Y M
FS -  Food substances, M - mercurials
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distribution of these groups are shown in Table 43. There was a significant 
difference between the ages of groups C and D with those in group C being 
an average of 7 years older than those in group D. There were no significant 
differences in the sex ratio between group C and group D or in the age and 
sex distribution of groups A and B, and groups E and F.
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Table 43. A ge And Sex Distribution O f Patients
Mean Age Age No.
(SD) Range Significance (%) Significance
[years] [years] Male
Group A and B
Amalgams in 
mouth (n=28)
49.9(10.6) 30-69 p=0.19 
CIa (-11.0, 
2.2)
8
(28.6)
p=0.89* 
CIb (-2.9, * 
0.25)
No amalgam in 
mouth (n=14)
54.3 (9.5) 36-65
3
(21.4)
Group C and D
Taking
medications0
(n=12)
56.8 (6.6) 43 -68
p=0.009 
CIa (2.0, 
13.2)
3(25)
p=0.911 
CIb (-0.31, 
0.27)
Not taking
medications
(n=30)
49.2(10.8) 30-69
8
(66.7)
Group E and F
Positive patch 
test (n=32)
52.5 (9.8) 35- 69 p=0.27
c r  (-4 .1,
13.5)
7
(21.9)
p=0.29 
CIb (-51.7, 
15.4)
Negative patch
tests (n=10)
----- *--------- -----------
47.8
(11.6)
30-65
4
(40.0)
a 95% confidence interval for the difference in age (A minus B)/(C minus 
D)/(E minus F).
b 95% confidence interval for the difference in the proportions of male 
patients (A minus B)/(C minus D)/(E minus F). 
c Medications that could cause OLE.
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The positive reactions from the patch tests which were recorded in the 42 
patients are shown in Tables 44 and 45. The patients were all tested to the 
European Standard Series of environmental allergens, the food additives, 
chocolate, and perfumes and flavourings series as outlined in Chapter 3 
(both DHT and CUT in the latter three series). In addition 36 were tested to 
organic mercurials, 41 to peppermint (1% in petrolatum) and menthol (5% 
in petrolatum), and 30 to a series that included gold sodium thiosulphate 
(0.5% in aqueous solution). A total of 50% of the 42 patients tested positive 
to one or more of the organic mercurials which is similar to the 45% 
recorded for all the OLE patients in Chapter 3. The sample size was too 
small to consider analysing the rest of the positive reactions individually. 
Out of the 11 patients with positive reactions to one or more of the food 
additive series, nine were positive to benzoic acid (four had positives on 
DHT only, three had positives on CUT only, and two had positives to both 
tests). The other food additives which elicited positives were sodium 
metabisulphite (two patients -  DHT) and sorbic acid (two patients -  CUT). 
Most of these patients reacted positively to more than one food additive. Of 
the five patients who reacted to the individual components of the perfumes 
and flavourings series the results were as follows; three patients reacted to 
cinnamaldehyde (CUT), one to isoeugenol (DHT) and one to oak moss 
absolute (DHT). A further two patients reacted to the fragrance mix in the 
European Standard Series of allergens. The small numbers involved 
precluded analysing those with DHT positive reactions and CUT positive 
reactions, separately.
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Table 44. Patch Test Results -  to Testing with Food Additives. Perfumes
And Flavourings And Organic Mercurials 
[Y = Yes/positive, blank = no/negative]
CU FAPatient
N um ber
CU P&F Organic
m ercurials
2 
3
~J
5
6
7
8
9
10 
11 
12
13
14
15
16
17
1 8 ......
1 9
20 
21 
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42 
Total
Not tested
Y
Y
Y
Y
Y
Y
Y 
NT
Y
Y 
NT
NT
Y
Y
Y
Y
Y
Y
Y 
18
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Table 45. Patch Test Results -  Environmental Allergens
[Y = Yes/positive, blank = no/negative]
1
2 j !  ;
3
4 i ! I
5 .... j ............ i ! I
6 I ................. !..............:...........r ............................. ; . . ........ ..... .........I.............
7 . . . . . . . . . . . . . . . .
8 I ......_ ..... ].... y .. ; ..........■.........
......9 .... i Y
. . . . . . . . . . . . . . . . . . . . .10 i .......... i ;  :
11 ; i i
' 12 .. : ............. ! ........... Y i ;
13
. . . . . . . . . . . . . . . j . . . . . . . . . . . . . . . . . . . . . . . . : . . . . . . . . . . . . . . . . . . : . . . . . . . . . . . . . . . . '  . . . . . . . . . . . . <14 Y Y
15 . . . . . . . . . . . . . . . .
16 Y Y Y
17 ;
18 Y
19
20
21
22 i : Y
23
24 :
25 i
26
27
28
29 ............ i Y : ........ .
30
31 Y
32 Y
33 Y
34 Y
35 ....;
36 ! . . . . . . . . . . j . . . . . . . . . . . . . . . . . .
.... 37 .....; ■
38 ;i ............. : Y
39 ;
40 Y Y
41
42 Y
Total 1 3 3 2 3 2 1 1 1 1
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The number of patients with a positive reaction to one or more food 
substances was 13 and those with a positive reaction to one or more 
mercurial allergens amounted to 18 patients. These are shown in Table 
The microscopy results for all patients are shown in Tables 46 to 48.
Table 46. H istopathology Results -  Ordinal Data
: 1 1 1 ! 2 2 1 1 i 2 i 2 i 2
2 2 s 1 2 3 3 3 f 2 ! 3 . 2
I 3 2 i 2 1 2 1 1 1 „ I 2 i 2
4 2 ! 2 2 2 2 3 3 I 3 H ~ 3
! 5 2 ! 2 2 2 1 2 3 I 3 i 2
r 6 3 I 2 2 2 1 2 “ 1 3 ! 2 27 3 ! 2 2 2 2 1 ! 3 ! 2 2
8 1 I 1 2 2 1 2 2 I 3 -  r 2
9 2 2 3 3 3 2 3 ! 3 2
10 2 2 3 3 2 3 2 I 3 1
11 3 3 3 3 3 3 i 2 I 3 2
12 2 1 2 3 3 3 2 I 1
13 3 ; 3 2 2 2 1 ' 1 2 | 2
14 2 2 2 2 3 3 ' T 3 i 2
15 3 i 3 2 3 3 2 ! 2 I 2
16 3 2 2 2 3 2 2 ..r 2
17 2 2 2 2 3 1 3 ! 3
18 3 3 2 2 2 1 3 ! 2
19 2 2 2 3 1 1 2 i 2
20 2 3 1 2 1 1 2 2 2
21 1 1 2 2 1 1 3 I 3 2
22 2 1 3 3 3 3 3 I 3 2
23 3 3 3 3 1 1 3 I 2 2
24 1 1 3 3 2 2 3 j 2 1
25 3 2 2 3 1 1 3 ; 2 1
26 3 2 2 2 2 1 3 ; 2 2
27 2 2 2 3 1 2 3 i 2 3
28 2 2 2 3 3 2 3 i 2 2
29 3 3 3 3 2 3 3 I 2 1
30 3 3 2 2 3 3 3 ; 3 2
31 3 2 2 2 1 1 3 ; 2 1
32 1 3 3 3 2 2 2 I 3 1
33 1 1 2 2 3 2 2 ; 2 1
34 2 2 2 3 2 3 3 2 2
35 2 1 3 3 3 3 2 3 2
36 3 2 1 2 3 2 2 2 2
37 2 2 2 3 3 2 3 2 2
38 2 2 2 3 3 2 2 2 2
39 2 2 1 2 1 2 3 2 3
40 2 3 2 2 1 2 2 2 1
41 2 1 3 2 1 2 2 2 1
42 2 3 2 2 2 2 2 1 . 1
307
Table 47. H istopathology Results -  Binary Data
1 ! Y
2 Y Y Y
3 Y Y
4 Y Y Y Y
5 Y Y
6 Y Y Y
7 ____________ Y Y Y
8 Y I Y
9 Y : ! Y Y
11
Y ! Y Y
Y Y I Y
. .  J 2  i __._ Y Y
_ .13..... . L „ ....
14 Y
Y Y f
Y Y
1 5 ... i      ■ .......  y t ..... ... f"  .........r ” :.......
16 J~............... I Y 7 Y "  '     T  ....  • " "  " ' Y
17 Y ...... L....y ....j ..... Y : !
18 ; Y | :
19 Y Y
20 Y Y .... Y .........I
21 Y Y : Y
22 Y Y Y
23 Y Y Y Y
24 Y
25 Y Y Y
26 Y
27 Y Y
28 : ; ! Y
29 Y Y Y
30 Y Y
31 Y Y
32 Y Y
33 Y Y Y
34 Y Y Y Y
35 Y Y Y Y
36 Y Y Y
37 Y
38 Y Y Y
39 ■ ..Y..... ■■ Y Y
40 Y Y
41 Y Y Y
42 Y Y
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Table 48. Histopathology Results -  Number o f  Apoptotic Cells
I
1
1 0 i 546 o
.. 2 17 1 2292 7.42
3 15 i 5915 2.54
4 11 | 1799 6.11
5 3 i 6292 0.47
6 17 r 9065 1.9
7 18 | 20565 0.88 ' "
8 5 I 4016 1.25
9 6 ! 19043 0.32 1
10 ~ ' ~ T ~  \ 7888 0.89 " 1
11 9 ! 9873 0.91
12 12 | 4471 2.68
13 16 i 8330 1.92........
r— 14 9 ! 8579 1.05" “
15 7 4465 -1.57 1
16 18 i 6714 2.68 1
17 9 5333 1.69
18 3 3265 0.92
19 5 7179 0.7
20 4 3969 1.01
21 2 6979 0.5
22 4 3079 1.3
23 4 3502 0.22
24 6 2630 2.28
25 8 9582 0.83
26 15 18478 0.8
27 5 8329 0.75
28 7 13840 0.51
29 19 3836 4.95
30 39 12428 3.14
31 5 7876 0.63
32 2 4705 0.57
33 11 1167 9.43
34 14 9373 1:49
35 9 2091 4.3
36 4 3897 1.03
37 22 15271 1.44
38 25 22826 1.1
39 22 4283 9.64
40 13 4270 3.05
41 2 5008 0.4
42 2 3631 0.55
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As in the previous chapter, the tables that follow utilise the following 
abbreviations: the use of bold italics indicates a significant result (p=<0.05), 
results in italics indicate borderline significance (p=>0.05 and <0.085) and 
indicates that the statistical results may be invalid due to the small sizes 
of some of the results.
4.4.1. Histology Results -  Groups A and B
The results are shown in Tables 49 and 50. There were no significant 
differences between those with amalgam dental restorations present and 
those without in the microscopic findings except for the presence of 
acanthosis which was found in more of the patients who had amalgam 
restorations than those without.
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Table 49 . Results O f Patient Groups A  And B. - Ordinal Data
Patients with Patients
3.2.2. Histological amalgam [A] without Statistical
param eters G rade 6 . . .
(=28) amalgam [Bj Analysis
r (=14) p value
Keratin Thickness 1 4 14.3 2 14.3
2 14 50.0 8 57.1 0.89
3 10 35.7 4 28.6
Epithelial thickness 1 5 17.9 5 35.7
2 16 57.1 5 35.7 0.34
3 7 25.0 4 28.6
Infiltrate thickness 1 3 10.7 1 7.1 0.31
2 17 60.7 11 78.6 (Grades 1 and 2
3 8 28.6 2 14.3 combined)
Infiltrate density 1 0 0 0 0
0.832 15 53.6 8 57.1
3 13 46.4 6 42.9
Basal cell layer 
disruption
1 10 35.7 5 35.7
0.382 9 32.1 2 14.3
3 9 32.1 7 50.0
Cellular tropism 1 8 28.6 5 35.7
0.802 13 46.4 5 35.7
3 7 25.0 4 28.6
Mast cells 1 0 0 0 0
2 12 42.9 7 50.0 0.66
3 16 57.1 7 50.0
Plasma cells 1 1 3.6 1 7.1 0.64
2 19 67.9 8 57.1 (Grades 1 and 2
3 8 28.6 5 35.7 combined)
Eosinophils 1 11 39.3 5 35.7 0.82
2 14 50.0 9 64.3 (Grades 2 and 3 
combined)3 3 10.7 0 0
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Table 50. Results O f Patient Groups A  And B -  Binary And Continuous
Data
Candidal sp. present Present 4 14.3 3 21.4 0.58*
Acanthosis Present 23 82.1 7 50.0 0.034“
Hypergranulosis Present 20 71.4 8 57.1 0.36
Germinal centres Present 3 10.7 1 7.1 0.69*
M arginating PMNL’s Present 9 32.1 6 42.9 0.50
Perivascular infiltrate Present 14 50.0 8 57.1 0.66
Apoptotic cells Range 0.4 - 9.6 0 -9 .4
0.61
(per mm] Mean 1.9 2.3
a The (Bonferroni corrected) 95% confidence interval for the difference in the proportions 
of the two groups (amalgam minus no amalgam) was, (2.4, 61.9%)
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4.4.2. Histology Results -  Groups C and D
The results are shown in Tables 51 and 52. Patients taking medications 
were more likely to have a thin oral epithelium and those not taking 
medications were more likely to have a medium thickness of oral 
epithelium, these were statistically significant. The presence of acanthosis 
was more likely in group D though this was of borderline significance 
(p=0.064). None of the other histological parameters investigated were 
statistically significant.
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Table 51. Results o f  Patient Groups C and D  -  Ordinal Data
3.2.3. Histological 
param eters G rade
Patients tak ing  
m edications 
[Cl (=12)
Patients not 
tak ing  
m edications 
IDJ (=30) 
%
Statistical
Analysis
K eratin  Thickness 1 3 25.0 3 10.0 0.15
2 7 58.3 15 50.0 (Grades 1 and
3 2 16.7 12 40.0 2 combined)
Epithelial thickness 1 6 50.0 4 13.3
2 3 25.0 18 60.0 0.031a
3 3 25.0 8 26.7
Infiltra te  thickness 1 1 8.3 3 10.0 0.46
2 9 75.0 19 63.6 (Grades 1 and
3 2 16.7 8 26.7 2 combined)
In filtra te  density 1 0 0 0 0
0.282 5 41.7 18 60.0
3 7 58.3 12 40.0
Basal cell layer 
d isruption
1 4 33.3 11 36.7
0.802 4 33.3 7 23.3
3 4 33.3 12 40.0
C ellular tropism 1 5 41.7 8 26.7
0.332 3 25.0 15 50.0
3 4 33.3 7 23.3
M ast cells 1 0 0 0 0
2 7 58.3 12 40.0 0.25
3 5 41.7 18 60.0
Plasm a cells 1 1 8.3 1 3.3 0.60
2 8 66.7 19 63.6 (Grades 1 and
3 3 25.0 10 33.3 2 combined)
Eosinophils 1 5 41.7 11 36.7 0.76
2 7 58.3 16 53.5 (Grades 2 and
3 0 0 3 10.0 3com bined)
a The (Bonferroni corrected) 95% confidence intervals for the differences between the 
population proportions in each grade (C minus D) were; grade 1 (21.7, 50.9%), grade 2 (- 
52.6, -21.1%) and grade 3 (-14.1, 15.3%).
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Table 52. Results o f  Patient Groups C And D - Binary And Continuous
Data
Candidal sp. present Present 1 8.3 5 16.7 0.43
Acanthosis Present 6 50.0 24 80.0 0.064°
Hypergranulosis Present 6 50.0 22 73.3 0.16
Germinal centres Present 1 8.3 3 10.0 0.86
M arginating PMNL’s Present 5 50.0 10 33.3 0.62
Perivascular infiltrate Present 7 58.3 15 50.0 0.62
Apoptotic cells Range 0 -  7.42 0 .32-9 .64
0.60
[per mm] Mean 1.79 2.17
a The (Bonferroni corrected) 95% confidence interval for the difference in the percentage 
of positive results (C minus D) was (-61.7, 1.7%).
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4.4.3. Histology Results -  Groups E and F
The results of the histopathological grading of these specimens are shown in 
Tables 53 and 54.
The difference between the grades given for the infiltrate density was 
statistically significant between the two groups of patients, with those with a 
negative patch test result more likely to have a moderately dense 
inflammatory infiltrate, and those with positive patch tests more likely to 
have a dense infiltrate.
Over half of the specimens from patients who had had positive patch tests 
exhibited a high degree of basal cell layer disruption whilst over half of 
those from negative patients exhibited a low degree of basal cell layer 
disruption, though these results were of borderline statistical significance. 
The number of eosinophils in the negative group was higher than that of the 
positive group, with over three quarters of the negative group having 
eosinophils visible in the section whereas just under half of the positive 
group had no demonstrable eosinophils present.
There was a significantly higher proportion of specimens in the negative 
group that had marginating PMNL’s in the dermal vessels.
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Table 53. Results o f  Patient Groups E And F. - Ordinal Data
Patients with Patients with
positive patch negative patch
test results test results Statistical
(=32) (=10) Analysis
n %  n %
Keratin Thickness 1 5 15.6 1 10.0 o00©IIQ
2 16 50.0 6 60.0 (Grades 1 and
3 11 34.4 3 30.0 2 com bined)
Epithelial thickness 1 8 25.0 2 20.0
p=0.762 15 46.9 6 60.0
3 9 28.1 2 20.0
Infiltrate thickness 1 1 3.1 3 30.0 p=0.043
2 21 65.6 7 70.0 (Grades 1 and
3 10 31.3 0 0 2 combined)
Infiltrate density 1 0 0 0 0 p=0.006 b
(Grades 1 and 
2 combined)
2 13 40.6 9 90.0
3 19 59.4 1 10.0
Basal cell layer 
disruption
1 9 28.1 6 60.0
p=0.084c2 8 25.0 3 30.0
3 15 46.9 1 10.0
Cellular tropism 1 8 25.0 5 50.0
p=0.332 15 46.9 3 30.0
3 9 28.1 2 20.0
Mast cells 1 0 0 0 0 p=0.70
2 15 46.9 4 40.0 (Grades 1 and
3 17 53.1 6 60.0 2 combined)
Plasma cells 1 0 6.2 0 0 p=0.94
2 20 62.5 7 70.0 (Grades 1 and
3 10 31.3 3 30.0 2 combined)
Eosinophils 1 15 46.9 1 10.0 p=0.036d
2 16 50.0 7 70.0 (Grades 2 and
3 1 3.1 2 3 combined)
a The (Bonferroni corrected) 95% confidence intervals for the difference in the percentage 
of positive results (E minus F) were; grades 1 and 2 (-49.6, -12.9%), grade 3 (12.9, 
49.6%).
b The (Bonferroni corrected) 95% confidence intervals for the difference in the percentage 
of positive results (E minus F) were; grades 1 and 2 (-78.2, -20.6%), grade 3 (20.6, 
78.2%).
c The (Bonferroni corrected) 95% confidence intervals for the difference in the percentage 
of positive results (E minus F) were; grade 1 (-73.6, 9.8%), grade 2 (-44.2,34.2) and grade 
3(5.9,67.9%).
d The (Bonferroni corrected) 95% confidence intervals for the difference in the percentage 
o f positive results (E minus F) were; grade 1 (7.8, 65.9%), grades 2 and 3 (-65.9, -7.8)
3.2.4. Histological 
param eters G rade
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Table 54. Results o f  Patient Groups E And F -  Binary And Continuous
Data
Candidal sp. present Present 4 12.5 2 20.0 p=0.59
Acanthosis Present 25 78.1 6 60.0 p=0.29
Hypergranulosis Present 21 65.6 8 80.0 p=0.34
Germinal centres Present 3 9.4 1 10.0 p=0.95
M arginating PMNL’s Present 10 31.3 7 70.0 p= o.or
Perivascular infiltrate Present 18 56.3 4 40.0 p=0.36
Apoptotic cells 
[per mm]
Range [0 - 9.6] [0.2 - 9.4]
p=0.21
Mean [2.9] [1.7]
a The (Bonferroni corrected) 95% confidence interval for the difference in the percentage 
of positive results (E minus F) was (6.1, 71.4%).
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4.4.4. Correlations With Apoptosis
The infiltrate thickness and density were correlated to the number of 
apoptotic cells found. There was no significant correlation between the 
thickness or the density of the inflammatory infiltrate with the number of 
apoptotic cells per mm of basal cell layer length (thickness p=0.67, density 
p=0.57).
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CHAPTER 5 DISCUSSION
5.1. Clinical Allergy Studies
5.1.1. Comparability Of Patients And Controls
The patient group was tested over a 16 year period which could have 
affected the results when comparing these patients to the control group 
tested in 1996. However, over half of the patients were in fact tested within 
5 years of the control group (724 were tested between 1991 and 1996).
The control population, by necessity only had one mean age and one sex 
distribution, whereas the disease groups all differed because individual 
diseases affect different sections of the population. This effect where there 
is in fact no overlap in the inter-quartile range between the control group 
and the OLE group, would have been minimised by a wider age range in the 
control group. The difference that the age discrepancy could possibly make 
is that the OLE group would be more likely to react to fragrances and less 
likely to react to nickel than the control group. This in fact proved to be the 
case with the percentage of OLE patients reacting to fragrance mix and 
nickel was 13 5% and 13.1%, while the corresponding results for the control 
group was 6% and 23%.
Likewise the sex ratio of the control group (71% were female) was 
comparable to the OLE and RAS groups whose percentages of females were 
76% and 66% respectively, but differed from the AE (49% were female) 
and OFG (43% were female) groups. This also could have affected some of 
the comparisons between the control and disease populations in that while
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some allergens seem to elicit positive responses equally in males and females, 
positive reactions to others such as nickel and fragrances are more frequent in 
females than males.
The geographical spread of patients and controls was similar though individual 
home and background environments may have been shown to be considerably 
different if social class and/or years lived in the West of Scotland had been taken 
into account.
There was a far higher percentage of medical/health workers in the control group 
(61% compared to 5.2% of the patient group) which may have affected the 
results. The high incidence of thiomersal allergy detected in the control group 
could be related to the differences in occupation, in that medical personnel 
involved in clinical work are vaccinated against Hepatitis B Virus, with a vaccine 
that contains thiomersal. Although other vaccines also contain thiomersal this 
group would have had greater exposure than the general population with at least 
three injections for the vaccination programme, plus any boosters that may have 
been administered. The increased incidence of thiomersal allergy so affected the 
results, that the positive reactions to thiomersal were discounted in the control 
and patient groups and the totals separately computed. There may have been 
other, less obvious differences in reaction between the two groups because of the 
selected nature of the control group.
The size of the control group was greater than the numbers in the AE and EM 
groups but less than the others, though still valid statistically. The same control 
group was used for each of the disease groups.
Bearing all these factors in mind, the control group was comparable to the 
different disease populations.
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5.1.2. Patch Test Results
The control population self-volunteered by responding to a poster display. 
Therefore, there was perhaps a bias towards those who thought that they 
may have allergies and wanted to find out what they were allergic to. This 
was minimised by excluding those who had been referred for patch testing 
for medical reasons but there may have been some who had low levels of 
inconvenience caused by allergic dermatitis and had not sought medical help 
for it but who wanted to come forward for patch testing to investigate it 
themselves. The high prevalence of allergic reactions during the patch 
testing in the control group would tend to indicate that this could have been 
the case. This would tend to minimise the differences between the results of 
the disease groups when compared to the control group. Thus if there is a 
significant difference it is not contradicted by this fact but likely to be more 
so, likewise, results with no significant differences may in fact have been 
significant, if a more random control sample had been used.
There are significant difficulties in enrolling appropriate control subjects to 
voluntarily participate in studies and this study has been no exception. 
Ideally, a much larger number of control subjects with a wider base of 
education, occupation and age range should have been sought. This group 
could then have been divided up into age and sex matched groups to be 
compared individually to the different disease groups. This would 
minimise the age and sex differences between disease and control group and 
also the differences between the sizes of the disease and control groups.
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A total of 50% of RAS and 55% of OFG patients reacted to the food 
additive series which was significantly more than controls (to CUT and to . 
the food additive testing as a whole). A total of 55% of the 45 AE patients 
also reacted to this series though half (n=10) reacted to food additives upon 
CUT and two thirds (n=14) to DHT. These reactions consisted mainly of 
positives to benzoic acid and when considered as an individual allergen, 
benzoic acid elicited significantly more reactions in RAS, EM and OFG 
patients on CUT and to AE patients on DHT, than controls. The significant 
percentages compared to the control group, of the positive reactions among 
different patient groups involved, when considering both types of tests were, 
RAS 46%, EM 48% and OFG 51%.
Sorbic acid is another allergen that provoked significantly greater numbers 
of positive reactions than controls, in this case in RAS, OFG and OLE 
patients.
Of the number of positives to the perfumes and flavourings series, most 
reactions were caused by one allergen, cinnamaldehyde. This flavouring 
agent elicited positive reactions in 18-38% of the patient groups and mostly 
to CUT. Oak moss absolute was the perfume agent most likely to provoke a 
positive reaction (to the DHT) and given a larger control group, this would 
probably have been a significant result.
OFG patients reacted to chocolate more than other patients or controls and 
this would probably have been significant again if the control group had 
been larger.
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Taking all the food substances as a whole, over two thirds of patients with 
RAS, AE, EM and OFG, and half of the patients with OLE had one or more 
positive reaction to a food substance.
The control group reacted to the modified European Standard Series 
significantly more than RAS, EM and OFG patients did. The allergens that 
most commonly elicited positives were nickel, cobalt, fragrance mix, 
neomycin, colophony, balsam of Peru and thiomersal. Balsam of Peru and 
fragrance mix are related allergens and are found in perfumed products. 
Cobalt and nickel are often positive together partly because it has been 
suggested that it is almost impossible to obtain nickel-free cobalt and cobalt- 
free nickel (Dotterud & Flak 1994). The 15.6% positive to nickel in this 
patient group correlates well with reported nickel allergy prevalences of 9% 
(Prystowsky et al. 1979) and 17.2% (Dotterud & Flak 1994). The female 
preponderance of 93.8% in patients and 95.7% in the control group, is also 
in accord with a previously published figure of 98.8% female in nickel 
positive patients (Gollhausen et al. 1988).
The high incidence of thiomersal sensitivity can be explained by the 
thiomersal containing vaccines used among health professionals to protect 
against Hepatitis B Vaccine. When the thiomersal results are excluded from 
the analysis, the numbers of patients and controls who had positive reactions 
to the modified European Standard Series were not significantly different, 
except for the OFG patients who had significantly less positives than 
controls. This was probably due to the younger age of these patients (the 
age of most of the group was in the first to third decades), while it is
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considered that the highest numbers of positive reactions are found in those 
from the second to fifth decades (Husain 1977).
The null hypotheses that patients with OLE, RAS, AE, EM and OFG have 
no greater number of positive reactions is is proven to be false in relation to 
food additives, perfumes and flavouings and chocolate, and true in relation 
to environmental allergens.
The null hypotheses that patients with OLE, RAS, AE, EM and OFG have 
different allergy profiles is shown to be true as OFG patients reacted more 
to chocolate and OLE patients to mercurials, however all the patient groups 
had similar reactions in that most reacted to the benzoic acid and to 
cinnamaldhyde.
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OLE. The percentages of positives reactions in the total group (Table 32) 
would be artifically low as the number tested to different mercurials differed 
i.e. most were tested to thiomersal but not to other mercurials. However, it 
was shown that a greater percentage of the OLE group were positive to one 
or more mercurial allergen when compared to RAS or OLE patients.
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5.1.4. RAS Patients
It is likely that RAS is provoked by contact with food additives such as 
benzoic acid and sorbic acid, and flavourings such as cinnamaldehyde in 
susceptible patients. From the results presented here, the type of reaction 
involved is less likely to be a Type IV reaction, but either a Type I 
hypersensitivity reaction or a non immunologic contact urticarial (NICU) 
reaction. The mechanism for this is uncertain as inconclusive findings 
regarding the role of histamine in RAS lesions have been published (Dolby 
& Allison 1969; Wray, Vlagopolous, & Siraganian 1982) and to date, no 
specific circulating antibodies have been isolated in these patients. Again, 
not all RAS patients attending the Oral Medicine clinic were referred for 
patch testing so the results have been artificially increased by the selection 
process. However, patients did benefit from dietary advice and avoidance 
of the allergens that they were sensitive to. A total of 77.0% of RAS 
patients who responded had experienced an improvement in their symptoms 
following an avoidance diet.
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5.1.5. AE Patients
The results found for the AE patients showed that a significant proportion o f 
those referred for patch testing had positive reactions to delayed 
hypersensitivity testing with benzoic acid (25%) compared to 7% of 
controls. This may have been an incidental finding and given a larger 
disease group may not have been statistically significant. AE is 
characterised by the immediacy of the reaction and so the relevance of 
positive delayed hypersensitivity reactions is debatable. AE patients did 
however, react significantly more readily than controls to CUT with 
cinnamaldehyde. The numbers o f patients with AE responding to the 
questionnaire were too low to analyse meaningfully.
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5.1.6. EM Patients
Nearly half of the EM patients that were referred for patch testing had a 
positive reaction to benzoic acid, and this was mostly in response to the 
CUT. Significantly more EM patients than controls reacted to 
cinnamaldehyde. Overall, two thirds of this group o f patients (compared to 
just over one third of controls) reacted to one or more food substance which 
suggests that these substances may act as triggers to the episodes o f EM in 
susceptible patients. 23.8% (n=10) were concurrently taking mediations 
that could cause EM eruptions and six o f these also had positive reactions to 
one or more food substance.
No investigation into the HSV status of these patients was undertaken.
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5.1.7. OFG Patients
OFG patients were more likely to react to food additives, particularly 
benzoic acid and sorbic acid, perfumes and flavourings, particularly 
cinnamaldehyde and chocolate than controls. A total o f 51% reacted to 
benzoic acid, mostly on CUT (47%) which was the highest percentage o f 
positive reactions out of the different disease groups. All patients diagnosed 
with OFG in the Oral Medicine clinic at Glasgow Dental Hospital were 
routinely sent for patch testing so this high percentage was a true 
representation of the frequency of positive patch test results among OFG 
sufferers in the West of Scotland. This group of patients indicated the 
greatest relief o f symptoms following dietary avoidance out of all the 
disease groups (of those who showed good to full compliance with the 
dietary advice). It is clear that Type I hypersensitivity or NICU reactions to 
food additives, and Type IV hypersensitivity to chocolate, play a major role 
in the progression of OFG. This is likely to be due to the allergic reaction in 
the tissues superimposed on the granuloma formation, blocking the 
lymphatic drainage to the area, leading in turn to lymphoedema.
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5.1.8. Outcome Of Dietary Avoidance
The response rate to the questionnaire was low (48%), but considering but 
considering that the time difference between the patch testing and avoidance 
diet and receiving the questionnaire was up to 15 years in a few patients, 
this was hardly surprising. There were no significant differences in the age 
and sex of responders and non responders. The outcome measure took no 
account of spontaneous remission that could have occurred in all disease 
groups, though less likely in the OLE group where the disease often persists 
for years. The patients were sent the questionnaire and had to work out the 
linear analogue scale with only brief written instructions which may have 
affected some of the responses as these may not be clear to some without 
skilled help (Huskisson 1974). Though the patients record of symptoms is 
necessarily subjective, the patients own testimony has been shown to be 
reliable, especially when comparing pain before and after treatment in the 
same patient (Huskisson 1974). The time delay (years in some patients) 
also could have affected the results, and outcome measures closer to the 
time of treatment would have been more accurate. The accuracy of such 
recall information offered by some of these patients could indeed be 
questionable. Though over two thirds of the responders had been patch 
tested within five years of receiving the questionnaire, even this length of 
time could have clouded the subjective assessment given by the patients. 
There may have been a bias among responders of those who felt strongly 
(positive or negative) about their treatment and its outcome.
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Assuming the worst case scenario, that all non-responders experienced no 
benefit (as they were unlikely to experience worsening of their symptoms 
due to the diet alone) there would still be a subjective benefit ascertained 
from the pre and post testing symptom scores in 37.8% of OLE patients, 
38.7% of RAS patients, and 32.8% of OFG patients. These figures are 
calculated assuming accuracy of patients’ recall over the years and accuracy 
in filling in the questionnaire, so are a rough indication only. However, 
given these provisos it is clear that a significant number of patients with 
OLE, RAS and OFG did improve with allergen avoidance therapy. The 
results of the AE and EM groups were not calculated, as the numbers 
responding were so small.
Thus the null hypothesis that there would be no subjective benefit from 
following dietary avoidance advice was proven to be false in the disease 
groups that could be analysed, i.e., OLE, RAS and OFG.
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5.2. Histopathology Studies
No obvious patterns that involved a variety of histological features, emerged 
during this study that could relate the microscopic features to different 
causes of OLE. This may be either because there are no actual differences 
in the histological features of OLE lesions arising from hypersensitivity to 
different substances and those with no hypersensitivity component, or, that 
the sample size and methods used were insufficient to demonstrate these 
results. Koch and Bahmer also found when studying the histology of 
specimens from positive patch test reactions to various metal salts, that there 
was a wide variation in the microscopic features observed and that they 
could detect no clear relationships between the histology and the different 
metals tested (Koch & Bahmer 1999).
However, the fact that the experienced pathologist can recognise different 
patterns, indicates that they do exist and the fact that some of the features 
did seem to differ between groups supports this. In a larger sample size, 
more features may have been recognised that were associated with certain 
groups. The sample size in this study was very small and only one section 
was examined from each specimen which may have resulted in some missed 
features. As the features may exist in groups, the sample size would need to 
be large enough to analyse the results using multiple comparison analysis 
between the different variables.
The basic principle was that of a hypersensitivity response being a likely 
aetiological factor in the pathogenesis of OLE. In both the amalgam group, 
drug group and the group who had identifiable allergens after patch testing,
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similar allergic processes are taking place. It is therefore perhaps not 
surprising that only a few differences were found in the groups examined. 
Unfortunately, the sample size was such that only two patients had no 
identifiable causative factors and therefore these could not be analysed in 
the same way or compared to the 40 with suspected aetiological factors. 
Given that half of all OLE patients in the larger group described in chapter 
3, had one or more positive reactions to a food substance and that 65% had 
one or more positive reactions on patch testing to a larger range of allergens, 
the likelihood of OLE being caused by a Type IV hypersensitivity reaction 
which may or may not be modulated by Type I or non immunologic contact 
urticaria reaction, is very high. This is also borne out by the fact that when 
comparing groups of patients with positive and negative responses to patch 
testing an increase in the density of the inflammatory infiltrate was found in 
the positive group. Given a larger sample size, the basal cell layer 
disruption scores may have shown that severe basal cell layer disruption was 
also correlated with allergy in this group.
The increase in inflammatory infiltrate in the lamina propria of OLE lesions 
indicates an aetiology originating in the immune system. The 
histopathology of Type IV hypersensitivity reactions elicited by patch 
testing, show a remarkable similarity to those of OLE, and certainly the 
predominantly T cell infiltrate in close apposition to the epithelium, the 
disruption of the basal cell layer and the degrees of cellular tropism (the 
grading for this did not include a ‘none’ category which may have 
downplayed the effect that this feature may have had in these sections)
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indicate that they are reacting to either antigens in the epithelium or to the 
activated keratinocytes there.
The null hypothesis relating to the number of apoptotic cells was proven 
true in both the patients with amalgam restorations and in those with 
positive patch tests. No differences were found.
The null hypothesis relating to the amount of inflammatory infiltrate was 
proved to be true in the patients with amalgam restorations but was not 
proven in those with positive patch test results.
The null hypothesis relating to the amount of disruption of the basal cell 
layer of the epithelium was proved to be true in the amalgam patients but 
not in those with positive reactions to patch testing though this result was of 
borderline statistical significance.
When considering the possibility of DILR, the patients isolated as having 
their medication as a possible aetiological factor were not actually proven to 
have DILR, i.e. they did not undergo drug withdrawal followed by 
(preferably double blind, placebo) controlled rechallenge to the suspected 
drug agent. The null hypothesis that there were no distinguishing features 
was proven and there was no correlation between a mild reaction in the 
lamina propria with a florid epithelial reaction, nor was the vice versa 
situation noted. However, for the reason stated above, these results may not 
be valid.
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5.3. Conclusions
Patients attending Glasgow Dental Hospital and School with RAS and OFG 
were significantly more likely to be suffering from hypersensitivity 
reactions or intolerances to food additives, perfumes and flavourings and 
chocolate, than controls. Dietary advice given to these patients, was 
efficacious in that compliance to the dietary avoidance o f appropriate 
allergens resulted in subjective improvement in three quarters of all patients 
with OFG and three quarters of those patients with RAS who were referred 
for patch testing. In addition, OLE patients were significantly more likely 
to be sensitised to mercurials than patients in other disease groups, which 
could be detected by patch testing. These patients also had significantly 
more positive reactions to cinnamaldehyde on CUT and to which dietary 
avoidance resulted in improvement in symptoms in nearly two thirds of 
patients.
Regarding the results of dietary avoidance o f appropriate allergens, even if it 
is assumed that the non responders experienced no subjective benefits at all, 
still a significant proportion improved (around one third of patients with 
OLE, RAS and OFG).
The AE and EM groups were small but the results did indicate some 
definate trends. Just over one quarter o f AE patients reacted to 
cinnamaldehyde on CUT which suggests that this allergen may cause 
angioedematous reactions in certain subjects. Benzoic acid and to a lesser 
extent cinnamaldehyde seem to be important allergens in the aetiology of 
EM.
The numbers o f responders to the questionnaire in the AE and EM groups 
were too small to analyse.
Density o f inflammatory infiltrate was shown to be associated with patients 
who had positive reactions on patch testing and contact urticaria testing and 
given a larger patient group, the amount of disruption to the basal cell layer 
may have proved significant too.
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5.4. Future Studies
A prospective study that continued to investigate the response to dietary 
modification in patients with positive contact urticaria tests and/or positive 
patch tests would be useful. It would be interesting to measure the clinically 
observed benefit to the patient in terms of improvement in the oral mucosa 
as well as the subjective benefit experienced by the patients themselves. It 
would also be of benefit to monitor the effects of dietary avoidance in 
patients closer to the dietary changes taking place. Double blind, placebo 
controlled, allergen rechallenge would also be of great value in identifying 
the exact mechanisms of hypersensitivity involvement in disease processes, 
as it would help to isolate the allergen involved in provoking the reaction in 
patients who reacted to more than one allergen.
In regard to the histopathology studies, it is possible that given a larger 
sample size, and one in which there were a greater proportion of patients 
with OLE with negative patch test results, no amalgam association and not 
on medications that could cause OLE, differences would be seen at a 
microscopic level that could be evaluated and categorised, between that 
‘allergic’ group and those with no obvious causative factors involved. It is 
also likely that differences between sections from patients in contact with 
relevant topical allergens (mercury in amalgam and food stuffs particularly 
those kept in contact with the oral mucosa for longer periods of time such as 
flavouring in toothpastes, hard candy and chewing gum), and those 
ingesting allergens systemically (medications), would be found. A more 
clinically correlated study would be more useful, in terms of isolating 
patients with not just a suspicion of allergen involvement but a clinically
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observed response to allergen withdrawal and preferably, difficult though it 
is to achieve, a recurrence on double blind placebo controlled exposure to 
the offending allergen.
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APPENDICES
Appendix A Volunteer Information Sheet 1
STUDY OF THE PREVALENCE OF SKIN REACTIVITY TO PATCH TESTING
This is a joint project on behalf of the Department of Oral Medicine and the Contact Dermatitis Unit in the 
Royal Infirmary, Glasgow. We are studying the prevalence of skin reactivity to various patch test 
substances in a "normal" population. At present we extensively use this test to identify potential allergens 
in individuals who suffer from a number of oral diseases, but we do not know how the skin of normal 
individuals without these diseases reacts.
In order to participate in this study you will be given an appointment to visit the Oral Medicine 
Department on either a Monday, Wednesday or Friday, where a sticking plaster with a number erf 
substances will be placed on the skin of your back and left there for 48 hours when you will be reviewed. 
You will then be reviewed two days thereafter to assess the response of your skin to these substances. This 
test will reveal for us how your skin reacts and does not necessarily imply that you are allergic to these 
substances, and in the absence of any symptoms the substances to which you react are probably not 
important We will however, if you so wish, give you a list of the positive results. The process is painless 
and the only potential risk is that of sensitising yourself to one of the substances, although this is extremely 
unlikely if you do not have an open dermatitis, in which case you would be excluded from the study. Also 
you will need to keep your back dry for the period of the testing.
We hope that you will freely and voluntarily agree to take part in this project If you wish to decline, 
however, this will not affect any future care that you receive in Glasgow Dental Hospital and will not be to 
your prejudice.
If you wish to discuss the project please do not hesitate to contact Mrs Shiona Rees in the Oral Medicine 
Clinic.
During your patch testing you may call at any time for information or advice at the numbers given below:
Mrs Shiona Rees: Day - 
Night-
Professor David Wray: Day - 
Night -
APPENDIX B VOLUNTEER INFORMATION SHEET 2
Thank you for taking the time and effort for this project.
It is important that you keep all three appointments this week, if there is a 
problem and you need to adjust the times of your appointment, please phone 
9642 (oral medicine reception).
The tests on your arms should be kept dry for 6 hours during which you 
should observe at hourly intervals what, if anything, happens to the test 
sites. After the 6 hours are over you can wash the pen marks off and treat as 
normal skin.
The tests on your back will remain on for 48 hours. These should be 
removed 1 hour prior to the 2nd visit. It is important that you keep the test 
area dry at all times during the 5 days.
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APPENDIX C VOLUNTEER HISTORY SHEET
CONTACT DERMATITIS RESEARCH PROJECT 
Glasgow Dental Hospital
Name.........................................  Occupation..............
DOB.........................Sex: M \ F Dept..........................
GDH number............................
HISTORY
SkimPast Present
Allergies: Asthma Hay fever Conjunctivitis Rhinitis
Migraine Travel sickness
Family H istory.............................................................Atopic/ Healthy
Medications: Antihistamines______________________________________
Others
Intolerance YesYNo 
Intolerant of: Elastoplasts Jewellery
Disease State: RAS
Lichenoid eruption 
Erythema multiforme 
Infant Feeding Status: Breastfed
Cosmetics\Toiletries Chemicals 
OFG
Clinically Yes/No
Angioedema
Yes/No
If yes, for how long?
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Appendix D Consent Form
STUDY OF THE PREVALENCE OF SKIN REACTIVITY TO PATCH TESTING
I .......................... ...................................................... freely and voluntarily agree to participate in the
clinical research study on die prevalence of skin reactivity to patch testing. The nature and the purpose of
this study has been explained to me by ................................................................  I have had the
opportunity to ask questions and I understand fully what is proposed.
I recognise that I may receive no benefit from this study. I accept that there are other risks associated with 
die procedure which are not directly attributed to negligence on the part of those undertaking the 
procedures.
I understand that I am free to withdraw my consent at any time without prejudice.
I have been reassured that any information obtained from me will not be disclosed without my permission 
to any other party in a manner that will reveal my identity.
Signature.....................................................................
Date .....................................................................
I confirm that I....................................................................have explained the nature and purpose of the
clinical research study and the procedure in respect of which consent has been given by the above named.
Signature.....................................................................
Date .....................................................................
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APPENDIX E VOLUNTEER WORKING SHEET
Contact Dermatitis 
Research
CDIUNo...................
Ref
diagnosis......................
DELAYED
HYPERSENSITIVITY
til
Food Additives
1 Benzoic acid
2 Salicylic acid
3 Tartrazine
4 Glutamic acid
5 BHT
6 BHA
7 Propylene glycol
8 Sorbic acid
9 Sodium metabisulphite
1 Essence o f Choc(soln)
2 Essence o f Choc(PMF)
PT diagnosis,
CONTACT URTICARIA
1
Food Additives
1 Benzoic acid
2 Salicylic acid
3 Tartrazine
4 Glutamic acid
5 BHT
6 BHA
7 Propylene glycol
8 Sorbic acid
9 Sodium metabisulphite
1 Essence o f Choc, (soln)
2 Essence o f Choc. 
(PMF)
Perfumes and Flavours
1 Cinnamyl alcohol
2 Cinnamaldehyde
3 Eugenol
4 Amylcinnamaldehyde
5 Hydroxycitraonellal
6 Geraniol
7 Isoeugenol
8 Oak moss absolute
9 Benzyl alcohol
10 Musk ambrette
11 Sorbitan sesquiolate
Perfumes and Flavours
1 Cinnamyl alcohol
2 Cinnamaldehyde
3 Eugenol
4 Amylcinnamaldehyde
5 Hydroxycitraonellal
6 Geraniol
7 Isoeugenol
8 Oak moss absolute
9 Benzyl alcohol
10 Musk ambrette
BHT = Butylated Hydroxytoluene 
BHA = Butylated Hydroxyanisole
Appendix F Benzoate And Cinnamaldehyde Diet Sheets
GLASGOW ROYAL INFIRMARY UNIVERSITY NHS TRUST 
DEPARTMENT OP NUTRITION & DIETETICS
CINNAMON FREE DIET
You have been found to be allergic to cinnamon. This is a natural substance which does not require to be 
stated on food labels. Therefore, always look for the term ‘spices' on food labels which are not included 
in the Manufactured Products List here.
Foods to be avoided
Soup; Tinned or packet soup with tomato or spices on the label
Meat; Canned meat in spicy sauce. Cold meat containing spices.
Avoid spice for beef ham.
Fish: Canned fish in spicy sauce. Avoid made up meat or fish dishes containing
spices e.g. pies, bridies, fish pie, lasagne, pizza.
AVOID curries and Chinese food. Curry pastes, curry sauces.
Spices: Mixed spice, cinnamon, curry powder. Allspice.
Check labels on any other spice mixes.
Baked beans in tomato sauce, ravioli, spaghetti in tomato sauce. "Invaders”. Pork sauces and beans. 
Spaghetti Hoops.
Manufactured cakes and biscuits on list overleaf - and those containing spice. Check label.
Gingerbread.Cofree Buns. Rich Fruit Cake. Keep to home-baking whenever possible.
Pickles and ketchup - see list.
Nuts - Dry Roasted type. Bombay Mix, Spicy Nut Mixes.
Crisps -  Snacks - avoid spices. Check labels and Products List.
Mincemea: and Christmas pudding. Mincemeat pies and Christmas cake. Apple Strudel.
Apple cake tart vrfth cinnamon or spices.
Soft drinks: Coca Cola, Red cola, Vimto, Pepsi Cola, Dr. Peppers.
.Alcoholic drinks: Red wine, gin, red and white Martini and Cinzano. Avoid the perfumed
type of alcoholic drinks, e.g. Dubonnet, Malibu, Dark Rum, Tia Maria etc.
Mailed wine.
Toothpaste: .AH others apart from on Allowed List.. No "Tartar Controlled” toothpaste.
AVOID MOUTHWASHES .ALSO, unless otherwise stated on Manufactured 
Products List.
Cola sweets: Cola cubes, Cola Chewits, cinnamon sticks, cola chews, etc.
.Also see Lbt of manufactured products containing cinnamon.
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Foods Allowed
Soup; Homemade or tinned or packet soup not containing spices or tomato.
Meat: All fresh or frozen.
Fish: .All fresh or frozen.
Eggs: .AH types.
Dairy Produce: Milk - all types. Yoghurt. Butter, cheese, cream - all types. Ice cream.
Fats & Ofls: Margarine, cooking oils, lard.
Fruit: All types.
Vegetables: All types including potatoes, salad vegetables.
Bread: AD types.
Rice. pasta. pulses (peas, beans, barley, lentils), nuts (avoid dry roasted type).
Cereals: .AH cereals. Breakfast cereals, porridge. Also flour, tapioca, sago, custard 
powder, cornflour.
Cakes & Biscuirs: Homemade. Shopbought cakes and biscuits avoiding spices on label.
Drinks: Tea. coffee, Oxo, BovriL Marariie, Boumvita. Cocoa, Drinking Chocolate, 
Horiicks. Squashes, lemonade and any other fizzy drinks apart from those on 
the'Avoid List’. Soda water. Appletise, fresh fruit juices. Spring waters.
Alcoholic D r i n k s :  White wine, cider, lager, beer, whisky, vodka.
Miscellaneous: Sugar, salt, pepper, herbs, spices not mentioned on ‘Avoid List’, e.g. nutmeg,
chilli powder, ginger etc. Tams.marmalade, honey, lemon curd, peanut butter, 
saccharin and other artificial sweeteners.
KAM/RS
12.12.95.
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MANUFACTURED PRODUCTS INFORMATION FOR CINNAMON
AjSDA: No information available.
BARR: Strike Cola only product containing cinnamon.
B A T t M lX Q RS: No information available.
BERNARD MA'TI'HkWS: Turkey Tikka only product containing cinnamon.
CADBURY:fTNCL. Chocolate Cream, Old Jamaica only products containing cinnamon. 
SWEFPESt
r  \>rPBFT T.S: Avoid Tomato Soup only
COLMANS: Products containing cinnam on:
OK Fruit Sauce, Wholegrain Mustard, French Mustard, Dijon Mustard, 
Tikka Masala Dry Sauce Mix. Traditional Herb Mustard.
ANY Curry Sauce or Products.
CO-OP PRODUCTS 
CONTAINING
CINNAMON: Frozen: American Style Double Cream Apple Pie Ice Cream
Apple Strudel 
Summer Fruit Strudel
Canned Traditional Rice Pudding
Apple, Sultana & Cinnamon Custard Style Yoghurt
Apple & Cinnamon Fruit Filled Biscuits
Plain Chocolate Ginger Rings
Milk Chocolate Ginger Rings
Ground Mixed Spice
Ground Cinnamon
It is also recommended to avoid any product with SPICES in the 
ingredients.
DAIRY CREST: No products containing cinnamon
FARLEY’S: No products containing cinnamon
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GOLDEN WONDER: Products free from Cinnamon:
HALLS:
HEINZ:
H.P. FOODS: 
JACOBS: 
KELLOGS: 
KRAFT:
LYONS TETLEY: 
MARS:
Crisps Ready Salted 
Salt & Vinegar 
Cheese & Onion 
Smokey Bacon
Spring Onion 
Steak & Onion 
Pickled Onion 
Roast Chicken
Rrngos 
W otsits 
Golden Lights
Salt & Vinegar Cheese & Onion 
Bacon Cheese Barbequed Beef
Lightly Salted
Pot Noodles Chicken & Mushroom 
Bolognaise 
Vegetable Korma
Fruit Pudding )
Economy Black Pudding )
Puritan Black Pudding )
Marks & Spencer Black Pudding )
Grilled Chicken
Chicken Curry 
Spicy Chicken
ALL CONTAIN 
CINNAMON
See attached list for products free from cinnamon.
See attached list for products free from cinnamon
Fruit & Nut Crunch only product containing cinnamon
Apple Pop Tarts and also Chocos contain cinnamon
Tomato Ketchup contains cinnamon
No products containing cinnamon
Honey flavoured Tunes only product containing cinnamon
MARKS & 
SPENCER:
No information available.
MR. KIPLING: Products containing cinnamon:
N ESllF:
incii
Mr. Kipling Country Fruit Lemon Tan 
“ Country Slices 
“ Mince Pies 
“ Luxury Mince Pies
“ Glazed Mince Tartlets
“ Mince + Brandy Sauce Pies 
“ Country Fruit Cake 
“ Christmas Slices
“ Christmas Cake
“ Stolen Slices
Ice Cream Division: No products containing cinnamon
Food Division: — Creamola Foam - Raspberry flavour
:U— Pan Yan Sandwich Piccalilli
^  Pan Yan Original Pickle
NESILEfiad.
ROWNt KEE  Rowntree’s Fruit Gums only product containing cinnamon
CONFECTIONERY!;
ROW ATS O R 
R O lH W L L L ;
SAFEWAY:
SAjySRURY:
Products containing cinnam on;
Tomato Ketchup 
Family Sauce
Pickles Silverskin & Cocktail Onions 
Pickled Chip Onions 
Pickled Red Cabbage 
Piccalilli
Hamburger Relish 
No information available at present 
Products containing cinnam on:
Soft P rinks: All products free from cinnamon
Confectionery: Milk chocolate covered almonds dusted with
cinnamon
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SAINSBURY - Cont’d.
ST. I\~EL: 
TESCO:
Cakes & Biscuits: 1) Chocolate hearts - spicy jam filled Lebkuchen
2) Lebkuchen
3) Lebkuchen Gingerbread Men
4) Milk/Plain Chocolate Continental biscuit 
assortment
5) Pfeffemusse
6) Phim Pudding
7) Alcohol-free Christmas Pudding
8) Raisin & Walnut Malt Loa£
No products containing cinnamon
Follow general guidelines - avoid coke, baked beans, sauces, curried 
and spicy foods. Fresh Chicken Korma (in chilled cabinet) and 
Baibeque Sauce are free from cinnamon.
T R P O R  BASSETT: No products containing cinnamon
THORNTONS; No products containing cinnamon
THOMAS TUNNOCK: Chocolate Perkins and Perkins contain cinnamon.
WAT TS: ‘Country Fair’ Vermont Apple Cinnamon Pie contains cinnamon
FOX’S BISCUITS: Fruit Shrewsbury are only products containing cinnamon
WRIGT .FV: Big Red and Juicy Fruit are only products containing cinnamon
TOO l HLPASTE; Colgate/Palmolive - Products containing cinnamon
Colgate Blue Minty Gel 
Colgate Plax 
Colgate Actibmsh
Stafford Miller
Smith Kline Beerham 
Procter & Gamble
Search Dental Rinse contains 
cinnamon. All other products 
suitable for use.
All products free from cinnamon
All products free from cinnamon 
Le. Crest.
KAMRS
2 0 .1 1 9 5 .
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The following Heinz products are free from Cinnam on 
WEIGHT WATCHERS FROM  HEINZ PRODUCTS
SAUCES, SALADS & PICKLES
Cooking Sauce, French White Wine & Dill 
Cooking Sauce, Indian Koima 
Cooking Sauce, Italian Tomato & Onion 
Cooking Sauce, Oriental Sweet & Sour 
Low Fat Dressing 
Low Fat Dressing, Mild Mustard 
Low Fat Dressing, Thousand Island 
Low Fat Dressing, Yogurt & Herb 
Mayonnaise. Reduced Calorie
PASTA
TtaHaaa Bokognese Shells
Italiana. Pasta Tubes in Cheese Sauce with Bacon
Italiana. Tortellini
Italiana, Tuna Twists
Italiana. Vegetable Ravioli with Tomato Sauce 
Spaghetti in Tomato Sauce, No Added Sugar
DAIRY PRODUCTS
Cheese Slices, Reduced Fat
Dairy Spread with Cheese & Ham, Reduced Fat
Dairy Spread with Cheese, Reduced Fat
Dairy Spread,Cheese, Onions & Chives, Reduced Fat
Hard Cheese. Reduced Fat
FRENCH BREAD PIZZAS
French Bread Pizza, Cheese & Tomato 
French Bread Pizza. Ham & Mushroom 
French Bread Pizza. Ham & Pineapple 
French Bread Pizza. Pepperoni
WEIGHT WATCHERS FROM HEINZ PRODUCTS Cont’d.
FROZEN READY MEALS
Beef Lasagne
Beef Oriental with Rice
Big DeaL Beef Goulash with Parsley Rice
Big DeaL Cajun Chicken
Big DeaL Chilli Con Came with Rice
Big DeaL Keema Curry with Cumin Rice
Cannelloni Filled with Vegetables
Cauhfower Cheese
Chicken & Broccoli Pasta Bake
Chicken Chasseur with Rice
Chicken Curry with Rice
Chicken Marengo with Rice
Chicken Supreme
Fish Provincale with Noodles
Mediterranean Chicken
Pasta Bolognese
Pasta Shells with Vegetables & Prawns
Salmon & Prawn Fricasse
Salmon Momay
Seafood Bake with Broccoli
Smoked Fisa with Pasta Bows
Spaghetti Bolognese
Sweet & Scrar Chicken with Rice
Sweet & Sour Vegetables
Taghatelle Carbonari
Vegetable an Gratin
Vegetable Chilli with Rice
Vegetable Hotpot
Vegetable Lasagne
Vegetable Moussaka
DESSERTS
Cheesecake. Blackcurrant 
Cheesecake. Strawberry 
Dairy Ice Cream, Chocolate Ripple 
Dairy Ice Cream, Neapolitan 
Dairy Ice Cream, Strawberry 
Dairy Ice Cream, Vanilla
Dessert Bombes, Chocolate with Orange Liqueur 
Dessert Bombes, Lemon 
Dessert Bombes, Mint Chocolate 
Dessert Bombes, Tropical Fruit 
Premium Ice Cream. Lemon Meringue 
Premmn Ice Cream. Strawberries & Cream 
Premium Ice Cream. Triple Chocolate Fudge 
Premmn Ice Cream. Triple Toffee Fudge 
Rice Padding, No Added Sugar, Low Fat 
Tone. Orange & Lemon 
Tone. Peach & Apricot 
Tone: Raspberry
JAMS & MARMALADES
Apricot Jam. Reduced Sugar 
Blackcurrant Jam, Reduced Sugar 
Fruits of the Forest Jam, Reduced Sugar 
Marmalade. Reduced Sugar 
Moreno Cherry Jam. Reduced Sugar 
Raspberry Jam, Reduced Sugar 
Strawberry Jam, Reduced Sugar
BREAD & ROLLS
Brown Bread
Danish Brown Bread
Danish Mailed Sofigrain Bread
Damsi White Bread
Oat Danish Bread
Soft Brown Rolls
Soft White Rolls
While Bread
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CANNED SOUPS
Chicken & Ham wiih Rice Soup 
Chicken Noodle Soup 
Chicken Soap
Coumry Vegetable & Beef Soup 
Country Vegetable Soup 
Lenm & Carrot Soup 
Mushroom Soup 
Vegetable Soup
Whoiesome Soup. Lendl & Chicken 
Whoiesome Soup. Winter Vegetable
INSTANT SOUPS
Asparagus Si Leek Soup. 40kcal
Chicken & Sweet com Soup, 60kcal
Chicken & Vegetable Soup with Noodles, 60kcal
Chicken & Vegetable Soup, 40kcals
Chicken Soap, 40kcal
Minestrone Soup, 60kcal
Mushroom Soup, 40kcal
Mushroom Soup, 60kcal
Tomato Soap, 40kcal
Tomato Soap, 60kcal
Vegetable Soup with Croutons, 60kcal
Vegetable Soup, 40kcal
BISCTTTS & SNACKS
Cookies, Dark Treacle 
Cookies, Real Chocolate Chip 
Cookies. Stem Ginger
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The milowing Heinz products are free from Cinnamon
CORE PRODUCTS
BAKED BEANS
Barbecue Beans
Cumed Beans with Suit anas
LUNCH BOWLS
Beef Curry with Rice 
Beef Goulash with Noodles 
Chicken Curry with Rice 
ChiHi Con Came wiih Rice 
Lamb and Vegetable Casserole
PASTA
Chef 5 Specials, Chicken Ravioli in Tomato Sauce
Chef s Specials, Macaroni Cheese
Chef s Specials, Pasta Pipes with Tuna & Bacon
Chef s Specials, Ravioli in Spicy Sauce
Chef s Specials, Sausage Hotpot with Pasta
Chef s Specials, Spicy Beef Pasta Twists
Dinosaurs with Mini Meat Boulders
Dinosaurs, Pasta Shapes in Tomato Sauce
Mask Roundabout. Spaghetti Shapes in Tomato Sauce
Noodle Doodles, Spaghetti Shapes in Tomato Sauce
Spaghetti Hoops in Tomato Sauce
Spaghetti in Tomato Sauce
Spaghetti with Sausages
Super Mario. Spaghetti Shapes in Tomato Sauce 
Thomas the Tank Engine, Spaghetti in Tomato Sauce
SAUCES, SALADS & PICKLES
Apple Sauce
Coleaaw Salad
Coronation Sauce
Mayonnaise
Mixed Bean Salad
Pasta Salad
Ploughman' 5 Piccalilli
Ploughman's Pickle
Plougiunan' s Tangy Sandwich Pickle
9
CINNAMON FREE PRODUCTS
HEINZ CORE PRODUCTS C ont’d.
SAUCES, SALADS & PICKLES Cont’d.
Ploughman' Tomato Pickle
Potaio Salad
Salad Cream
Salad Cream. Spoonable
Salsa. Median-Hot
Salsa. Milk-Medium
Sandwich Spread, Cucumber
Sandwich Spread, Spicy
Sandwich Spread, Sweetcom & Red Pepper
Sdversrin Onions
Vegetable Salad
SPONGE PUDDINGS
Sponge Pudding, Banana with Toffee Sauce 
Sponge Pudding, Chocolate with Chocolate Sauce 
Sponge Pudding, Lemon 
Sponge Pudding, Mixed Fruit 
Sponge Pudding, Strawberry Jam 
Sponge Pudding, Treacle
READY TO  SERVE SOUPS
Beer" Soup
Big Soup, B.eef & Bacon Hotpot
Big Soup, B-eef & Vegetable
Big Soup, B eef Broth
Big Soup, Chicken & Ham
Big Soup, Chicken & Vegetable
Big Soup, Chicken. Leek & Potato
Big Soup, Giant Minestrone
Big Soup, Spicy Tomato with Beef Pasta Parcels
Big Soup, Thick Country Vegetable with Ham
Chicken & Mushroom Soup
Cream of Asparagus Soup
Cream of Cedery Soup
Cream of Chicken Soup
Cream of Mushroom Soup
Farmhouse Beef & Vegetable Soup
Farmhouse 3eef Broth
10
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CINNAMON FREE PRODUCTS Cont’d.
READY TO  SERVE SOUPS C ont’d.
Farmhouse Chicken •& Vegetable Soup 
Farmhouse Potato & Leek Soup 
Farmhouse Scotch Broth 
MuDmrawuy Soup 
Oxiaii Soup
Pasta Soup. Beef & Tomato Bolognese
Pasta Soup. Chicken Pastini
Pasta Soup. Minestrone
Pasta Soup. Mushroom Carbonara
Pasta Soup. Tomato Napoli
Premium Soup, Beef Potato & Red Pepper
Premium Soup, Canot, Potato & Coriander
Premium Soup, Chicken Sweet Pepper & Dill
Prenamn Soup, Chicken, Sweetcom & Asparagus
Premzmi Soup, Country Bean with Mushroom
Premium Soup, Seven Vegetable
Scotcsa Vegetable Soup with Lentils
Spicy Soup. Chilli Bean & Beef
Spicy Soup. Curried Chicken with Rice
Spring Vegetable Soup
Vegetable Soup
Whoksoup. Farmhouse Vegetable 
Whoksoup. Ham & Butter Bean 
Whoksoup. Lentil 
Whoksoup. Pea & Ham 
Whoksoup. Winter Vegetable
TOPPERS
Toast Toppers, Chicken & Mushroom 
Toast Toppers, Ham & Cheese 
Toast Toppers, Mushroom & Bacon
CANNED TUNA
Tima Chunks. Canned in Brine 
Tuna Chunks. Canned in Vegetable Oil 
Tuna Steak. Canned in Brine 
Tuna Steak. Canned in Vegetable Oil
11
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HP FOODS LTD NUTRITION INFORMATION: 
CINNAMON CONTENT
21/03 /94
PRESENT
HP
HP
SAUCE
FRUITY
HP
HP
HP
HP
HP
HP
HP
HP
HP
HP
/
/
/
/
SAUCE 
HP TCMATO KETCHUP 
HP SPICY TOMATO SAUCE 
CHILLI SAUCE 
CURRY SAUCE 
FRUITY BARBECUE SAUCE 
SWEET 5 SOUR SAUCE 
HP ORIGINAL BARBECUE SAUCE 
HP MEXICAN SPICY BARBECUE SAUCE 
HP RICH JAMAICAN BARBECUE SAUCE 
HP MINT SAUCE 
HP MAYONNAISE (BULK)
HP MALT VXNEGAR 
HP BEANS IN TOMATO SAUCE 
HP HEALTHY BEANS
HP BAKED BEANS IN TOMATO SAUCE (CATERING)
HP HEALTHY BEANS IN TOMATO SAUCE (CATERING)
HP BEANS AND BEEFBURGERS 
HP BEANS AND SAUSAGE 
HP SAUCY BEANS 
HP BIG BREAKFAST BIG BEANS IN TOMATO SAUCE 
HP BIG BREAKFAST BIG BEANS & JUMBO SAUSAGES 
HP BATMAN BOLOGNESE 
HP PASTA S HAP ESIN TOMATO SAUCE 
HP SPAGHETTI IN TOMATO SAUCE
HP GLADIATORS IN TOMATO SAUCE (REDUCED SUGAR)
HP GLADIATORS IN SMOKEY BACON SAUCE 
HP GLADIATORS IN PIZZA PIZZA SAUCE WITH PEPPERONI 
SCMIC AND SAUSAGES IN TOMATO SAUCE 
SCNIC RAVIOLI SHAPES IN TOMATO SAUCE 
CHICKEN KORMA BISTRO BREAK /
SWEET i  SOUR BISTRO BREAK 
CAJfNELLONI BISTRO BREAK 
LASAGNE BOLOGNESE BISTRO BREAK
DADDIES TOMATO KETCHUP 
DADDIES EROWN SAUCE 
DADDIES EURGER RELISH 
DADDIES SALAD CREAM
FLETCHERS TIGER SAUCE 
FLETCHERS TITBITS SAUCE 
FLETCHERS BROWN SAUCE
FLETCHERS TOMATO KETCHUP /
FLETCHERS BAKED BEANS IN TOMATO SAUCE /
FLETCHERS SHORT CUT SPAGHETTI IN TOMATO SAUCE
ABSENT
/
/
/
/
/
/
/
/
/
/
✓
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
/
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'0 WORCESTERSHIRE SAUCE /
CHILLI & GARLIC SAUCE /
GINGER & ORANGE SAUCE /
GARLIC & SPRING ONION SAUCE /
HOT PEPPER SAUCE /
MUSTARD & PEPPERCORN SAUCE /
GARLIC SAUCE /
FRUTT SAUCE /
WORCESTER KETCHUP /
TOMATO KETCHUP WITH MILD CURRY SPICES /
SOY & GARLIC /
HOT PEPPER & LIME /
SOY & FIVE SPICE /
/CURRY CONCENTRATE
ITALIAN VINAIGRETTE MAKER /
WHITE WINE & GARLIC VINAIGRETTE MAKER /
CLASSIC FRENCH VINAIGRETTE MAKER . /
PICKLE WITH WORCESTER SAUCE /
SWEET PEPPERS WITH CHILLI SAUCE /
GINGER SAUCE /
GREEN JALAP ENO SAUCE /
LF YOl BLAM ANY QUERIES REGARDING THE DIETARY INFORMATION 
OR IF YOU WOULD LIKE AN APPOINTMENT TO DISCUSS THE DIET IN 
MORE DETAIL. PLEASE CONTACT :
DLL 111 LAN: Karen Milligan
HOSPITAL: Glasgow Roval Infirmary
TELEPHONE NUMBER:  s ( Mon-Wed)
OR
PAGE NO :
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GLASGOW ROYAL INFIRMARY 
DEPARTMENT OF NUTRITION & DIETETICS
MENU PLAN FOR BENZOATE + CINNAMON FREE DIETS
Fruit juice or tinned/fresh grapefruit (p.f.)
Any breakfast cereal milk, sugar, banana.
Egg/bacon/grilled tomatoes/mushrooms.
Wholemeal or unbleached white bread or rolls.
Spread or butter.
Jam, marmalade or honey (p.f.)
Sandwiches:
Wholemeal or unbleached white bread sandwiches or rolls. 
Spread or butter
Sandwich fillings:
Cheese, egg, mayonnaise (Heilmans) onion + tomato 
Chicken mayonnaise 
Tuna mayonnaise 
Salmon and blackpepper
* Cold ham, roast meat, tongue, corned beef (+ tomato/salad) 
v Peanut butter
Banana
Cold meat + homemade coleslaw 
Cottage cheese 
Sardines 
Cold bacon 
Edam cheese
N.B. Any item marked (D.f.) — please check for preservatives 
E210 - E219 ’ .
* Do not use meat loaf, haslet^or any spicy meats 
e.g. Chicken tikka, Italian and German sausage
Other Lunch Ideas:
Toasties - Cheese and onion 
Cheese and bacon 
Cheese and tuna
Baked potatoes and any sandwich fillings 
Fish fingers
Homemade thick soup with bread and butter 
Scrambled egg and cheese. French toast 
Omelette - cheese, ham, mushroom, tomato
Main Meal Suggestions:
Starters: Homemade soup, fruit juice, (p.f.) grapefruit segments (p.f.
Grilled grapefruit ( no cinnamon)
Prawn cocktail (homemade sauce — Heilmans mayonnaise + 
tomato puree (p.f.)
Egg mayonnaise - Heilmans mayonnaise 
Melon
Breakfasts:
Lunches:
MENU PLAN FOR BENZOATE + CINNAMON FREE DIETS
Main Course: Stewed beef, stewed lamb, pork stew, chicken stew,
rabbit stew
(Make into casserole by adding different vegetables, 
p.f. tomato puree, herbs, garlic,onion, mushrooms 
and allowed spices.
Egg Dishes - Omelette, fried egg, scrambled egg, 
baked egg
Salads - Tuna, salmon, cold meat, corned beef,
cottage cheese, egg
Mince - Minced beef, cottage pie, mince cobbler
(Mince + savoury scone on top)
Spag Bolog mix — garlic,onion, mushrooms, add tinned 
tomatoes (p.f.), tomato paste (p.f.)
Black pepper, salt, bay leaves, mixed 
herbs.
Use as a base with spaghetti, in lasagne, cannelloni, 
mock moussaka with potato and cheese sauce/real 
moussaka with aubergines. Make spag. bolog. mix add 
in chilli powder and tinned kidney beans.
Pizza - buy bases from supermarket, use p.f. tomato 
paste/puree. Add on ham, tuna, anchovy (p.f.), cheese, 
mushrooms. fresh tomatoes.
Beefburgers — make with mince, onion, breadcrumbs, egg.
Grill or fry
Sausages - Bernard Matthews sausages are free from 
cinnamon: use in casseroles with mix as for spag. bolog.
Gammon Steaks / with pineapple (p.f.)
Lamb or pork chops
Pork or beef steaks
Chicken in homemade white sauce with vegetables as Lasagne.
Pasta - 1. Boil pasta — make homemade Spag Bolog. mix sauce 
add cheese if wished.
2. Make white sauce — add bacon/ham, cheese, 
mushrooms, onions etc.
3- Cabonara type pasta — using bacon, eggs, cream 
and cheese to mix.
Fish - All types of fresh fish including smoked, oily fish 
and seafood. Poach, steam, grill cr fry.
Use with a homemade white, mushroom or cheese sauce.
Fish finger. Haddock in batter.
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MENU PLAN FOR BENZOATE + CINNAMON FREE DIETS
Vegetables: 
Desserts:
All fresh or frozen vegetables are suitable 
Potatoes - boiled, mashed, saute, chips
Fresh fruit
Yoghurt - check for p.f.
Tinned fruit - check for preservatives
Milk puddings — custard, rice semolina, tapioca
Ice Cream - check for preservatives, -
No fruit or fruit sauce
Jelly — No lime or blackcurrant jellies
Fruit crumbles - using fresh fruit or p.f. tinned/
bottles fruit
Sponge puddings — Eve's pudding'using fresh fruit 
or tinned fruit
Sponge puddings with dried fruit - check dried fruit 
for p.f.
KAM/EMT. FEB 95
SOFT DRINKS FREE FROM BENZOATES, CINNAMON AND SORBIC ACID
Fizzy Drinks
7-Up - ordinary and diet (bottles & cans)
Piermont
Rio Riva - (cans only)
Britvic Citrus Spring - (cans only)
Diet Kiri 
Kiri
Orangina - Diet and ordinary (cans only)
Schweppes Indian Tonic - slimline and ordinary (bottles) 
Canada Dry — Ordinary Ginger Ale (not diet)
Asda — Soda Water
Diluting Drinks
Sainsbury Ruby Red Grapefruit Squash —
St. Clements High Juice Orange Squash 
Sunquick
Robinsons - Lemon Barley Squash
Wells - Orange Squash with Vitamins added
KAM/RS.
23.6.94.
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The following Heinz produce arc free from Cinnamon
BAKED BEANS
Barbecue Beans 
Curried Beans with Sultanas
LUNCH BOWLS
Beef Curry with Rice 
Beef Goulash with Noodles 
Chicken Cuny with Rice 
Chilli Con Came with Rice 
Lamb and Vegetable Casserole
PASTA
Chefs Specials, Chicken Ravioli in Tomato Sauce
Chefs Specials, Macaroni Cheese
Chefs Specials, Pasta Pipes with Tuna & Bacon
Chefs Specials, Ravioli in Spicy Sauce
Chefs Specials, Sausage Hotpot with Pasta
Chefs Specials, Spicy Beef Pasta Twists
Dinosaurs with Mini Meat Boulders
Dinosaurs. Pasta Shapes in Tomato Sauce
Flintstones, Spaghetti Shapes in Tomato Sauce
Magic Roundabout, Spaghetti Shapes in Tomato Sauce
Noodle Doodles, Spaghetti Shapes in Tomato S a u c e —
Spaghetti Hoops in Tomato Sauce
Spaghetti in Tomato Sauce
Spaghetti with Sausages
Super Mario, Spaghetti Shapes in Tomato Sauce 
Thomas the Tank Engine, Spaghetti in Tomato Sauce
SAUCES, SALADS & PICKLES
Apple Sauce
Coleslaw Salad
Coronation sauce
Mayonnaise
Mixed Bean Salad
Pasta Salad
Ploughman's Piccalilli
Ploughman's Pickle
Ploughman's Tangy Sandwich Pickle
Ploughman's Tomato Pickle
Potato Salad
Salad Cream
Salad Cream, Spoonable
Salsa, Medium-Hot
©  H J Heinz Company Lid. - March 1994
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Salsa, Mild-Medium
Sandwich Spread, Cucumber
Sandwich Spread, Spicy
Sandwich Spread, Sweetcom & Red Pepper
Silveiskin Onions
Vegetable Salad
SPONGE PUDDINGS
Sponge Pudding, Banana with Toffee Sauce 
Sponge Pudding, Chocolate with Chocolate Sauce 
Sponge Pudding, Lemon 
Sponge Pudding, Mixed Fruit 
Sponge Pudding, Strawberry Jam 
Sponge Pudding. Treacle
READY TO SERVE SOUPS
Beef Soup
Big Soup, Beef & Bacon Hotpot
Big Soup, Beef & Vegetable
Big Soup, Beef Broth
Big Soup, Chicken & Ham
Big Soup, Chicken & Vegetable
Big Soup, Chicken. Leek & Potato
Big Soup, Giant Minestrone
Big Soup, Spicy Tomato with Beef Pasta Parcels
Big Soup, Thick Country Vegetable with Ham
Chicken & Mushroom Soup
Cream of Asparagus Soup
Cream of Celery Soup
Cream of Chicken Soup
Cream of Mushroom Soup
Farmhouse Beef & Vegetable Soup
Farmhouse Beef Broth
Farmhouse Chicken & Vegetable Soup
Farmhouse Potato & Leek Soup
Farmhouse Scotch Broth
Mulligatawny Soup
Oxtail Soup
Pasta Soup, Beef & Tomato Bolognese
Pasta Soup, Chicken Pastini
Pasta Soup, Minestrone
Pasta Soup, Mushroom Carbonara
Pasta Soup, Tomato Napoli
Premium Soup, Beef, Potato & Red Pepper
Premium Soup, Carrot, Potato & Coriander
Premium Soup, Chicken. Sweet Pepper & Dill
Premium Soup, Chicken, Sweetcom &. Asparagus
Premium Soup, Country Bean with Mushroom
Premium Soup. Seven Vegetable
©  H J  Heinz Company Lid  -  March 1994
Scottish Vegetable Soup with Lentils 
Spicy Soup, Chilli Bean & Beef 
Spicy Soup, Curried Chicken with Rice 
Spring Vegetable Soup 
Vegetable Soup
Wholesoup, Farmhouse Vegetable 
Whoiesoup, Ham & Butler Bean 
Wholesoup, Lentil 
Wholesoup, Pea & Ham 
Wholesoup, Winter Vegetable
TOPPERS
Toast Toppers, Chicken & Mushroom 
Toast Toppers, Ham & Cheese 
Toast Toppers, Mushroom & Bacon
CANNED TUNA
Tuna Chunks, Canned in Brine 
Tuna Chunks, Canned in Vegetable Oil 
Tuna Steak. Canned in Brine 
Tuna Steak, Canned in Vegetable Oil
©  H J  Heinz Company Lid  - March 1994
BREAD & ROLLS
Brown Bread
Danish Brown Bread
Danish Malted Softgrain Bread
Danish White Bread
Oat Danish Bread
Soft Brown Rolls
Soft White Rolls
White Bread
CANNED SOUPS
Chicken & Ham with Rice Soup 
Chicken Noodle Soup 
Chicken Soup
Country Vegetable & Beef Soup 
Country Vegetable Soup 
Lentil & Carrot Soup 
Mushroom Soup 
Vegetable Soap
Wholesome Soup, Lentil & Chicken 
Wholesome Soup, Winter Vegetable
INSTANT SOUPS
Asparagus & Leek Soup, 40 kcal
Chicken & Sweetcom Soup. 60 kcal
Chicken & Vegetable Soup with Noodles. 60 kcal
Chicken & Vegetable Soup, 40 kcal
Chicken Soup, 40 kcal
Minestrone Soup, 60 kcal
Mushroom Soup, 40 kcal
Mushroom Soup, 60 kcal
Tomato Soup, 40 kcal
Tomato Soup, 60 kcal
Vegetable Soup with Croutons, 60 kcal
Vegetable Soup, 40 kcal
BISCUITS & SNACKS
Cookies, Dark Treacle 
Cookies, Real Chocolate Chip 
Cookies, Stem Ginger
©  H J  Heinz Company L id  - March 1994
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Glasgow Royal Infirmary 
Dietetic Department 
Benzoate Free Diet
As most of the Benzoates in the diet are added to foods as a PRESERVATIVE it is very 
important that you read the labels of any manufactured or prepared foods you consume. If 
Benzoates are added to the food, the manufacturer may name the particular Benzoate & 
serial number known as an E number, avoid those from E210 - E219 inclusive. If you axer 
unsure whether a food / drink may contain Benzoate it is best to avoid it.
Avoid any food which just lists the word “"Preservative'' or “Permitted Preservative'’ as an 
ingredient.
The Benzoates used in foods are :
E2 1 0  - Benzoic acid.
E211 - Sodium Benzoate.
E212 - Potassium Benzoate.
E213 - Calcium Benzoate.
E214 - EthvI 4-hydroxybenzoate.
E215 - EthvI 4-hydroxybenzoate sodium salt.
E216 - Propyl 4-hydroxvbenzoate.
E217 - Propyl 4-hydroxvbenzoate sodium salt.
E218 - Methyl 4-hydroxvbenzoate.
E219 - Methyl 4-hydroxybenzoate sodium salt.
AVOID ANY ITEM CONTAINING THESE
In general - AVOID
Commercially prepared meat and fish dishes o f which the exact composition is not fcnownsr-. 
- lasagne, pizza, cum', Chinese foods, flans, quiches. Keep to fresh or home cooked food' 
wherever possible. - i r ;;
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Check I-abds On
1. Squashes, cordials and diluting drinks.
2 . Fizzv drinks.
3. Glucose drinks, e.g. Lucozade.
4. Non alcoholic grape juice drinks, e.g. Schloer.
5. Slush puppies, ice poles, ice lollies. Tip Top.
6 . Bottles shandy. Avoid Tennants *L.A.‘ on draught.
7. Chocolate drinks.
8 . Liquid coffee and chicory drinks e.g. Camp coffee.
9. Flavoured milk drinks and milk shake syrup.
10. Yoghurt. -
11. Colourings and flavourings used in home baking.
12. Jams, marmalades, chocolate spreads and also diabetic jam.
13. Liquid artificial sweetener, e.g. Sweetex liquid.
14. Pickled products, e.g. herring, onions, beetroot, pickles. Canned fish in tomato
sauce, pickled herring.
15. .Also check sauces - horseradish, brown sauce, tomato sauce, mustard and vinegar.
16. Mayonnaise, salad cream, and salad dressings. Coleslaw and any salads in
Delicatessen counters. Potato salad.
17. Dried fruit. Tins or jars o f fruit or fruit puree. Avoid ice cream with fruit / fruit
sauce in it.
18. White bread. Avoid bread made with bleached flour - check labels.
19. Fruit sauces, toppings on cheesecakes, gateaux etc.
Fruit pie fillings. Dessert sauces. Bought dessert cakes and gateaux.
Fruit pies.
20. Crystallised or glace fruit. Any preserved fruits.
The recommended toothpastes are :
1. Kingfisher. • ..-sr-
2. Colgate Regular. Colgate Junior. Colgate Tartar Control, Ultrabrite. Colgate Bluev, . 
Minty GeL
3. Crest.- alltypes. . •
4. Macleans Original. Macleans Sensitive. Macleans Milk Teeth. Aquafresh.
Anv queries please contact your Dietitian :
Name:
Hospital:
Telephone N o : ^ K.A.M. Dec 1995
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APPENDIX G LETTER ACCOMPANYING FOLLOW UP
QUESTIONNAIRE
Glasgow Dental Hospital & School 
378 Sauchiehall St.
Glasgow 
G2 3JZ
20 January 1997
Dear Sir/Madam,
I would be very grateful if you could take time to help me in my research study.
I am looking at the benefits of following advice in avoiding food allergens after 
being patch tested.
Enclosed is a short questionnaire. Please could you complete it as soon as 
possible and return it using the reply paid envelope. There is no need to put 
your name on the returned questionnaire and the results will be treated in the 
strictest confidence.
Thank you for your time in answering these questions. Your involvement will 
help us provide better care in the future.
Yours faithfully,
Shiona R Rees
(Senior House Officer and Clinical Research Assistant in Oral 
Medicine)
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Appendix H Patient Follow Up Questionnaire
No_________ analague hue. fb'&de]
QUESTIONNAIRE
REASON FO R  PATCH TESTING
l.What was the reason you were sent for patch testing?
Please circle all that apply to you
Mouth ulcers? White patches? Angioedema? Erythema multiforme?
Orofacial Granulomatosis? Other? Please explain ................................
DIET ADVICE
2. Did you understand the written dietary avoidance sheets? Yes / No / Didn’t receive
Please circle the answer that most applies to you.
3. How closely did you follow the dietary avoidance advice?
Didn’t 
follow it at 
all Please indicate with a  'x '  on the line where best indicates your answer.
Followed the 
diet advice 
completely
SYMPTOMS PR IO R  TO PATCH TESTING
4. How bad were your symptoms prior to attending for patch testing?
No
symptoms
Please indicate with a ‘x ’ on the line where best indicates your answer.
Symptoms as 
bad as they 
could be
SYMPTOMS A FTER RECIEVTNG D IET ADVICE
5. How bad were your symptoms after receiving dietary avoidance advice?
No
symptoms
Please indicate with a ‘x ‘ on the line where best indicates your answer.
Symptoms as 
bad as they 
could be
PLEASE TURN OVER
379
O TH ER FACTORS
6 . Were there any other factors that may have influenced any change in symptoms?
Removal of amalgam fillings? Yes / No Change of denture ? Yes / No
Change of crowns? Yes / No
Medications? Yes /N o ...................................................................................please specify
Other? Yes / No.................................................................................................please specify’
7. Do you have any medical conditions? Yes / No 
If yes, please specify...........................
8 . What medications do you take?
9. Do you smoke? Yes / No / In the past
If yes, how many per day? .................................................................................
THANK YOU FOR ANSWERING THESE QUESTIONS 
PLEASE POST TODAY
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